<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29873955</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>3</Issue><PubDate><MedlineDate>2018 May/Jun</MedlineDate></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Risk Factors Associated With Antidepressant Exposure and History of Antidepressant-Induced Mania in Bipolar Disorder.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.17m11765</ELocationID><ELocationID EIdType="pii" ValidYN="Y">17m11765</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Despite their widespread use in bipolar disorder, there is controversy surrounding the inclusion of antidepressant medications in the disorder's management. We sought to identify which demographic, socioeconomic, and clinical factors are associated with antidepressant exposure in bipolar disorder and which bipolar disorder patients are most likely to report a history of antidepressant-induced mania (AIM) when exposed to antidepressants.</AbstractText><AbstractText Label="METHODS">Our study included subjects with bipolar I disorder (n = 309), bipolar II disorder (n = 66), and bipolar disorder not otherwise specified (n = 27) and schizoaffective disorder, bipolar type (n = 14), from a longitudinal, community-based study. Subjects were evaluated using the Diagnostic Interview for Genetic Studies, modified for DSM-IV criteria. We applied multivariate logistical regression modeling to investigate which factors contribute to antidepressant exposure in bipolar disorder patients. We also used a logistic regression modeling approach to determine which clinical factors in bipolar disorder patients are associated with a history of AIM. Data were gathered from February 2006 through December 2010.</AbstractText><AbstractText Label="RESULTS">Our results suggest that the risk factors most strongly associated with antidepressant exposure are female sex (OR = 2.73, P = .005), older age (OR = 1.03, P = .04), greater chronicity of illness (OR = 2.29, P = .04), and, to a lesser extent, white race (OR = 0.44, P = .051). Factors associated with reduced antidepressant exposure include history of affective psychosis (OR = 0.36, P = .01) and a greater number of previous manic episodes (OR = 0.98, P = .03). In subjects who reported a history of AIM, regression analysis revealed that the only statistically significant factor associated with AIM history was female sex (OR = 3.74, P = .02).</AbstractText><AbstractText Label="CONCLUSIONS">These data suggest that there are certain identifiable factors associated with antidepressant exposure in bipolar disorder patients, and some of these, specifically female sex, are also associated with a history of AIM. These data may be useful in designing prospective trials to identify interventions that can reduce the risk of this adverse outcome.</AbstractText><CopyrightInformation>Â© Copyright 2018 Physicians Postgraduate Press, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Aislinn J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Michigan Depression Center, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr Williams is now with the Department of Psychiatry, University of Iowa, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Zongshan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pathology, Beaumont Health, Royal Oak, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knight</LastName><ForeName>Seth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Grove Emotional Health Collective, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamali</LastName><ForeName>Masoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Michigan Depression Center, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assari</LastName><ForeName>Shervin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Michigan Depression Center, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Research on Ethnicity, Culture and Health (CRECH), School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McInnis</LastName><ForeName>Melvin G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>University of Michigan Depression Center, Rachel Upjohn Bldg, 4250 Plymouth Rd, Ann Arbor, MI 48109-2700. mmcinnis@umich.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Michigan Depression Center, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KL2 TR002241</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>06</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29873955</ArticleId><ArticleId IdType="doi">10.4088/JCP.17m11765</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11816872</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>30</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>10</Issue><PubDate><Year>2001</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study.</ArticleTitle><Pagination><MedlinePgn>818-25</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The goal of this study was to assess the efficacy and safety of risperidone in bipolar and schizoaffective disorders.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">541 patients entered this open, multicenter, 6-month study. Patients were entered provided that they fulfilled DSM-IV criteria for bipolar disorder or schizoaffective disorder, bipolar type, during a manic, hypomanic, mixed, or depressive episode. Risperidone was added to any previous mood-stabilizing medication that the patients were taking. Efficacy was assessed with the Young Mania Rating Scale (YMRS), the Hamilton Rating Scale for Depression (HAM-D), the Positive and Negative Syndrome Scale (PANSS), and the Clinical Global Impressions scale (CGI). Extrapyramidal symptoms (EPS) were assessed using the UKU Side Effect Rating Scale.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">430 patients completed the study. Addition of risperidone produced highly significant improvements (p &lt; .0001) on the YMRS and HAM-D at both 6 weeks and 6 months and on the CGI and the scales of the PANSS at both 4 weeks and 6 months. There was a significant reduction in UKU total and subscale scores at 6 months. The mean dose of risperidone was 3.9 mg/day. There was no single case of new-emergent tardive dyskinesia, and there was a very low incidence of exacerbation of mania within the first 6 weeks (2%). Adverse events were few and mostly mild. the most frequent being EPS and weight gain.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This large study provides additional evidence that risperidone is effective and well tolerated when combined with mood stabilizers in the treatment of bipolar disorder and schizoaffective disorder, bipolar type. Previous concerns about exacerbation of manic symptoms were not confirmed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Hospital Clinic, University of Barcelona, Spain. EVIETA@clinic.ub.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goikolea</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Corbella</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Benabarre</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Reinares</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>MartÃ­nez</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>FernÃ¡ndez</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Colom</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>MartÃ­nez-ArÃ¡n</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Torrent</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><CollectiveName>Group for the Study of Risperidone in Affective Disorders (GSRAD)</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Clin Psychiatry 2002 Jan;63(1):79</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>31</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>31</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>31</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11816872</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25592045</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1379</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales.</ArticleTitle><Pagination><MedlinePgn>40-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2014.12.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-3956(14)00356-2</ELocationID><Abstract><AbstractText>Although antidepressant trials typically use weekly ratings to examine changes in symptoms over six to 12 weeks, antidepressant treatments may improve symptoms more quickly. Thus, rating scales must be adapted to capture changes over shorter intervals. We examined the use of the 17-item Hamilton Depression Rating Scale (HDRS) to evaluate more rapid changes. Data were examined from 58 patients with major depressive disorder or bipolar disorder enrolled in double-blind, placebo-controlled, crossover studies who received a single infusion of ketamine (0.5 mg/kg) or placebo over 40 min then crossed over to the other condition. HDRS subscales, a single HDRS Depressed mood item, and a visual analogue scale were used at baseline, after a brief interval (230 min), and one week post-infusion. Effect sizes for the ketamine-placebo difference were moderate (d &gt; 0.50), but one and two-item HDRS subscales had the smallest effects. Response rates on active drug were lowest for the complete HDRS (43%); the remaining scales had higher response rates to active drug, but the shortest subscales had higher response rates to placebo. Correlations between the changes from baseline to 230 min post-ketamine across scores were similar for most subscales (r = 0.82-0.97), but correlations using the single items were lower (r &lt; 0.74). Overall, effect sizes for drug-placebo differences and correlations between changes were lower for one- and two-item measures. Response rates were lower with the full HDRS scale. The data suggest that, to best identify rapid antidepressant effects, a scale should have more than two items, but fewer items than a full scale.</AbstractText><CopyrightInformation>Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luckenbaugh</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, MD, USA. Electronic address: dave.luckenbaugh@nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ameli</LastName><ForeName>Rezvan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, MD, USA. Electronic address: rezvan.ameli@nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brutsche</LastName><ForeName>Nancy E</ForeName><Initials>NE</Initials><AffiliationInfo><Affiliation>Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, MD, USA. Electronic address: nancy.brutsche@nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zarate</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, MD, USA. Electronic address: zaratec@mail.nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00088699</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>ZIA MH002857-10</GrantID><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA MH002927-05</GrantID><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>690G0D6V8H</RegistryNumber><NameOfSubstance UI="D007649">Ketamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007649" MajorTopicYN="N">Ketamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antidepressant</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">HDRS</Keyword><Keyword MajorTopicYN="N">Ketamine</Keyword><Keyword MajorTopicYN="N">Ratings</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>07</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25592045</ArticleId><ArticleId IdType="pii">S0022-3956(14)00356-2</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2014.12.015</ArticleId><ArticleId IdType="pmc">PMC4308518</ArticleId><ArticleId IdType="mid">NIHMS651921</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Depress Anxiety. 2008;25(9):774-86</Citation><ArticleIdList><ArticleId IdType="pubmed">17935212</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2009 Aug;43(12):1049-56</Citation><ArticleIdList><ArticleId IdType="pubmed">19344914</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2010 Aug;67(8):793-802</Citation><ArticleIdList><ArticleId IdType="pubmed">20679587</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2011 Sep;45(9):1202-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21453932</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2012 Jun 1;71(11):939-46</Citation><ArticleIdList><ArticleId IdType="pubmed">22297150</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Mar 5;145(3):363-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22959683</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacopsychiatry. 2010 Nov;43(7):271-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20830664</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2000 Jan-Feb;34(1):3-10</Citation><ArticleIdList><ArticleId IdType="pubmed">10696827</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2002 Jul;27(4):235-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12174732</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2002 Nov-Dec;36(6):437-48</Citation><ArticleIdList><ArticleId IdType="pubmed">12393314</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 2002 Nov;17(6):273-80</Citation><ArticleIdList><ArticleId IdType="pubmed">12409680</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2004 May-Jun;38(3):275-84</Citation><ArticleIdList><ArticleId IdType="pubmed">15003433</ArticleId></ArticleIdList></Reference><Reference><Citation>Mod Probl Pharmacopsychiatry. 1974;7(0):151-69</Citation><ArticleIdList><ArticleId IdType="pubmed">4412100</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1981 Mar;63(3):290-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7015793</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1993 Mar;46(3):213-27</Citation><ArticleIdList><ArticleId IdType="pubmed">8493292</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1993 Jul-Sep;27(3):259-73</Citation><ArticleIdList><ArticleId IdType="pubmed">8295158</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005 Feb;66(2):148-58</Citation><ArticleIdList><ArticleId IdType="pubmed">15704999</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2005 Nov-Dec;46(6):417-27</Citation><ArticleIdList><ArticleId IdType="pubmed">16275208</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 2005 Nov 22;173(11):1327-34</Citation><ArticleIdList><ArticleId IdType="pubmed">16301700</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2006 Feb;26(1):56-60</Citation><ArticleIdList><ArticleId IdType="pubmed">16415707</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2006 Jul;20(4 Suppl):47-53</Citation><ArticleIdList><ArticleId IdType="pubmed">16785270</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Aug;63(8):856-64</Citation><ArticleIdList><ArticleId IdType="pubmed">16894061</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Sep;102(1-3):93-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17258323</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 Jun;69(6):946-58</Citation><ArticleIdList><ArticleId IdType="pubmed">18435563</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2008 Oct;42(12):1000-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18206909</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16566627</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>67</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Menstrual dysfunction prior to onset of psychiatric illness is reported more commonly by women with bipolar disorder than by women with unipolar depression and healthy controls.</ArticleTitle><Pagination><MedlinePgn>297-304</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Preliminary reports suggest that menstrual cycle irregularities occur more commonly in women with bipolar disorder and unipolar depression than in the general population. However, it is not always clear whether such abnormalities, reflecting disruption of the hypothalamic-pituitary-gonadal (HPG) axis, are caused by psychotropic treatments or associated with the disorder per se.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The prevalence of early-onset (within the first 5 postmenarchal years) menstrual cycle dysfunction (menstrual cycle length unpredictable within 10 days or menstrual cycle length&lt;25 days or &gt;35 days) occurring before onset of psychiatric illness was compared between subjects with DSM-IV bipolar disorder participating in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) and subjects with DSM-IV unipolar depression or no psychiatric illness participating in the Harvard Study of Moods and Cycles. Data from the Harvard Study of Moods and Cycles were gathered from September 1995 to September 1997, and data from STEP-BD were gathered from November 1999 to May 2001.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Early-onset menstrual cycle dysfunction was reported to have occurred in 101/295 women with bipolar disorder (34.2%), 60/245 women with depression (24.5%), and 134/619 healthy controls (21.7%). Women with bipolar disorder were more likely to have early-onset menstrual cycle dysfunction than healthy controls (chi2=16.58, p&lt;.0001) and depressed women (chi2=6.08, p=.01), while depressed women were not more likely to have early-onset menstrual cycle dysfunction than healthy controls (chi2=0.81, p=.37).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Compared with healthy controls and women with unipolar depression, women with bipolar disorder retrospectively report early-onset menstrual dysfunction more commonly prior to onset of bipolar disorder. Future studies should evaluate potential abnormalities in the hypothalamic-pituitary-gonadal axis that are associated with bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Joffe</LastName><ForeName>Hadine</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Perinatal and Reproductive Psychiatry Clinical Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. hjoffe@partners.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Deborah R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Foris</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Baldassano</LastName><ForeName>Claudia F</ForeName><Initials>CF</Initials></Author><Author ValidYN="Y"><LastName>Gyulai</LastName><ForeName>Laszlo</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Cindy H</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>McLaughlin</LastName><ForeName>Wren L</ForeName><Initials>WL</Initials></Author><Author ValidYN="Y"><LastName>Sachs</LastName><ForeName>Gary S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Thase</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Harlow</LastName><ForeName>Bernard L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Lee S</ForeName><Initials>LS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH80001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-MH50013</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>33515-09-2</RegistryNumber><NameOfSubstance UI="D007987">Gonadotropin-Releasing Hormone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Psychiatry. 2006 Dec;67(12):2032</RefSource><PMID Version="1">17194289</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007987" MajorTopicYN="N">Gonadotropin-Releasing Hormone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008572" MajorTopicYN="N">Menarche</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008597" MajorTopicYN="N">Menstrual Cycle</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008599" MajorTopicYN="N">Menstruation Disturbances</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16566627</ArticleId><ArticleId IdType="doi">10.4088/jcp.v67n0218</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8010358</PMID><DateCompleted><Year>1994</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>151</Volume><Issue>7</Issue><PubDate><Year>1994</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Suicide in bipolar disorder in Finland.</ArticleTitle><Pagination><MedlinePgn>1020-4</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The authors examined suicides of persons with bipolar disorder in aspects relevant to suicide prevention, including clinical features, treatment contacts, adequacy of treatment received, communication of suicidal intent, and suicide methods.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">All suicide victims with DSM-III-R bipolar I disorder among all 1,397 suicides in Finland within a 12-month period were carefully studied using the psychological autopsy method and were compared to suicide victims with unipolar major depression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-one bipolar I victims were identified. Most suicides of persons with bipolar disorder occurred during a major depressive episode (79%), but in some cases it occurred during a mixed state (11%) or even during or immediately after remission of psychotic mania (11%). Men had a higher rate of comorbid alcoholism, a lesser mean age, and shorter treatment histories than women. Although 74% of the victims were receiving psychiatric care at the time of suicide, and 39% had even explicitly communicated their intent to health care personnel during the last 3 months, only 11% of those who were depressed had received adequate doses of antidepressants and none had received ECT. Only 32% of the bipolar patients were prescribed lithium. In comparison to unipolar depressed suicide victims, the bipolar victims had more divorces, longer treatment histories, and more frequent hospitalizations.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although late suicides were common among both male and female bipolar victims, suicide seemed to occur earlier among males. Most bipolar victims had had a recent psychiatric treatment contact, but few had received adequate treatment immediately before death. Suicide victims with unipolar and bipolar disorders differed in marital status and treatment history.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>IsometsÃ¤</LastName><ForeName>E T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>Department of Mental Health, National Public Health Institute, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henriksson</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Aro</LastName><ForeName>H M</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>LÃ¶nnqvist</LastName><ForeName>J K</ForeName><Initials>JK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003142" MajorTopicYN="N">Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005387" MajorTopicYN="N">Finland</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017533" MajorTopicYN="N">Marital Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008605" MajorTopicYN="N">Mental Health Services</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8010358</ArticleId><ArticleId IdType="doi">10.1176/ajp.151.7.1020</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10646232</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2009</Year><Month>02</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0350-6134</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>2</Issue><PubDate><Year>1999</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Collegium antropologicum</Title><ISOAbbreviation>Coll Antropol</ISOAbbreviation></Journal><ArticleTitle>Dermatoglyphic analysis in bipolar affective disorder and schizophrenia--"continuum of psychosis" hypothesis corroborated?</ArticleTitle><Pagination><MedlinePgn>589-95</MedlinePgn></Pagination><Abstract><AbstractText>Dermatoglyphic features are thought to be indicators of events in the early embryonal stages. They might also be associated with the developmental disorders of the central nervous system (CNS) including schizophrenia. Dermatoglyphic features of 92 male patients with bipolar affective disorder (BPAD) (unipolar depression and schizoaffective psychosis were excluded from the study) were compared with those of 195 males with schizophrenia (SCH) and both with those of 200 male controls (control group-CG). DSM-III-R criteria were used for the diagnostic evaluation. Quantitative analysis showed only one statistically significant difference between BPAD and SCH patients groups, regarding the c-d ridge count of the left hand. The canonical discriminant analysis did not permit correct classification (only 59.23% of cases were correctly classified) between BPAD and SCH. Numerous quantitative dermatoglyphic features of both BPAD and SCH differed significantly from those of the control subjects. Finger ridge counts as well as palmar ridge counts were markedly lower in BPAD and SCH as compared to the controls. These findings are not in contradiction with the hypothesis claiming that psychoses are a set of diverse expressions (due also to noninherited factors) of a single underlying entity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jelovac</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Psychiatric Clinic, University of Split, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MiliciÄ</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Milas</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Dodig</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Turek</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>UgrenoviÄ</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Croatia</Country><MedlineTA>Coll Antropol</MedlineTA><NlmUniqueID>8003354</NlmUniqueID><ISSNLinking>0350-6134</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003878" MajorTopicYN="Y">Dermatoglyphics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10646232</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10686970</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>29</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0755-4982</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>Jan</Month><Day>29</Day></PubDate></JournalIssue><Title>Presse medicale (Paris, France : 1983)</Title><ISOAbbreviation>Presse Med</ISOAbbreviation></Journal><ArticleTitle>[Manic-depressive conditions in adolescents. Epidemiological and clinical aspects].</ArticleTitle><Pagination><MedlinePgn>157-60</MedlinePgn></Pagination><Abstract><AbstractText>EPIDEMIOLOGY CONTEXT: The prevalence of maniac depressive disorders is similar in adolescents and adults, i.e. about 1% with a 1:1 sex-ratio. Risk is higher in families with a diseased member and early episodes of mood disorders are probably correlated with the genotypic severity or the presence of a unique susceptibility gene. HIGHLY VARIABLE CLINICAL SIGNS: Until recent years, the highly variable clinical expression with rapid changes in mood, bipolar states, variable somatic, behavioral or addictive symptomatology, cognition disorders, and disturbed ideation or hallucinations, probably contributed to our poor understanding of juvenile forms of the disease. EARLY MANAGEMENT: Early diagnosis and psychiatric care is crucial due to the short-, mid- and long-term risk of unfavorable or even fatal consequences. Indeed, while still in the process of structuralization, the predisposed personality is particularly reactive to positive or negative events. It is most difficult to achieve flexibility once a restrictive organization of the personality has been installed. In addition, these families often have a painful past and lack sufficient capacity to successfully deal with the stress of emotions and conflicts occurring in the future adult during the self-identification and independence-seeking processes. This familial situation points out the importance of implicating the family and close friends in the treatment strategy as a complement to drug therapy and psychotherapy proposed to the adolescent.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bochereau</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Service du Pr Jeammet, Institut Mutualiste Montsouris, Paris.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcos</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Troubles maniaco-dÃ©pressifs Ã  l'adolescence. Aspects Ã©pidÃ©miologiques et cliniques.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Presse Med</MedlineTA><NlmUniqueID>8302490</NlmUniqueID><ISSNLinking>0755-4982</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000296" MajorTopicYN="Y">Adolescent Psychiatry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009446" MajorTopicYN="N">Neurobiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011627" MajorTopicYN="N">Puberty</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10686970</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">22835849</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>148</Volume><Issue>2-3</Issue><PubDate><Year>2013</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Antisocial personality disorder and borderline symptoms are differentially related to impulsivity and course of illness in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>384-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2012.06.027</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(12)00490-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Interactions between characteristics of bipolar and Axis II cluster B disorders are clinically and diagnostically challenging. Characteristics associated with personality disorders may be dimensional aspects of bipolar disorder. We investigated relationships among antisocial personality disorder (ASPD) or borderline personality disorder symptoms, impulsivity, and course of illness in bipolar disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Subjects with bipolar disorder were recruited from the community. Diagnosis was by structured clinical interview for DSM-IV (SCID-I and -II), psychiatric symptom assessment by the change version of the schedule for affective disorders and schizophrenia (SADS-C), severity of Axis II symptoms by ASPD and borderline personality disorder SCID-II symptoms, and impulsivity by the Barratt impulsiveness scale (BIS-11).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">ASPD and borderline symptoms were not related to clinical state or affective symptoms. Borderline symptoms correlated with BIS-11 impulsivity scores, and predicted history of suicide attempts independently of the relationship to impulsivity. ASPD symptoms were more strongly related to course of illness, including early onset, frequent episodes, and substance-related disorders. These effects persisted after allowance for gender and substance-use disorder history.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Personality disorder symptoms appear to be dimensional, trait-like characteristics of bipolar disorder. ASPD and Borderline symptoms are differentially related to impulsivity and course of illness.</AbstractText><CopyrightInformation>Copyright Â© 2012 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Swann</LastName><ForeName>Alan C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, TX, USA. Alan.C.Swann@uth.tmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lijffijt</LastName><ForeName>Marijn</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Scott D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Steinberg</LastName><ForeName>Joel L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Moeller</LastName><ForeName>F Gerard</ForeName><Initials>FG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KO2-DA00403</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 DA000403</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH069944</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-MH69944</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024148</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1-RR024148</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000987" MajorTopicYN="N">Antisocial Personality Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007175" MajorTopicYN="N">Impulsive Behavior</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>10</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>12</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>06</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22835849</ArticleId><ArticleId IdType="pii">S0165-0327(12)00490-9</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2012.06.027</ArticleId><ArticleId IdType="pmc">PMC3484175</ArticleId><ArticleId IdType="mid">NIHMS390129</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Am Acad Psychiatry Law. 2005;33(2):188-95</Citation><ArticleIdList><ArticleId IdType="pubmed">15985661</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Pract. 2004 Mar;10(2):81-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15330403</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 May;61(5):393-6; quiz 397</Citation><ArticleIdList><ArticleId IdType="pubmed">10847318</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002 Aug;4(4):237-42</Citation><ArticleIdList><ArticleId IdType="pubmed">12190712</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Mar;106(3):241-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17822778</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2009 Aug;43(12):1057-63</Citation><ArticleIdList><ArticleId IdType="pubmed">19345957</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1992 Nov;149(11):1473-83</Citation><ArticleIdList><ArticleId IdType="pubmed">1415815</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2001 Mar;158(3):420-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11229983</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1999 Mar-Apr;33(2):97-104</Citation><ArticleIdList><ArticleId IdType="pubmed">10221741</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2000 May;109(2):222-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10895560</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Dec;67(1-3):221-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11869772</ArticleId></ArticleIdList></Reference><Reference><Citation>Suicide Life Threat Behav. 2001;32(1 Suppl):49-59</Citation><ArticleIdList><ArticleId IdType="pubmed">11924695</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2001 Apr;35(2):166-73</Citation><ArticleIdList><ArticleId IdType="pubmed">11284897</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2002 Dec;25(4):713-37</Citation><ArticleIdList><ArticleId IdType="pubmed">12462857</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2004 Dec;110(6):401-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15521823</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1994 Jun;182(6):349-52</Citation><ArticleIdList><ArticleId IdType="pubmed">8201307</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Disord. 1997 Fall;11(3):279-84</Citation><ArticleIdList><ArticleId IdType="pubmed">9348491</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Sep;162(9):1680-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16135628</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2001 Sep;58(9):844-50</Citation><ArticleIdList><ArticleId IdType="pubmed">11545667</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2002 Jun 15;51(12):988-94</Citation><ArticleIdList><ArticleId IdType="pubmed">12062883</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 May;64(5):506-15</Citation><ArticleIdList><ArticleId IdType="pubmed">12755652</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2005 Jul;56(7):847-52</Citation><ArticleIdList><ArticleId IdType="pubmed">16020818</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 1994 Apr;62(2):285-96</Citation><ArticleIdList><ArticleId IdType="pubmed">8201066</ArticleId></ArticleIdList></Reference><Reference><Citation>Suicide Life Threat Behav. 2004 Winter;34(4):374-85</Citation><ArticleIdList><ArticleId IdType="pubmed">15585459</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2001 Nov-Dec;35(6):307-12</Citation><ArticleIdList><ArticleId IdType="pubmed">11684137</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Nov;162(11):2116-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16263852</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1994 Mar 23-30;271(12):918-24</Citation><ArticleIdList><ArticleId IdType="pubmed">8120960</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Feb;8(1):1-14</Citation><ArticleIdList><ArticleId IdType="pubmed">16411976</ArticleId></ArticleIdList></Reference><Reference><Citation>J Subst Abuse Treat. 2001 Dec;21(4):193-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11777668</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004 Feb;65(2):198-203</Citation><ArticleIdList><ArticleId IdType="pubmed">15003073</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 1998 Jul;19(1):95-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9608581</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Jun;9(4):339-44</Citation><ArticleIdList><ArticleId IdType="pubmed">17547580</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Feb;156(2):181-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9989552</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 1999 Dec;11(4):187-95</Citation><ArticleIdList><ArticleId IdType="pubmed">10596733</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 Feb;61(2):134-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10732661</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Apr;85(3):301-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15780700</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1996 Aug 30;64(1):69-75</Citation><ArticleIdList><ArticleId IdType="pubmed">8888366</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 May;11(3):280-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19419385</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Apr;64(4):425-32</Citation><ArticleIdList><ArticleId IdType="pubmed">12716245</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Jun;100(1-3):227-31</Citation><ArticleIdList><ArticleId IdType="pubmed">17097740</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Aug;9(5):536-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17680926</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1991 Oct;39(1):55-63</Citation><ArticleIdList><ArticleId IdType="pubmed">1771209</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Sep;163(9):1633-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16946191</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Jun;6(3):204-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15117399</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Jul;116(1-2):30-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19038460</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Mar;161(3):459-65</Citation><ArticleIdList><ArticleId IdType="pubmed">14992971</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Mar;13(2):173-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21443571</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychol. 1995 Nov;51(6):768-74</Citation><ArticleIdList><ArticleId IdType="pubmed">8778124</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 1993 Oct;34(7):1173-85</Citation><ArticleIdList><ArticleId IdType="pubmed">8245140</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2000 May-Jun;41(3):206-15</Citation><ArticleIdList><ArticleId IdType="pubmed">10834630</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Psychiatry Law. 2008;36(1):27-34</Citation><ArticleIdList><ArticleId IdType="pubmed">18354120</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2007 Oct;68(10):1533-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17960968</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005 Mar;66(3):339-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15766300</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2013 Mar;14(2):121-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21486110</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Apr;61(4):361-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15066894</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2002 Apr;68(2-3):167-81</Citation><ArticleIdList><ArticleId IdType="pubmed">12063145</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1997 Jul-Aug;38(4):237-42</Citation><ArticleIdList><ArticleId IdType="pubmed">9202881</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1999 Jun;53(3):211-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10404706</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2006 Oct;32(4):626-36</Citation><ArticleIdList><ArticleId IdType="pubmed">16574783</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2008 Jul;42(9):778-86</Citation><ArticleIdList><ArticleId IdType="pubmed">17935734</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2009 Mar-Apr;50(2):115-20</Citation><ArticleIdList><ArticleId IdType="pubmed">19216887</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2000 Nov-Dec;41(6):432-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11086148</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 Nov;69(11):1794-803</Citation><ArticleIdList><ArticleId IdType="pubmed">19026249</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15723025</PMID><DateCompleted><Year>2005</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2017</Year><Month>12</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0010-440X</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>2</Issue><PubDate><MedlineDate>2005 Mar-Apr</MedlineDate></PubDate></JournalIssue><Title>Comprehensive psychiatry</Title><ISOAbbreviation>Compr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Care satisfaction, hope, and life functioning among adults with bipolar disorder: data from the first 1000 participants in the Systematic Treatment Enhancement Program.</ArticleTitle><Pagination><MedlinePgn>98-104</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) is designed to evaluate the longitudinal outcome of patients with bipolar disorder. The STEP-BD disease-management model is built on evidence-based practices and a collaborative care approach designed to maximize specific and nonspecific treatment mechanisms. This prospective study examined the longitudinal relationships between patients' satisfaction with care, levels of hope, and life functioning in the first 1000 patients to enter STEP-BD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study used scores from the Care Satisfaction Questionnaire, Beck Hopelessness Scale, Range of Impaired Functioning Tool, Young Mania Rating Scale, and Montgomery-Asberg Depression Rating Scale at 5 time points during a 1-year interval. Analyses tested mediational pathways between care satisfaction, hope, and life functioning, depression, and mania using mixed-effects (random and fixed) regression models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Increases in care satisfaction were associated with decreased hopelessness (P &lt; .01) but not related to symptoms of depression or mania. Similarly, decreased hopelessness was associated with better life functioning (P &lt; .01) but not related to symptoms of depression or mania. Depression was independently associated with poorer life functioning (P &lt; .0001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study provided support for the hypothesized mediational pathway between care satisfaction, hopelessness, and life functioning. Findings suggest that providing care that maximizes patient hope may be important. By so doing, patients might overcome the learned helplessness/hopelessness that often accompanies a cyclical illness and build a realistic illness-management strategy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Chad D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Colorado Health Sciences Center, Denver, CO 80220, USA. chad.morris@uchsc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miklowitz</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>Stephen R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Giese</LastName><ForeName>Alexis A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Marshall R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Michael H</ForeName><Initials>MH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01MH80001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Compr Psychiatry</MedlineTA><NlmUniqueID>0372612</NlmUniqueID><ISSNLinking>0010-440X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019468" MajorTopicYN="Y">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="Y">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="Y">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="Y">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>2</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>9</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>2</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15723025</ArticleId><ArticleId IdType="doi">10.1016/j.comppsych.2004.07.026</ArticleId><ArticleId IdType="pii">S0010-440X(04)00114-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23545475</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>25</Day></DateCompleted><DateRevised><Year>2013</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Sep</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Ramadan and bipolar disorder: Example of circadian rhythm disturbance and its impact on patients with bipolar disorders].</ArticleTitle><Pagination><MedlinePgn>306-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.encep.2012.11.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0013-7006(13)00030-4</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Fasting during the Ramadan month is a cornerstone of Islam. Several disorders of the chronobiological rhythms occur during this month and impact on mood. Through this paper the authors provide a literature review of the impact of fasting on patients with bipolar disorders.</AbstractText><AbstractText Label="MATERIALS AND SUBJECTS" NlmCategory="METHODS">A literature review using Mesh keywords through Medline database. From 1970Â to 2011, articles in French and English were selected.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Circadian rhythm refers to the approximately 24-hour cycles that are generated by an organism. Most physiological systems demonstrate circadian variations. Many hormones and other metabolisms, such as gastric pH, insulin, glucose, calcium and plasmatic gastrine, have been shown to exhibit circadian oscillation. The role of social rhythm in behaviors and its influence on circadian rhythms in humans is now obvious. It has been shown that the lack of concentration and irritability increased continuously during Ramadan month and reached its peak at the end of the month. Mood and vigilance are significantly decreased during the fasting month. Several authors have stated that the course of bipolar illness may be affected by the changes in social rhythm that occur during Ramadan (fasting month). Studies which have been devoted to this topic are sparse. Kadri et al., in 2000, studied 20Â bipolar patientsÂ during the fasting month of Ramadan of 1417 (Hegirian calendar, corresponding to January 1997). Diagnosis of bipolar disorder was made according to ICD-10Â criteria. Patients were assessed during the week before Ramadan, the second and the fourth weeks of the fasting month and the first week after its end, with the Hamilton Depression and Bech-Rafaelsen scales. The plasma concentration of lithium was also assessed. The main finding of the study was that 45% of the patients relapsed, 70% during the second week, and the remaining patients at the end of Ramadan. These relapses were not related to plasma concentration of lithium. Most of the relapses were manic (71,4%). Patients who did not relapse had more insomnia and anxiety during the second and third weeks of the study. The side effects of lithium increased and were seen in 48% of the sample, mostly dryness of the mouth with thirst and tremor. However, Farooq et al. in 2006Â studied 62Â bipolar patients during the fasting month of Ramadan 1427Â (from 25Â September to 24Â October 2006). Serum lithium, electrolytes, Hamilton Depression Rating Scale (HDRS) and Young Mania Rating Scale (YMRS) were assessed, one week before Ramadan, mid Ramadan and one week after Ramadan. The side effects and toxicity were measured by symptoms and signs checklist. There was no significant difference in mean serum lithium levels at three time points. The scores on HDRS and YMRS showed significant decrease during Ramadan (F=34,12, P=0,00, for HDRS and F=15,6, P=0,000Â for YMRS). Also the side effects and toxicity did not differ significantly at the three point's assessment.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">All physiologic parameters are influenced by the circadian rhythm, which is influenced in its turn by the food rhythm. So far, the results of these two main studies, with opposite results, do not help us advise bipolar patients to fast or not to fast. Other studies in this field are badly needed.</AbstractText><CopyrightInformation>Copyright Â© 2013 LâEncÃ©phale, Paris. Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eddahby</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratoire de santÃ© mentale, cognition et psychopathologie, facultÃ© de mÃ©decine et de pharmacie, universitÃ© Hassan II, centre psychiatrique universitaire Ibn Rochd, Casablanca, Maroc. Electronic address: siham.eddahby@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadri</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Moussaoui</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Ramadan et trouble bipolaireÂ : exemple de perturbation du rythme circadien et son impact sur la maladie.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2013</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="Y">Circadian Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005215" MajorTopicYN="Y">Fasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007514" MajorTopicYN="Y">Islam</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009018" MajorTopicYN="N" Type="Geographic">Morocco</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012069" MajorTopicYN="Y">Religion and Psychology</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biological clock</Keyword><Keyword MajorTopicYN="N">Bipolar patients</Keyword><Keyword MajorTopicYN="N">Circadian rhythm and mood disorder</Keyword><Keyword MajorTopicYN="N">Horloge biologique</Keyword><Keyword MajorTopicYN="N">Patients bipolaires</Keyword><Keyword MajorTopicYN="N">Ramadan</Keyword><Keyword MajorTopicYN="N">Rythme circadien</Keyword><Keyword MajorTopicYN="N">Rythme social</Keyword><Keyword MajorTopicYN="N">Social rhythm</Keyword><Keyword MajorTopicYN="N">Troubles de lâhumeur</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>01</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23545475</ArticleId><ArticleId IdType="pii">S0013-7006(13)00030-4</ArticleId><ArticleId IdType="doi">10.1016/j.encep.2012.11.008</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33494281</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>01</Month><Day>21</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Using iPSC Models to Understand the Role of Estrogen in Neuron-Glia Interactions in Schizophrenia and Bipolar Disorder.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">209</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells10020209</ELocationID><Abstract><AbstractText>Schizophrenia (SCZ) and bipolar disorder (BIP) are severe mental disorders with a considerable disease burden worldwide due to early age of onset, chronicity, and lack of efficient treatments or prevention strategies. Whilst our current knowledge is that SCZ and BIP are highly heritable and share common pathophysiological mechanisms associated with cellular signaling, neurotransmission, energy metabolism, and neuroinflammation, the development of novel therapies has been hampered by the unavailability of appropriate models to identify novel targetable pathomechanisms. Recent data suggest that neuron-glia interactions are disturbed in SCZ and BIP, and are modulated by estrogen (E2). However, most of the knowledge we have so far on the neuromodulatory effects of E2 came from studies on animal models and human cell lines, and may not accurately reflect many processes occurring exclusively in the human brain. Thus, here we highlight the advantages of using induced pluripotent stem cell (iPSC) models to revisit studies of mechanisms underlying beneficial effects of E2 in human brain cells. A better understanding of these mechanisms opens the opportunity to identify putative targets of novel therapeutic agents for SCZ and BIP. In this review, we first summarize the literature on the molecular mechanisms involved in SCZ and BIP pathology and the beneficial effects of E2 on neuron-glia interactions. Then, we briefly present the most recent developments in the iPSC field, emphasizing the potential of using patient-derived iPSCs as more relevant models to study the effects of E2 on neuron-glia interactions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reis de Assis</LastName><ForeName>Denis</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-2984-0279</Identifier><AffiliationInfo><Affiliation>NORMENT, Institute of Clinical Medicine, University of Oslo &amp; Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Genetics, Oslo University Hospital, 0450 Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szabo</LastName><ForeName>Attila</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NORMENT, Institute of Clinical Medicine, University of Oslo &amp; Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Genetics, Oslo University Hospital, 0450 Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Requena Osete</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9766-5556</Identifier><AffiliationInfo><Affiliation>NORMENT, Institute of Clinical Medicine, University of Oslo &amp; Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Genetics, Oslo University Hospital, 0450 Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puppo</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>NORMENT, Institute of Clinical Medicine, University of Oslo &amp; Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, University of California San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Connell</LastName><ForeName>Kevin S</ForeName><Initials>KS</Initials><Identifier Source="ORCID">0000-0002-6865-8795</Identifier><AffiliationInfo><Affiliation>NORMENT, Institute of Clinical Medicine, University of Oslo &amp; Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>A Akkouh</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-6810-9999</Identifier><AffiliationInfo><Affiliation>NORMENT, Institute of Clinical Medicine, University of Oslo &amp; Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Genetics, Oslo University Hospital, 0450 Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>NORMENT, Institute of Clinical Medicine, University of Oslo &amp; Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Genetics, Oslo University Hospital, 0450 Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frei</LastName><ForeName>Evgeniia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>NORMENT, Institute of Clinical Medicine, University of Oslo &amp; Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Genetics, Oslo University Hospital, 0450 Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>A Andreassen</LastName><ForeName>Ole</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>NORMENT, Institute of Clinical Medicine, University of Oslo &amp; Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Mental Health and Addiction, Oslo University Hospital, 0372 Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djurovic</LastName><ForeName>Srdjan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8140-8061</Identifier><AffiliationInfo><Affiliation>NORMENT, Institute of Clinical Medicine, University of Oslo &amp; Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NORMENT, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>801133</GrantID><Agency>European Union's Horizon 2020 Research and Innovation Programme under the Marie SkÅodowska-Curie Grant Agreement</Agency><Country/></Grant><Grant><GrantID>2018094</GrantID><Agency>South-Eastern Norway Regional Health Authority</Agency><Country/></Grant><Grant><GrantID>223273</GrantID><Agency>Research Council of Norway</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004967">Estrogens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002450" MajorTopicYN="Y">Cell Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004967" MajorTopicYN="N">Estrogens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">brain organoids</Keyword><Keyword MajorTopicYN="Y">drug target</Keyword><Keyword MajorTopicYN="Y">estrogen</Keyword><Keyword MajorTopicYN="Y">iPS cells</Keyword><Keyword MajorTopicYN="Y">in vitro model</Keyword><Keyword MajorTopicYN="Y">neuronâglia interactions</Keyword><Keyword MajorTopicYN="Y">pathophysiological mechanisms</Keyword><Keyword MajorTopicYN="Y">schizophrenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>01</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>26</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33494281</ArticleId><ArticleId IdType="pii">cells10020209</ArticleId><ArticleId IdType="doi">10.3390/cells10020209</ArticleId><ArticleId IdType="pmc">PMC7909800</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Neurosci. 2007 Oct 24;27(43):11496-500</Citation><ArticleIdList><ArticleId IdType="pubmed">17959792</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Cell Neurosci. 2014 Jan 30;8:12</Citation><ArticleIdList><ArticleId IdType="pubmed">24523672</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2016 Apr 19;7:61</Citation><ArticleIdList><ArticleId IdType="pubmed">27148090</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 2017 Jan 2;95(1-2):462-471</Citation><ArticleIdList><ArticleId IdType="pubmed">27870410</ArticleId></ArticleIdList></Reference><Reference><Citation>Handb Exp Pharmacol. 2012;(213):267-95</Citation><ArticleIdList><ArticleId IdType="pubmed">23027419</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Mol Brain Res. 2002 Apr 30;100(1-2):75-83</Citation><ArticleIdList><ArticleId IdType="pubmed">12008023</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Stem Cell. 2019 Oct 3;25(4):558-569.e7</Citation><ArticleIdList><ArticleId IdType="pubmed">31474560</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2017 May;54(4):2518-2538</Citation><ArticleIdList><ArticleId IdType="pubmed">26984740</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2013 Nov 9;382(9904):1575-86</Citation><ArticleIdList><ArticleId IdType="pubmed">23993280</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurobiol. 2001 Jun;64(3):251-67</Citation><ArticleIdList><ArticleId IdType="pubmed">11240308</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2018 Nov 06;9:544</Citation><ArticleIdList><ArticleId IdType="pubmed">30459650</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathol Appl Neurobiol. 2004 Feb;30(1):80-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14720179</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2020 Jun;582(7813):577-581</Citation><ArticleIdList><ArticleId IdType="pubmed">32499649</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2008 Oct 5;147B(7):1270-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18444252</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2010 Apr;333(1):218-27</Citation><ArticleIdList><ArticleId IdType="pubmed">20042529</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1997 Mar 1;17(5):1848-59</Citation><ArticleIdList><ArticleId IdType="pubmed">9030643</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Endocrinol. 1988 Apr;2(4):332-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2837664</ArticleId></ArticleIdList></Reference><Reference><Citation>Redox Biol. 2018 Apr;14:178-186</Citation><ArticleIdList><ArticleId IdType="pubmed">28942195</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 2003 Sep;43(1):70-84</Citation><ArticleIdList><ArticleId IdType="pubmed">14499463</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Methods. 2015 Jul;12(7):671-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26005811</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2009 Jul;110(1):1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">19457121</ArticleId></ArticleIdList></Reference><Reference><Citation>World Psychiatry. 2007 Oct;6(3):168-76</Citation><ArticleIdList><ArticleId IdType="pubmed">18188442</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurosci. 2015 Feb 20;9:37</Citation><ArticleIdList><ArticleId IdType="pubmed">25750611</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Methods. 2019 Jan;16(1):75-78</Citation><ArticleIdList><ArticleId IdType="pubmed">30573846</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Endocr Metab Disord. 2012 Sep;13(3):187-207</Citation><ArticleIdList><ArticleId IdType="pubmed">21603930</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jan 10;36(1):1-4</Citation><ArticleIdList><ArticleId IdType="pubmed">22001950</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2014 Aug;40:219-25</Citation><ArticleIdList><ArticleId IdType="pubmed">24703991</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2008 Mar;11(3):334-43</Citation><ArticleIdList><ArticleId IdType="pubmed">18297067</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Psychiatry. 2010;22(5):417-28</Citation><ArticleIdList><ArticleId IdType="pubmed">21047156</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2015 Nov 5;527(7576):95-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26524527</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2012 Sep;38(5):942-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22899397</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2020 Jan;25(1):148-167</Citation><ArticleIdList><ArticleId IdType="pubmed">31391546</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurosci. 2018 Feb 27;12:94</Citation><ArticleIdList><ArticleId IdType="pubmed">29535595</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Hum Neurosci. 2019 Jul 05;13:224</Citation><ArticleIdList><ArticleId IdType="pubmed">31333434</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroendocrinol. 2012 Dec;24(12):1553-61</Citation><ArticleIdList><ArticleId IdType="pubmed">22845879</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2013 Feb 13;33(7):2761-72</Citation><ArticleIdList><ArticleId IdType="pubmed">23407936</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 1999 Sep;21(3):372-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10457534</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2019 Apr;24(4):474-478</Citation><ArticleIdList><ArticleId IdType="pubmed">30617271</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 2013 Nov;249:120-31</Citation><ArticleIdList><ArticleId IdType="pubmed">23994069</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Oct;156(10):1646-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10518181</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Hypotheses. 2020 Jan;134:109443</Citation><ArticleIdList><ArticleId IdType="pubmed">31644973</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2020 Feb;163:107631</Citation><ArticleIdList><ArticleId IdType="pubmed">31077728</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Hypotheses. 1998 Apr;50(4):269-88</Citation><ArticleIdList><ArticleId IdType="pubmed">9690763</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 2011 Oct;164(4):1162-94</Citation><ArticleIdList><ArticleId IdType="pubmed">21449915</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Learn Mem. 2009 Mar;91(3):315-22</Citation><ArticleIdList><ArticleId IdType="pubmed">18938255</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Protein Chem Struct Biol. 2019;116:135-170</Citation><ArticleIdList><ArticleId IdType="pubmed">31036290</ArticleId></ArticleIdList></Reference><Reference><Citation>Autophagy. 2014;10(12):2324-32</Citation><ArticleIdList><ArticleId IdType="pubmed">25484074</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2012 Mar;62(3):1574-83</Citation><ArticleIdList><ArticleId IdType="pubmed">21277876</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2019 Feb;33(2):177-184</Citation><ArticleIdList><ArticleId IdType="pubmed">30741085</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroendocrinol. 2008 Jul;20(7):930-41</Citation><ArticleIdList><ArticleId IdType="pubmed">18445124</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Aug;14(5):478-87</Citation><ArticleIdList><ArticleId IdType="pubmed">22834460</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroendocrinology. 2009;89(2):171-86</Citation><ArticleIdList><ArticleId IdType="pubmed">18772582</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2013 Aug 08;4:87</Citation><ArticleIdList><ArticleId IdType="pubmed">23964248</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Genomics. 2006;7(8):497-508</Citation><ArticleIdList><ArticleId IdType="pubmed">18369406</ArticleId></ArticleIdList></Reference><Reference><Citation>Endocr Rev. 1999 Jun;20(3):279-307</Citation><ArticleIdList><ArticleId IdType="pubmed">10368772</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2017 May 15;81(10):886-897</Citation><ArticleIdList><ArticleId IdType="pubmed">27449797</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene. 2013 Aug 1;525(1):107-15</Citation><ArticleIdList><ArticleId IdType="pubmed">23644028</ArticleId></ArticleIdList></Reference><Reference><Citation>Endocrinology. 2003 May;144(5):2055-67</Citation><ArticleIdList><ArticleId IdType="pubmed">12697714</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 2005 Aug;145(7):862-71</Citation><ArticleIdList><ArticleId IdType="pubmed">15912132</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2020 Apr;25(4):844-853</Citation><ArticleIdList><ArticleId IdType="pubmed">30610197</ArticleId></ArticleIdList></Reference><Reference><Citation>Endocrinology. 2003 Oct;144(10):4562-74</Citation><ArticleIdList><ArticleId IdType="pubmed">12959972</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Stress. 2018 Oct 25;2(11):282-291</Citation><ArticleIdList><ArticleId IdType="pubmed">31225453</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2017 Feb;71(2):77-103</Citation><ArticleIdList><ArticleId IdType="pubmed">27800654</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1992 Aug;12(8):3217-25</Citation><ArticleIdList><ArticleId IdType="pubmed">1353794</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2002 Apr 1;22(7):2650-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11923430</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2000;95(2):333-42</Citation><ArticleIdList><ArticleId IdType="pubmed">10658612</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Physiol. 2017 Feb 10;79:619-643</Citation><ArticleIdList><ArticleId IdType="pubmed">27959620</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 2002 Oct 21;452(3):276-87</Citation><ArticleIdList><ArticleId IdType="pubmed">12353223</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2019 Dec;101:103417</Citation><ArticleIdList><ArticleId IdType="pubmed">31678567</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Cell Neurosci. 2020 Feb 11;14:20</Citation><ArticleIdList><ArticleId IdType="pubmed">32116564</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2020 Nov;25(11):2860-2872</Citation><ArticleIdList><ArticleId IdType="pubmed">30940904</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Rev. 2007 Jul;87(3):905-31</Citation><ArticleIdList><ArticleId IdType="pubmed">17615392</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Protoc. 2014 Oct;9(10):2329-40</Citation><ArticleIdList><ArticleId IdType="pubmed">25188634</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2019 Oct;280:112503</Citation><ArticleIdList><ArticleId IdType="pubmed">31446215</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2011 Jul 20;8:82</Citation><ArticleIdList><ArticleId IdType="pubmed">21774811</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2000 Jul;23(1):69-78</Citation><ArticleIdList><ArticleId IdType="pubmed">10869887</ArticleId></ArticleIdList></Reference><Reference><Citation>Einstein J Biol Med. 2016;31(1-2):34-39</Citation><ArticleIdList><ArticleId IdType="pubmed">28239307</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Jan 1;1(1):49-59</Citation><ArticleIdList><ArticleId IdType="pubmed">26949748</ArticleId></ArticleIdList></Reference><Reference><Citation>J Steroid Biochem Mol Biol. 2016 Jun;160:127-33</Citation><ArticleIdList><ArticleId IdType="pubmed">26435451</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2020 Jun 09;11:313</Citation><ArticleIdList><ArticleId IdType="pubmed">32581855</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2018 Mar;23(3):533-543</Citation><ArticleIdList><ArticleId IdType="pubmed">28696432</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Endocrinol. 2008 Nov;41(5):289-300</Citation><ArticleIdList><ArticleId IdType="pubmed">18753308</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron Glia Biol. 2009 Nov;5(3-4):45-55</Citation><ArticleIdList><ArticleId IdType="pubmed">19807941</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurosci. 2020 Jun 18;14:632</Citation><ArticleIdList><ArticleId IdType="pubmed">32625059</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Rep. 2018 May 15;23(7):1922-1931.e4</Citation><ArticleIdList><ArticleId IdType="pubmed">29768193</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1995 Dec;52(12):998-1007</Citation><ArticleIdList><ArticleId IdType="pubmed">7492260</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2011 Oct 1;70(7):663-71</Citation><ArticleIdList><ArticleId IdType="pubmed">21641581</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Tissue Res. 2014 Aug;357(2):477-92</Citation><ArticleIdList><ArticleId IdType="pubmed">24577622</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Toxicol Methods. 2017 Jan - Feb;83:72-79</Citation><ArticleIdList><ArticleId IdType="pubmed">27737794</ArticleId></ArticleIdList></Reference><Reference><Citation>Trans R Soc Trop Med Hyg. 2015 Jan;109(1):9-15</Citation><ArticleIdList><ArticleId IdType="pubmed">25573105</ArticleId></ArticleIdList></Reference><Reference><Citation>World Psychiatry. 2003 Oct;2(3):136-46</Citation><ArticleIdList><ArticleId IdType="pubmed">16946919</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2009 Jun;30(6):932-45</Citation><ArticleIdList><ArticleId IdType="pubmed">17950954</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2007 Apr;25(7):2170-81</Citation><ArticleIdList><ArticleId IdType="pubmed">17419756</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2015 Apr;16(4):343-53</Citation><ArticleIdList><ArticleId IdType="pubmed">25789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2018 Jan 10;663:48-54</Citation><ArticleIdList><ArticleId IdType="pubmed">28780170</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Genomics. 2006 Apr 04;7:70</Citation><ArticleIdList><ArticleId IdType="pubmed">16594998</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2019 Mar 21;14(3):e0214156</Citation><ArticleIdList><ArticleId IdType="pubmed">30897183</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Dis. 2018 May 29;9(6):645</Citation><ArticleIdList><ArticleId IdType="pubmed">29844355</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta Bioenerg. 2018 Jun;1859(6):423-433</Citation><ArticleIdList><ArticleId IdType="pubmed">29550215</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2009 May 1;65(9):732-41</Citation><ArticleIdList><ArticleId IdType="pubmed">19150053</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2005;135(1):47-58</Citation><ArticleIdList><ArticleId IdType="pubmed">16054770</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Clin Psychopharmacol. 2015 Feb;23(1):1-21</Citation><ArticleIdList><ArticleId IdType="pubmed">25643025</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Nov 1;64(9):820-2</Citation><ArticleIdList><ArticleId IdType="pubmed">18534557</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2018 May;50(5):668-681</Citation><ArticleIdList><ArticleId IdType="pubmed">29700475</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2006 Aug 11;141(1):391-406</Citation><ArticleIdList><ArticleId IdType="pubmed">16725270</ArticleId></ArticleIdList></Reference><Reference><Citation>eNeuro. 2019 Oct 17;6(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">31540999</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2018 Oct;24(10):1579-1589</Citation><ArticleIdList><ArticleId IdType="pubmed">30127392</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):11763-11768</Citation><ArticleIdList><ArticleId IdType="pubmed">29078280</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2012 Jan;45(1):37-47</Citation><ArticleIdList><ArticleId IdType="pubmed">21310238</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroendocrinol. 2013 Nov;25(11):1163-72</Citation><ArticleIdList><ArticleId IdType="pubmed">24112361</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 Oct 30;349(18):1738-49</Citation><ArticleIdList><ArticleId IdType="pubmed">14585943</ArticleId></ArticleIdList></Reference><Reference><Citation>Endocrine. 2003 Jun;21(1):27-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12777700</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2016 Apr 9;387(10027):1561-1572</Citation><ArticleIdList><ArticleId IdType="pubmed">26388529</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2003 Nov;1003:318-27</Citation><ArticleIdList><ArticleId IdType="pubmed">14684455</ArticleId></ArticleIdList></Reference><Reference><Citation>Stem Cell Reports. 2020 Jul 14;15(1):38-51</Citation><ArticleIdList><ArticleId IdType="pubmed">32502466</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroendocrinol. 2018 Feb;30(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">29024164</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 1995 Jan;9(1):57-63</Citation><ArticleIdList><ArticleId IdType="pubmed">22298694</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2009 Nov;50(11):1801-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19837763</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2020 Jul;16(7):366-379</Citation><ArticleIdList><ArticleId IdType="pubmed">32528109</ArticleId></ArticleIdList></Reference><Reference><Citation>Endocrinology. 1992 Aug;131(2):662-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1353442</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2020 Jul;87:634-644</Citation><ArticleIdList><ArticleId IdType="pubmed">32109548</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Stem Cell. 2017 Aug 3;21(2):195-208.e6</Citation><ArticleIdList><ArticleId IdType="pubmed">28736215</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2019 Oct;151(2):139-165</Citation><ArticleIdList><ArticleId IdType="pubmed">31318452</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 2009 May;40(5):1842-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19265047</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2017 Apr 15;1661:15-23</Citation><ArticleIdList><ArticleId IdType="pubmed">28202255</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Dev Res. 2016 Nov;77(7):400-406</Citation><ArticleIdList><ArticleId IdType="pubmed">27539538</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Endocrinol. 2002 Oct;29(2):175-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12370120</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2017 Sep;187:62-66</Citation><ArticleIdList><ArticleId IdType="pubmed">27839913</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1991 Oct;148(10):1301-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1654746</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16577-16582</Citation><ArticleIdList><ArticleId IdType="pubmed">31371505</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1965 Nov;122(5):509-22</Citation><ArticleIdList><ArticleId IdType="pubmed">5319766</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2018 Feb;227:31-37</Citation><ArticleIdList><ArticleId IdType="pubmed">29049933</ArticleId></ArticleIdList></Reference><Reference><Citation>Stem Cells. 2019 Apr;37(4):476-488</Citation><ArticleIdList><ArticleId IdType="pubmed">30664289</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 Sep 19;501(7467):373-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23995685</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Int. 2016 Sep;98:56-71</Citation><ArticleIdList><ArticleId IdType="pubmed">27013346</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:207-19</Citation><ArticleIdList><ArticleId IdType="pubmed">26190834</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2002 May 1;55(1-2):1-10</Citation><ArticleIdList><ArticleId IdType="pubmed">11955958</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomics. 1995 Sep 1;29(1):217-24</Citation><ArticleIdList><ArticleId IdType="pubmed">8530074</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2002 Jan 24;21(5):836-43</Citation><ArticleIdList><ArticleId IdType="pubmed">11850811</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 2002 Feb 15;67(4):544-50</Citation><ArticleIdList><ArticleId IdType="pubmed">11835321</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 2012 Jul;32(7):1107-38</Citation><ArticleIdList><ArticleId IdType="pubmed">22186669</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2013 Feb;27(2):135-53</Citation><ArticleIdList><ArticleId IdType="pubmed">23371914</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2015 Apr;14(4):388-405</Citation><ArticleIdList><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2002 Oct 1;22(19):8391-401</Citation><ArticleIdList><ArticleId IdType="pubmed">12351713</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2007 Jan;8(1):57-69</Citation><ArticleIdList><ArticleId IdType="pubmed">17180163</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 2019 Aug;97(8):897-913</Citation><ArticleIdList><ArticleId IdType="pubmed">30883896</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2019 Aug;278:180-187</Citation><ArticleIdList><ArticleId IdType="pubmed">31207455</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Endocrinol. 2018 Oct 8;2018:9516592</Citation><ArticleIdList><ArticleId IdType="pubmed">30402099</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2017 Aug 16;95(4):779-790.e6</Citation><ArticleIdList><ArticleId IdType="pubmed">28817799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Dec;11(8):787-806</Citation><ArticleIdList><ArticleId IdType="pubmed">19922550</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2017 Oct 11;550(7675):204-213</Citation><ArticleIdList><ArticleId IdType="pubmed">29022597</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2007 Jun;21(4):440-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17259207</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2010 Nov 5;330(6005):841-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychiatr Dis Treat. 2015 Dec 17;11:3111-25</Citation><ArticleIdList><ArticleId IdType="pubmed">26719696</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Biol Med. 2012 Jun 1-15;52(11-12):2151-60</Citation><ArticleIdList><ArticleId IdType="pubmed">22554613</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Psychiatry. 2015 Mar;2(3):258-270</Citation><ArticleIdList><ArticleId IdType="pubmed">26359903</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Psychiatry. 2017 Jan;4(1):8-9</Citation><ArticleIdList><ArticleId IdType="pubmed">27856397</ArticleId></ArticleIdList></Reference><Reference><Citation>J Bioenerg Biomembr. 2015 Apr;47(1-2):173-88</Citation><ArticleIdList><ArticleId IdType="pubmed">25293493</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurosci. 2017 Aug 04;11:440</Citation><ArticleIdList><ArticleId IdType="pubmed">28824363</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Biochem Biophys. 2013 Jun;534(1-2):3-10</Citation><ArticleIdList><ArticleId IdType="pubmed">23111185</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Sci. 2018 Aug 13;8(8):</Citation><ArticleIdList><ArticleId IdType="pubmed">30104506</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Dec;60(12):1187-92</Citation><ArticleIdList><ArticleId IdType="pubmed">14662550</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2009 Jan 17;373(9659):234-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19150704</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2018 Feb 9;359(6376):693-697</Citation><ArticleIdList><ArticleId IdType="pubmed">29439242</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2009 Mar 11;29(10):3276-87</Citation><ArticleIdList><ArticleId IdType="pubmed">19279265</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2019 Jan 25;363(6425):</Citation><ArticleIdList><ArticleId IdType="pubmed">30679343</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1988;14(2):297-315</Citation><ArticleIdList><ArticleId IdType="pubmed">3059473</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2017 Mar;181:75-82</Citation><ArticleIdList><ArticleId IdType="pubmed">28277309</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurosci. 2020 Jul 29;14:796</Citation><ArticleIdList><ArticleId IdType="pubmed">32848567</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2020 Mar 1;177(3):223-232</Citation><ArticleIdList><ArticleId IdType="pubmed">31906708</ArticleId></ArticleIdList></Reference><Reference><Citation>eNeuro. 2020 Jul 2;7(4):</Citation><ArticleIdList><ArticleId IdType="pubmed">32554430</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Neurosci. 2005 Feb 24;6:13</Citation><ArticleIdList><ArticleId IdType="pubmed">15730564</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmaceuticals (Basel). 2018 Jun 04;11(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">29867038</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2016 Jun 28;6(6):e844</Citation><ArticleIdList><ArticleId IdType="pubmed">27351598</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 1997 Apr;51(4):535-41</Citation><ArticleIdList><ArticleId IdType="pubmed">9106616</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucosal Immunol. 2017 Sep;10(5):1097-1107</Citation><ArticleIdList><ArticleId IdType="pubmed">28401937</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Endocrinol. 2015;2015:615356</Citation><ArticleIdList><ArticleId IdType="pubmed">26491441</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Endocrinol. 2014 May 25;389(1-2):48-57</Citation><ArticleIdList><ArticleId IdType="pubmed">24444786</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1981 Apr;138(4):460-4</Citation><ArticleIdList><ArticleId IdType="pubmed">6111227</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2016 Nov;19(11):1442-1453</Citation><ArticleIdList><ArticleId IdType="pubmed">27668389</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet C Semin Med Genet. 2003 Nov 15;123C(1):48-58</Citation><ArticleIdList><ArticleId IdType="pubmed">14601036</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2010 Apr;6(4):193-201</Citation><ArticleIdList><ArticleId IdType="pubmed">20234358</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2018 Dec 14;362(6420):</Citation><ArticleIdList><ArticleId IdType="pubmed">30545857</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2016 Jan 6;89(1):37-53</Citation><ArticleIdList><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Hypotheses. 2013 Jun;80(6):791-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23557849</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2003 Dec;1007:54-63</Citation><ArticleIdList><ArticleId IdType="pubmed">14993040</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol Endocrinol Metab. 2008 Sep;295(3):E637-47</Citation><ArticleIdList><ArticleId IdType="pubmed">18577698</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2018 Dec 20;87(Pt A):126-146</Citation><ArticleIdList><ArticleId IdType="pubmed">28989099</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1996 Sep 15;40(6):497-502</Citation><ArticleIdList><ArticleId IdType="pubmed">8879469</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 1997 Dec 1;388(4):507-25</Citation><ArticleIdList><ArticleId IdType="pubmed">9388012</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Int. 2007 Jul-Sep;51(2-4):173-84</Citation><ArticleIdList><ArticleId IdType="pubmed">17669558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippocampus. 2012 Apr;22(4):656-69</Citation><ArticleIdList><ArticleId IdType="pubmed">21538657</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2016 Sep;21(9):1167-79</Citation><ArticleIdList><ArticleId IdType="pubmed">27240529</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerebellum. 2018 Feb;17(1):37-41</Citation><ArticleIdList><ArticleId IdType="pubmed">29196977</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1998 Apr 1;18(7):2550-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9502814</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2018 Jun;177(4):454-467</Citation><ArticleIdList><ArticleId IdType="pubmed">29704319</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2016 May 19;165(5):1238-1254</Citation><ArticleIdList><ArticleId IdType="pubmed">27118425</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2017 May 4;545(7652):54-59</Citation><ArticleIdList><ArticleId IdType="pubmed">28445465</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2015 Jan;48:10-21</Citation><ArticleIdList><ArticleId IdType="pubmed">25446950</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10625-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7938003</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1992 May;58(5):1923-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1373180</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2020 Jan 21;10(1):16</Citation><ArticleIdList><ArticleId IdType="pubmed">32066698</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2016 May;54:38-44</Citation><ArticleIdList><ArticleId IdType="pubmed">26674997</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 2019 Nov;176(21):4119-4135</Citation><ArticleIdList><ArticleId IdType="pubmed">30658014</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Biomed Sci. 2014 Jun;10(2):85-102</Citation><ArticleIdList><ArticleId IdType="pubmed">25018677</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2008 Aug;131(Pt 8):2061-70</Citation><ArticleIdList><ArticleId IdType="pubmed">18669513</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2018 Mar 15;83(6):492-498</Citation><ArticleIdList><ArticleId IdType="pubmed">28987712</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1996 Jul 5;212(1):13-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8823751</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2008 Aug 1;17(15):2293-309</Citation><ArticleIdList><ArticleId IdType="pubmed">18424448</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12698-703</Citation><ArticleIdList><ArticleId IdType="pubmed">20616000</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2010 Apr;67(4):360-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20368511</ArticleId></ArticleIdList></Reference><Reference><Citation>NPJ Parkinsons Dis. 2019 Apr 5;5:5</Citation><ArticleIdList><ArticleId IdType="pubmed">30963107</ArticleId></ArticleIdList></Reference><Reference><Citation>EBioMedicine. 2019 Dec;50:274-289</Citation><ArticleIdList><ArticleId IdType="pubmed">31787569</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2010 Aug;12(4):335-44</Citation><ArticleIdList><ArticleId IdType="pubmed">20556669</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Aug;11(5):523-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19624391</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2018 Feb 20;48(2):380-395.e6</Citation><ArticleIdList><ArticleId IdType="pubmed">29426702</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Transplant. 2016 Oct;25(10):1833-1852</Citation><ArticleIdList><ArticleId IdType="pubmed">27075820</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroendocrinol. 2012 Jan;24(1):236-48</Citation><ArticleIdList><ArticleId IdType="pubmed">22070562</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2019 May 30;177(6):1522-1535.e14</Citation><ArticleIdList><ArticleId IdType="pubmed">31130380</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2019 Jun;570(7762):523-527</Citation><ArticleIdList><ArticleId IdType="pubmed">31168097</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2015 Feb 20;12:32</Citation><ArticleIdList><ArticleId IdType="pubmed">25889641</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2017 Oct;65:342-349</Citation><ArticleIdList><ArticleId IdType="pubmed">28619247</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1999 Nov-Dec;33(6):523-33</Citation><ArticleIdList><ArticleId IdType="pubmed">10628529</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2002 Mar;160(3):271-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11889496</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2019 Aug;19(8):477-489</Citation><ArticleIdList><ArticleId IdType="pubmed">31036962</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 1999 Dec;2(4):245-253</Citation><ArticleIdList><ArticleId IdType="pubmed">11285140</ArticleId></ArticleIdList></Reference><Reference><Citation>Mech Ageing Dev. 2020 Apr;187:111216</Citation><ArticleIdList><ArticleId IdType="pubmed">32084458</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2019 May;51(5):793-803</Citation><ArticleIdList><ArticleId IdType="pubmed">31043756</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2006 Oct;63(10):1372-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17030651</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2009 Sep;57(3):193-200</Citation><ArticleIdList><ArticleId IdType="pubmed">19523965</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2019 Aug;106:284-292</Citation><ArticleIdList><ArticleId IdType="pubmed">31039525</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2019 Jun;44(7):1291-1299</Citation><ArticleIdList><ArticleId IdType="pubmed">30575805</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2009 Oct 14;29(41):12982-93</Citation><ArticleIdList><ArticleId IdType="pubmed">19828812</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2004 Apr 1;67(2-3):269-75</Citation><ArticleIdList><ArticleId IdType="pubmed">14984887</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat New Biol. 1971 Nov 24;234(47):124-5</Citation><ArticleIdList><ArticleId IdType="pubmed">5289225</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1974;11:13-23</Citation><ArticleIdList><ArticleId IdType="pubmed">4461784</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2006 Oct;29(10):547-53</Citation><ArticleIdList><ArticleId IdType="pubmed">16938356</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroendocrinology. 2005;81(3):193-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16020928</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2011 Dec;168(12):1303-10</Citation><ArticleIdList><ArticleId IdType="pubmed">22193673</ArticleId></ArticleIdList></Reference><Reference><Citation>Stem Cell Reports. 2016 Apr 12;6(4):511-524</Citation><ArticleIdList><ArticleId IdType="pubmed">26997644</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2009 Jan 23;158(2):456-64</Citation><ArticleIdList><ArticleId IdType="pubmed">19049819</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 1998 Mar 9;9(4):593-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9559922</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2020 Nov;25(11):2873-2888</Citation><ArticleIdList><ArticleId IdType="pubmed">31019265</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2012 Apr 18;13(5):293-307</Citation><ArticleIdList><ArticleId IdType="pubmed">22510887</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2018 Jul;197:288-293</Citation><ArticleIdList><ArticleId IdType="pubmed">29395611</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2007 Nov 30;131(5):861-72</Citation><ArticleIdList><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2003 Nov 1;63(21):7158-66</Citation><ArticleIdList><ArticleId IdType="pubmed">14612509</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2018 Jul;265:25-38</Citation><ArticleIdList><ArticleId IdType="pubmed">29680514</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2011 Sep;131(1-3):101-4</Citation><ArticleIdList><ArticleId IdType="pubmed">21741216</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 2007 Aug 20;503(6):790-802</Citation><ArticleIdList><ArticleId IdType="pubmed">17570500</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2001 Nov;36(2):180-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11596126</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurosci. 2017 Sep 07;11:493</Citation><ArticleIdList><ArticleId IdType="pubmed">28936160</ArticleId></ArticleIdList></Reference><Reference><Citation>J Vis Exp. 2020 Jun 13;(160):</Citation><ArticleIdList><ArticleId IdType="pubmed">32597849</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2018 Oct 9;9(1):4167</Citation><ArticleIdList><ArticleId IdType="pubmed">30301888</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2018 Nov 10;392(10159):1923-1994</Citation><ArticleIdList><ArticleId IdType="pubmed">30496105</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2000 Nov;5(6):578-93</Citation><ArticleIdList><ArticleId IdType="pubmed">11126389</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Mol Neurosci. 2018 Feb 08;11:13</Citation><ArticleIdList><ArticleId IdType="pubmed">29472840</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurotoxicology. 1998 Apr;19(2):269-81</Citation><ArticleIdList><ArticleId IdType="pubmed">9553964</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2019 Apr;102:84-94</Citation><ArticleIdList><ArticleId IdType="pubmed">30529907</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2012 Mar;120(6):948-63</Citation><ArticleIdList><ArticleId IdType="pubmed">22182318</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2015 Mar;20(3):361-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24686136</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Pharmacol. 2020 Feb 07;10:1612</Citation><ArticleIdList><ArticleId IdType="pubmed">32116664</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Res. 1997;46(1):59-68</Citation><ArticleIdList><ArticleId IdType="pubmed">9728523</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscientist. 2015 Jun;21(3):306-21</Citation><ArticleIdList><ArticleId IdType="pubmed">24871624</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2009 Jan;14(1):10-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19002139</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2016 Sep 12;6:33095</Citation><ArticleIdList><ArticleId IdType="pubmed">27615800</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Sci. 2017 Oct 30;7(11):</Citation><ArticleIdList><ArticleId IdType="pubmed">29084144</ArticleId></ArticleIdList></Reference><Reference><Citation>J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S3-23</Citation><ArticleIdList><ArticleId IdType="pubmed">20176265</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2017 May 15;36(10):1316-1329</Citation><ArticleIdList><ArticleId IdType="pubmed">28283582</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2020 Feb 26;11:71</Citation><ArticleIdList><ArticleId IdType="pubmed">32174850</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2019 Dec;51(12):1670-1678</Citation><ArticleIdList><ArticleId IdType="pubmed">31740837</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Transplant. 2012;21(7):1547-59</Citation><ArticleIdList><ArticleId IdType="pubmed">21975034</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2018 Oct;19(10):610-621</Citation><ArticleIdList><ArticleId IdType="pubmed">30206330</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neuroendocrinol. 2017 Oct;47:19-33</Citation><ArticleIdList><ArticleId IdType="pubmed">28673758</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biol. 1998 Jan;18(1):442-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9418891</ArticleId></ArticleIdList></Reference><Reference><Citation>Endocrinology. 2004 Nov;145(11):5080-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15308615</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2013 Feb;43(2):239-57</Citation><ArticleIdList><ArticleId IdType="pubmed">22717193</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2010 Mar;167(3):261-80</Citation><ArticleIdList><ArticleId IdType="pubmed">20123911</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Psychiatry. 2016 Feb;3(2):171-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26851330</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2005 Apr;6(4):312-24</Citation><ArticleIdList><ArticleId IdType="pubmed">15803162</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurosci. 2018 May 11;12:296</Citation><ArticleIdList><ArticleId IdType="pubmed">29867314</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2004 Oct 1;500(1-3):399-411</Citation><ArticleIdList><ArticleId IdType="pubmed">15464048</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2011 May 12;473(7346):221-5</Citation><ArticleIdList><ArticleId IdType="pubmed">21490598</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2013 Oct;150(1):114-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23938177</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neuroendocrinol. 2019 Apr;53:100743</Citation><ArticleIdList><ArticleId IdType="pubmed">30922675</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Neurobiol. 1996 Jun;16(3):325-44</Citation><ArticleIdList><ArticleId IdType="pubmed">8818400</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 2004 May 1;76(3):306-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15079859</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2016 Aug;56:21-33</Citation><ArticleIdList><ArticleId IdType="pubmed">26348581</ArticleId></ArticleIdList></Reference><Reference><Citation>Endocrinology. 2001 Mar;142(3):969-73</Citation><ArticleIdList><ArticleId IdType="pubmed">11181507</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2017 Jul 21;14(1):141</Citation><ArticleIdList><ArticleId IdType="pubmed">28732515</ArticleId></ArticleIdList></Reference><Reference><Citation>Horm Behav. 2015 Aug;74:228-42</Citation><ArticleIdList><ArticleId IdType="pubmed">26143621</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Neurosci. 2019 Feb;67(2):265-275</Citation><ArticleIdList><ArticleId IdType="pubmed">30547416</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Endocrinol. 2008 Mar;22(3):609-22</Citation><ArticleIdList><ArticleId IdType="pubmed">18048642</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Rev. 2006 Sep;52(2):293-304</Citation><ArticleIdList><ArticleId IdType="pubmed">16759710</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurosci. 2014 Oct 07;8:315</Citation><ArticleIdList><ArticleId IdType="pubmed">25339862</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2019 Jun 10;9(1):8367</Citation><ArticleIdList><ArticleId IdType="pubmed">31182728</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2015 Feb;29(2):97-115</Citation><ArticleIdList><ArticleId IdType="pubmed">25586400</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2019 Jun 29;20(13):</Citation><ArticleIdList><ArticleId IdType="pubmed">31261897</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 1990;358:7-13</Citation><ArticleIdList><ArticleId IdType="pubmed">1978495</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 2007;(434):41-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17688462</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Nov 15;58(10):812-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16112656</ArticleId></ArticleIdList></Reference><Reference><Citation>NPJ Schizophr. 2018 Jan 10;4(1):1</Citation><ArticleIdList><ArticleId IdType="pubmed">29321530</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2017 Jun 6;12(6):e0178533</Citation><ArticleIdList><ArticleId IdType="pubmed">28586384</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2017 May;22(5):666-679</Citation><ArticleIdList><ArticleId IdType="pubmed">28289283</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroendocrinol. 2012 Jan;24(1):183-90</Citation><ArticleIdList><ArticleId IdType="pubmed">21564348</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2006 Mar 1;26(9):2571-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16510735</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2013 Jul 5;711(1-3):73-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23652162</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2012 Jul;73(7):1025-33</Citation><ArticleIdList><ArticleId IdType="pubmed">22901352</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2000 Nov 1;60(21):5977-83</Citation><ArticleIdList><ArticleId IdType="pubmed">11085516</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Oncol. 2007 Sep;1(2):138-43</Citation><ArticleIdList><ArticleId IdType="pubmed">19383291</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2009 Jul 7;161(3):877-86</Citation><ArticleIdList><ArticleId IdType="pubmed">19289156</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunobiology. 2006;211(6-8):511-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16920490</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Jun;11 Suppl 2:4-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19538681</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2017 Jun 15;12(6):e0179020</Citation><ArticleIdList><ArticleId IdType="pubmed">28617822</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):136-41</Citation><ArticleIdList><ArticleId IdType="pubmed">16996188</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2011 Aug;25(6):1206-13</Citation><ArticleIdList><ArticleId IdType="pubmed">21443944</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2018 Jun;36(5):432-441</Citation><ArticleIdList><ArticleId IdType="pubmed">29658944</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Neurodegener. 2019 Jul 12;8:21</Citation><ArticleIdList><ArticleId IdType="pubmed">31338163</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2016 Oct;41(11):2723-32</Citation><ArticleIdList><ArticleId IdType="pubmed">27272766</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2011 Mar 3;471(7336):63-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21368825</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2019 Mar;148(6):731-745</Citation><ArticleIdList><ArticleId IdType="pubmed">30582748</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Dev Brain Res. 2002 Jul 30;137(1):23-34</Citation><ArticleIdList><ArticleId IdType="pubmed">12128251</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2012 Aug;139(1-3):161-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22704639</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1987 Jan 6;400(2):353-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2880640</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2019 Oct 3;179(2):292-311</Citation><ArticleIdList><ArticleId IdType="pubmed">31585077</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20488462</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2011</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1379</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>White matter hyperintensities in affected and unaffected late teenage and early adulthood offspring of bipolar parents: a two-center high-risk study.</ArticleTitle><Pagination><MedlinePgn>76-82</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2010.04.019</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">White matter hyperintensities (WMHs) are among the most replicated neuroimaging findings in bipolar disorder (BD). It is not clear whether these lesions are an artifact of comorbid conditions, or whether they are directly associated with the disorder, or even represent biological risk factor for BD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To test whether WMHs meet criteria for an endophenotype of BD, we conducted a high-risk design study and recruited 35 affected, 44 unaffected relatives of bipolar probands (age range 15-30 years), matched by age and sex with 49 healthy controls without any personal or family history of psychiatric disorders. The presence of WMHs was determined from Fluid Attenuated Inversion Recovery (FLAIR) scans acquired on a 1.5 Tesla scanner using a validated semi-quantitative scale.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found mostly low grade WMHs in all groups. The proportion of WMH-positive subjects was comparable between the unaffected high-risk, affected familial and control groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">White matter hyperintensities did not meet criteria for an endophenotype of BD. Bipolar disorder in young subjects without comorbid conditions was not associated with increased rate of WMHs.</AbstractText><CopyrightInformation>Copyright ÃÂ© 2010 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gunde</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, Dalhousie University, Halifax, Nova Scotia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novak</LastName><ForeName>Tomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kopecek</LastName><ForeName>Miloslav</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Propper</LastName><ForeName>Lukas</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Stopkova</LastName><ForeName>Pavla</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>HÃ¶schl</LastName><ForeName>Cyril</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Duffy</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Alda</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hajek</LastName><ForeName>Tomas</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016241" MajorTopicYN="N">Child of Impaired Parents</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005192" MajorTopicYN="Y">Family Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009413" MajorTopicYN="N">Nerve Fibers, Myelinated</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>04</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>04</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20488462</ArticleId><ArticleId IdType="pii">S0022-3956(10)00129-9</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2010.04.019</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18037498</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>109</Volume><Issue>1-2</Issue><PubDate><Year>2008</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Treatment of bipolar depression: an update.</ArticleTitle><Pagination><MedlinePgn>21-34</MedlinePgn></Pagination><Abstract><AbstractText>This article attempts to summarize the current status of our knowledge and practice in the acute treatment and prophylaxis of bipolar depression. For prophylactic treatment, our knowledge about lithium firmly supports its usefulness against bipolar depression and its specific effectiveness for suicidal prevention. Valproic acid and carbamazepine could be effective, too, while lamotrigine which seems to be preferably effective against depression but not mania. The FDA has approved the olanzapine-fluoxetine combination and quetiapine monotherapy for the treatment of acute bipolar depression. The usefulness of antidepressants in bipolar depression is controversial both for acute and prophylactic treatment; guidelines suggest their cautious use and always in combination with an antimanic and mood stabilizer agent, because in some patients they may induce switching to mania or hypomania, mixed episodes and rapid cycling. Data on psychosocial intervention are restricted to the maintenance phase. Electroconvulsive therapy and transcranial magnetic stimulation are additional options for refractory patients. Bipolar depression seems to be a more difficult condition to treat than mania. Most patients need complex combination treatment although the published evidence on this type of treatment is limited.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fountoulakis</LastName><ForeName>Konstantinos N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>3rd Department of Psychiatry, Aristotle University of Thessaloniki, Greece. kfount@med.auth.gr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grunze</LastName><ForeName>Heinz</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Panagiotidis</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Kaprinis</LastName><ForeName>George</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>11</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>220</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>07</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18037498</ArticleId><ArticleId IdType="pii">S0165-0327(07)00378-3</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2007.10.016</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9040930</PMID><DateCompleted><Year>1997</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0706-7437</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>1</Issue><PubDate><Year>1997</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Canadian journal of psychiatry. Revue canadienne de psychiatrie</Title><ISOAbbreviation>Can J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Risperidone treatment of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>88-90</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>L T</ForeName><Initials>LT</Initials></Author><Author ValidYN="Y"><LastName>Hasey</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Patelis-Siotis</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>B D</ForeName><Initials>BD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Psychiatry</MedlineTA><NlmUniqueID>7904187</NlmUniqueID><ISSNLinking>0706-7437</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9040930</ArticleId><ArticleId IdType="doi">10.1177/070674379704200123</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19890236</PMID><DateCompleted><Year>2009</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1092-8529</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>8</Issue><PubDate><Year>2009</Year><Month>Aug</Month></PubDate></JournalIssue><Title>CNS spectrums</Title><ISOAbbreviation>CNS Spectr</ISOAbbreviation></Journal><ArticleTitle>Cytokine polymorphisms in the pathophysiology of mood disorders.</ArticleTitle><Pagination><MedlinePgn>419-25</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">An increasing amount of data suggests that dysregulation of the immune system, including the cytokine network, is associated with the etiology and pathophysiology of mood disorders. Genes encoding cytokines are highly polymorphic and single nucleotide polymorphisms, associated with increased or reduced cytokine production, have been described. The aim of this study was to define the genetic immunologic scenario associated with major depressive disorder (MDD) and bipolar disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Eighty-four Italian outpatients affected by bipolar disorder type I, bipolar disorder type II, or MDD, and 363 healthy controls were enrolled into the study. We analyzed allele and genotype distribution of -308 (G/A) tumor necrosis factor-a (TNF-a), +874 (T/A) interferon-g (IFN-g), -174 (G/C) interleukin (IL)-6, and -1082 (G/A) IL-10 promoter polymorphisms by Polymerase Chain Reaction Sequence Specific Primers technique.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We observed different genotype and allele distributions of TNF-a, IFN-g, and IL-10 polymorphisms in the three groups of patients analyzed. In particular, bipolar II patients were characterized by an absence of adenine (A) high producer allele of TNF-a (P&lt;.001) and a lower percentage of TT high producer genotype of IFN-g (P&lt;.001); bipolar I individuals showed reduced percentage of AA low producer genotype of IL-10 (P&lt;.001). Both bipolar I and bipolar II patients not carrying guanine (G) high producer IL-6 allele showed a lower mean age at onset (P=.048).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These data support the existence of a genetic profile related to pro-inflammatory cytokines in patients affected by mood disorders. The differences observed across the three clinical phenotypes suggest the presence of different pathogenetic mechanisms involved in the susceptibility of phenotypically different mood disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clerici</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences and Technologies, University of Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arosio</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Mundo</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Cattaneo</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Pozzoli</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Dell'osso</LastName><ForeName>Bernardo</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Vergani</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Trabattoni</LastName><ForeName>Daria</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Altamura</LastName><ForeName>A Carlo</ForeName><Initials>AC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>CNS Spectr</MedlineTA><NlmUniqueID>9702877</NlmUniqueID><ISSNLinking>1092-8529</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19890236</ArticleId><ArticleId IdType="doi">10.1017/s1092852900020393</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">23246364</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>148</Volume><Issue>2-3</Issue><PubDate><Year>2013</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>The impact of childhood trauma on cognitive functioning in patients recently recovered from a first manic episode: data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).</ArticleTitle><Pagination><MedlinePgn>424-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2012.11.022</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(12)00775-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Both bipolar disorder (BD) and childhood trauma are associated with cognitive impairment. People with BD have high rates of childhood trauma, which confer greater overall disease severity, but, it is unknown if childhood trauma is associated with greater neurocognitive impairment in BD patients early in the course of their illnesses. In this study, we investigated the impact of childhood trauma on specific cognitive dysfunction in patients who recently recovered from their first episode of mania.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data were available for 64 patients and 28 healthy subjects matched by age, gender and pre-morbid IQ, recruited from a large university medical center. History of childhood trauma was measured using the Childhood Trauma Questionnaire. Cognitive function was assessed through a comprehensive neuropsychological test battery.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Trauma was associated with poorer cognitive performance in patients on cognitive measures of IQ, auditory attention and verbal and working memory, and a different pattern was observed in healthy subjects.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">We had a modest sample size, particularly in the group of healthy subjects with trauma.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Childhood trauma was associated with poorer cognition in BD patients who recently recovered from a first episode of mania compared to healthy subjects. The results require replication, but suggest that the co-occurrence of trauma and bipolar disorder can affect those cognitive areas that are already more susceptible in patients with BD.</AbstractText><CopyrightInformation>Copyright Â© 2012 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>BÃ¼cker</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, Canada BC V6T2A1.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kozicky</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>I J</ForeName><Initials>IJ</Initials></Author><Author ValidYN="Y"><LastName>Kauer-Sant'anna</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Silveira</LastName><ForeName>L E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Bond</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>R W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Yatham</LastName><ForeName>L N</ForeName><Initials>LN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054523" MajorTopicYN="N">Adult Survivors of Child Abuse</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>11</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23246364</ArticleId><ArticleId IdType="pii">S0165-0327(12)00775-6</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2012.11.022</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6729002</PMID><DateCompleted><Year>1984</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0254-4962</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>1984</Year></PubDate></JournalIssue><Title>Psychopathology</Title><ISOAbbreviation>Psychopathology</ISOAbbreviation></Journal><ArticleTitle>Bipolar mood disorders: an affected sibling study. I. Genetic background and course of illness.</ArticleTitle><Pagination><MedlinePgn>67-79</MedlinePgn></Pagination><Abstract><AbstractText>The study uses the 'affected (and hospitalized) siblings method' to investigate aspects of correlation in the psychopathology of bipolar mood disorders. In part one, age of onset, duration of phases, and course of illness are the points of interest. The sample includes 307 sibling groups (701 hospitalized individuals). The incidence of pure or schizoaffective type mania in at least 1 sibling has been the criterion for selection. The genetic background is also presented and the question is raised whether double tainting is the rule rather than the exception. The hypothesis that schizophrenic syndromes and mood disorders develop from separate genetic pools is supported. Strong evidence against the unipolar/bipolar dichotomy is presented. The investigation brings the breadth of the cyclothymic spectrum and inhomogeneity with respect to the course of bipolar disorders into perspective.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pritz</LastName><ForeName>W F</ForeName><Initials>WF</Initials></Author><Author ValidYN="Y"><LastName>Mitterauer</LastName><ForeName>B J</ForeName><Initials>BJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychopathology</MedlineTA><NlmUniqueID>8401537</NlmUniqueID><ISSNLinking>0254-4962</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004200" MajorTopicYN="N">Diseases in Twins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005788" MajorTopicYN="N">Gene Pool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6729002</ArticleId><ArticleId IdType="doi">10.1159/000284006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26876322</PMID><DateCompleted><Year>2016</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-3147</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Psychiatric clinics of North America</Title><ISOAbbreviation>Psychiatr Clin North Am</ISOAbbreviation></Journal><ArticleTitle>Suicide Behaviors in Bipolar Disorder: A Review and Update for the Clinician.</ArticleTitle><Pagination><MedlinePgn>111-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psc.2015.09.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0193-953X(15)00097-0</ELocationID><Abstract><AbstractText>Suicide behaviors (ideation, attempts, and completions) are unfortunately common in patients with bipolar disorder. It is estimated that 25 to 50% attempt suicide at least once during their lifetime, and 6% to 19% complete suicide. Risk factors include a family history of suicide, previous suicide attempts, younger age of onset, comorbid psychiatric illnesses, and psychological constructs like hopelessness. Pharmacologic treatment may impact suicidal behaviors, either increasing vulnerability or resilience. Clinicians need to be particularly sensitive to their patient's thoughts and beliefs about death, particularly during stressful times of life or when in a depressive/mixed episode of bipolar disorder. </AbstractText><CopyrightInformation>Copyright Â© 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beyer</LastName><ForeName>John L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Duke University Medical Center, BoxÂ 3519, Durham, NC 27710, USA. Electronic address: john.beyer@dm.duke.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weisler</LastName><ForeName>Richard H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Duke University Medical Center, BoxÂ 3519, Durham, NC 27710, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychiatr Clin North Am</MedlineTA><NlmUniqueID>7708110</NlmUniqueID><ISSNLinking>0193-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="Y">Suicide, Attempted</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antidepressants</Keyword><Keyword MajorTopicYN="N">Bipolar</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Lithium</Keyword><Keyword MajorTopicYN="N">Risk factors</Keyword><Keyword MajorTopicYN="N">Suicide</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26876322</ArticleId><ArticleId IdType="pii">S0193-953X(15)00097-0</ArticleId><ArticleId IdType="doi">10.1016/j.psc.2015.09.002</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">24581821</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>157</Volume><PubDate><Year>2014</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Affect intensity measure in bipolar disorders: a multidimensional approach.</ArticleTitle><Pagination><MedlinePgn>8-13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2013.12.039</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(13)00892-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Emotional dysregulation, characterized by high levels of both arousal and intensity of emotional responses, is a core feature of bipolar disorders (BDs). In non-clinical populations, the 40-item Affect Intensity Measure (AIM) can be used to assess the different dimensions of emotional reactivity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analyzed the factor structure of the AIM in a sample of 310 euthymic patients with BD using Principal Component Analysis and examined associations between AIM sub-scale scores and demographic and illness characteristics.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The French translation of the AIM demonstrated good reliability. A four-factor solution similar to that reported in non-clinical samples (Positive Affectivity, Unpeacefulness [lack of Serenity], Negative Reactivity, Negative Intensity), explained 47% of the total variance. Age and gender were associated with Unpeacefulness and Negative reactivity respectively. 'Unpeacefulness' was also positively associated with psychotic symptoms at onset (p=0.0006), but negatively associated with co-morbid substance misuse (p=0.008). Negative Intensity was positively associated with social phobia (p=0.0005).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">We cannot definitively exclude a lack of statistical power to classify all AIM items. Euthymia was carefully defined, but a degree of 'contamination' of the self-reported levels of emotion reactivity may occur because of subsyndromal BD symptoms. It was not feasible to control for the possible impact of on-going treatments.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The AIM scale appears to be a useful measure of emotional reactivity and intensity in a clinical sample of patients with BD, suggesting it can be used in addition to other markers of BD characteristics and sub-types.</AbstractText><CopyrightInformation>Copyright Â© 2014 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mathieu</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Inserm, UMR-S958 - GÃ©nÃ©tique des DiabÃ¨tes, Site Villemin, Paris, France. Electronic address: Flavie.Mathieu@inserm.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etain</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Inserm, U955, CrÃ©teil, France; AP-HP, HÃ´pital H. Mondor - A. Chenevier, PÃ´le de Psychiatry, CrÃ©teil, France; Fondation Fondamental, CrÃ©teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daban</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Inserm, U955, CrÃ©teil, France; AP-HP, HÃ´pital H. Mondor - A. Chenevier, PÃ´le de Psychiatry, CrÃ©teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raymond</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Inserm, U955, CrÃ©teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raust</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Inserm, U955, CrÃ©teil, France; AP-HP, HÃ´pital H. Mondor - A. Chenevier, PÃ´le de Psychiatry, CrÃ©teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cochet</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>AP-HP, HÃ´pital H. Mondor - A. Chenevier, PÃ´le de Psychiatry, CrÃ©teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gard</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fondation Fondamental, CrÃ©teil, France; HÃ´pital Charles Perrens, Service de Psychiatrie Adulte, PÃ´le 3-4-7, Bordeaux, France; Laboratoire de Psychologie EA 4139, UniversitÃ© Victor Segalen, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M'Bailara</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Fondation Fondamental, CrÃ©teil, France; HÃ´pital Charles Perrens, Service de Psychiatrie Adulte, PÃ´le 3-4-7, Bordeaux, France; Laboratoire de Psychologie EA 4139, UniversitÃ© Victor Segalen, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desage</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Fondation Fondamental, CrÃ©teil, France; HÃ´pital Charles Perrens, Service de Psychiatrie Adulte, PÃ´le 3-4-7, Bordeaux, France; Laboratoire de Psychologie EA 4139, UniversitÃ© Victor Segalen, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>J P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Fondation Fondamental, CrÃ©teil, France; Service de Psychiatrie et Psychologie Clinique, CHU de Nancy, HÃ´pitaux de Brabois, Vandoeuvre Les Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wajsbrot-Elgrabli</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Fondation Fondamental, CrÃ©teil, France; Service de Psychiatrie et Psychologie Clinique, CHU de Nancy, HÃ´pitaux de Brabois, Vandoeuvre Les Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>R F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Fondation Fondamental, CrÃ©teil, France; Service de Psychiatrie et Psychologie Clinique, CHU de Nancy, HÃ´pitaux de Brabois, Vandoeuvre Les Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azorin</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Fondation Fondamental, CrÃ©teil, France; PÃ´le Universitaire de Psychiatrie, HÃ´pital Ste Marguerite, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leboyer</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Inserm, U955, CrÃ©teil, France; AP-HP, HÃ´pital H. Mondor - A. Chenevier, PÃ´le de Psychiatry, CrÃ©teil, France; Fondation Fondamental, CrÃ©teil, France; UniversitÃ© Paris Est, FacultÃ© de MÃ©decine, CrÃ©teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellivier</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Inserm, U955, CrÃ©teil, France; Fondation Fondamental, CrÃ©teil, France; APHP, HÃ´pital Fernand Widal, PÃ´le Addictologie-Toxicologie-Psychiatrie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Academic Psychiatry, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK; Centre for Affective Disorders, Institute of Psychiatry, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Inserm, U955, CrÃ©teil, France; AP-HP, HÃ´pital H. Mondor - A. Chenevier, PÃ´le de Psychiatry, CrÃ©teil, France; Fondation Fondamental, CrÃ©teil, France; UniversitÃ© Paris Est, FacultÃ© de MÃ©decine, CrÃ©teil, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001143" MajorTopicYN="N">Arousal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="Y">Psychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Arousal</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Emotion</Keyword><Keyword MajorTopicYN="N">Intensity</Keyword><Keyword MajorTopicYN="N">Self-report</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>07</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24581821</ArticleId><ArticleId IdType="pii">S0165-0327(13)00892-6</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2013.12.039</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18281836</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0951-7367</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Current opinion in psychiatry</Title><ISOAbbreviation>Curr Opin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The role of fatty acids in the development and treatment of mood disorders.</ArticleTitle><Pagination><MedlinePgn>19-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/YCO.0b013e3282f29841</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">There is increasing evidence from epidemiological, case-control and randomized clinical trials for a link between omega-3 deficiency and the development of mood disorders. This article examines recent evidence for this association.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">During the past year our understanding of the effect of omega-3 depletion on the structure and function of the brain has been furthered by research examining human brain tissue and by studies utilizing animal models of depression. Human and animal research has also provided further evidence for omega-3 affecting mood via its anti-inflammatory effects. Previous clinical trials indicated that omega-3 can be effective as an adjunctive treatment for those with treatment-resistant depression. More recent clinical trial data indicate that omega-3 may also be an effective monotherapy for childhood depression and for depressed mood in patients who engage in recurrent self-harm. The recent clinical trial data regarding omega-3 as a treatment for bipolar disorder are inconclusive, however, and clinical trials in postnatal depression are still lacking.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">This article reviews the most important recent papers in this burgeoning and interesting research area.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Black Dog Institute, Randwick, New South Wales, Australia. cath.owen@unsw.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rees</LastName><ForeName>Anne-Marie</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Gordon</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Psychiatry</MedlineTA><NlmUniqueID>8809880</NlmUniqueID><ISSNLinking>0951-7367</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="N">Fatty Acids, Omega-3</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>46</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18281836</ArticleId><ArticleId IdType="doi">10.1097/YCO.0b013e3282f29841</ArticleId><ArticleId IdType="pii">00001504-200801000-00005</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28503107</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>05</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-6190</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>04</Month></PubDate></JournalIssue><Title>Current neuropharmacology</Title><ISOAbbreviation>Curr Neuropharmacol</ISOAbbreviation></Journal><ArticleTitle>The Role of Electroconvulsive Therapy (ECT) in Bipolar Disorder: Effectiveness in 522 Patients with Bipolar Depression, Mixed-state, Mania and Catatonic Features.</ArticleTitle><Pagination><MedlinePgn>359-371</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2174/1570159X14666161017233642</ELocationID><Abstract><AbstractText Label="OBJECTIVE">We evaluated the effectiveness of Electroconvulsive Therapy (ECT) in the treatment of Bipolar Disorder (BD) in a large sample of bipolar patients with drug resistant depression, mania, mixed state and catatonic features.</AbstractText><AbstractText Label="METHOD">522 consecutive patients with DSM-IV-TR BD were evaluated prior to and after the ECT course. Responders and nonresponders were compared in subsamples of depressed and mixed patients. Descriptive analyses were reported for patients with mania and with catatonic features.</AbstractText><AbstractText Label="RESULTS">Of the original sample only 22 patients were excluded for the occurrence of side effects or consent withdrawal. After the ECT course, 344 (68.8%) patients were considered responders (final CGIi score â¤2) and 156 (31.2%) nonresponders. Response rates were respectively 68.1% for BD depression, 72.9% for mixed state, 75% for mania and 80.8% for catatonic features. Length of current episode and global severity of the illness were the only statistically significant predictors of nonresponse.</AbstractText><AbstractText Label="CONCLUSION">ECT resulted to be an effective and safe treatment for all the phases of severe and drug-resistant BD. Positive response was observed in approximately two-thirds of the cases and in 80% of the catatonic patients. The duration of the current episode was the major predictor of nonresponse. The risk of ECT-induced mania is virtually absent and mood destabilization very unlikely. Our results clearly indicate that current algorithms for the treatment of depressive, mixed, manic and catatonic states should be modified and, at least for the most severe patients, ECT should not be considered as a "last resort".</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perugi</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Behavioral Science â¨"G. De Lisio", Carrara-Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medda</LastName><ForeName>Pierpaolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toni</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Behavioral Science â¨"G. De Lisio", Carrara-Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariani</LastName><ForeName>Michela Giorgi</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Socci</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mauri</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Neuropharmacol</MedlineTA><NlmUniqueID>101157239</NlmUniqueID><ISSNLinking>1570-159X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002389" MajorTopicYN="N">Catatonia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar Disorder</Keyword><Keyword MajorTopicYN="Y">Bipolar depression</Keyword><Keyword MajorTopicYN="Y">Electroconvulsive Therapy (ECT)</Keyword><Keyword MajorTopicYN="Y">Mania</Keyword><Keyword MajorTopicYN="Y">Mixed State</Keyword><Keyword MajorTopicYN="Y">Mood stabilizer</Keyword><Keyword MajorTopicYN="Y">catatonia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28503107</ArticleId><ArticleId IdType="doi">10.2174/1570159X14666161017233642</ArticleId><ArticleId IdType="pii">CN-15-359</ArticleId><ArticleId IdType="pmc">PMC5405614</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J ECT. 2013 Sep;29(3):179-88</Citation><ArticleIdList><ArticleId IdType="pubmed">23899721</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1974 Mar;30(3):320-1</Citation><ArticleIdList><ArticleId IdType="pubmed">4813135</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002;4 Suppl 1:91-3</Citation><ArticleIdList><ArticleId IdType="pubmed">12479688</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2003 Dec;8(12):1-10; quiz 11</Citation><ArticleIdList><ArticleId IdType="pubmed">14986671</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1982 Aug;12(3):615-24</Citation><ArticleIdList><ArticleId IdType="pubmed">7134319</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 Feb;15(1):1-44</Citation><ArticleIdList><ArticleId IdType="pubmed">23237061</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1996 Mar;60(3):326-32</Citation><ArticleIdList><ArticleId IdType="pubmed">8609512</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2014 Jul;17(7):1053-61</Citation><ArticleIdList><ArticleId IdType="pubmed">24067291</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2010 Jun;71(6):e14</Citation><ArticleIdList><ArticleId IdType="pubmed">20573324</ArticleId></ArticleIdList></Reference><Reference><Citation>Convuls Ther. 1993;9(4):262-273</Citation><ArticleIdList><ArticleId IdType="pubmed">11941222</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1993 Dec;29(4):255-61</Citation><ArticleIdList><ArticleId IdType="pubmed">8126312</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2001 Apr;3(2):95-104</Citation><ArticleIdList><ArticleId IdType="pubmed">11333069</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2014 Dec 09;5:181</Citation><ArticleIdList><ArticleId IdType="pubmed">25538636</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Mar;129(1-3):14-26</Citation><ArticleIdList><ArticleId IdType="pubmed">20538341</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002 Feb;63(2):146-51</Citation><ArticleIdList><ArticleId IdType="pubmed">11874216</ArticleId></ArticleIdList></Reference><Reference><Citation>J ECT. 2013 Sep;29(3):206-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23965606</ArticleId></ArticleIdList></Reference><Reference><Citation>J ECT. 2000 Mar;16(1):1-2</Citation><ArticleIdList><ArticleId IdType="pubmed">10735326</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 May;74(3):279-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12738047</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2003 Jan;4(1):5-13</Citation><ArticleIdList><ArticleId IdType="pubmed">12582971</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Sep;10(6):701-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18837864</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Jun;8(3):304-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16696836</ArticleId></ArticleIdList></Reference><Reference><Citation>J ECT. 2012 Jun;28(2):118-23</Citation><ArticleIdList><ArticleId IdType="pubmed">22531205</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2015 Jan;172(1):41-51</Citation><ArticleIdList><ArticleId IdType="pubmed">25219389</ArticleId></ArticleIdList></Reference><Reference><Citation>J ECT. 2010 Jun;26(2):82-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19710623</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Aug;152(8):1130-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7625459</ArticleId></ArticleIdList></Reference><Reference><Citation>Convuls Ther. 1996 Sep;12(3):138-46</Citation><ArticleIdList><ArticleId IdType="pubmed">8872401</ArticleId></ArticleIdList></Reference><Reference><Citation>J ECT. 2003 Sep;19(3):139-47</Citation><ArticleIdList><ArticleId IdType="pubmed">12972983</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1995 Jan;56(1):5-13</Citation><ArticleIdList><ArticleId IdType="pubmed">7836345</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999;60 Suppl 5:5-13; discussion 14-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10192402</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Jun;7(3):205-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15898959</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1997 Sep 1;42(5):375-81</Citation><ArticleIdList><ArticleId IdType="pubmed">9276078</ArticleId></ArticleIdList></Reference><Reference><Citation>J ECT. 2010 Dec;26(4):248-52</Citation><ArticleIdList><ArticleId IdType="pubmed">19935090</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2012 Aug;262(5):425-30</Citation><ArticleIdList><ArticleId IdType="pubmed">22207031</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):727-30</Citation><ArticleIdList><ArticleId IdType="pubmed">17291654</ArticleId></ArticleIdList></Reference><Reference><Citation>Convuls Ther. 1992;8(3):174-178</Citation><ArticleIdList><ArticleId IdType="pubmed">11941167</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Mar;14(2):146-50</Citation><ArticleIdList><ArticleId IdType="pubmed">22420590</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1996 Feb;93(2):129-36</Citation><ArticleIdList><ArticleId IdType="pubmed">8686483</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 2000 Sep;12 (3):167-70</Citation><ArticleIdList><ArticleId IdType="pubmed">10984007</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1994 Jun;164(6):806-10</Citation><ArticleIdList><ArticleId IdType="pubmed">7952988</ArticleId></ArticleIdList></Reference><Reference><Citation>J ECT. 2000 Jun;16(2):97-109</Citation><ArticleIdList><ArticleId IdType="pubmed">10868320</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2001 Aug;158(8):1265-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11481161</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2011 Aug;68(8):791-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21810644</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1975 Nov;12(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Jan;112(1-3):212-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18501434</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Nov;118(1-3):55-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19223079</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Jun;11(4):418-24</Citation><ArticleIdList><ArticleId IdType="pubmed">19500095</ArticleId></ArticleIdList></Reference><Reference><Citation>Convuls Ther. 1988;4(4):306-313</Citation><ArticleIdList><ArticleId IdType="pubmed">11940980</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Pract. 2013 Jan;19(1):15-28</Citation><ArticleIdList><ArticleId IdType="pubmed">23334676</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2003 Dec;5(6):417-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14609495</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2008 Nov;118(5):347-56</Citation><ArticleIdList><ArticleId IdType="pubmed">18727689</ArticleId></ArticleIdList></Reference><Reference><Citation>Convuls Ther. 1988;4(1):81-83</Citation><ArticleIdList><ArticleId IdType="pubmed">11940945</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Rev. 2004 Oct;111(4):984-1002</Citation><ArticleIdList><ArticleId IdType="pubmed">15482070</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Jun;59(6):530-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12044195</ArticleId></ArticleIdList></Reference><Reference><Citation>Convuls Ther. 1994 Sep;10(3):195-205</Citation><ArticleIdList><ArticleId IdType="pubmed">7834256</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2001 Aug;52(8):1033-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11474046</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 Jan;170(1):31-42</Citation><ArticleIdList><ArticleId IdType="pubmed">23223893</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1986 Jul;47(7):366-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3722132</ArticleId></ArticleIdList></Reference><Reference><Citation>Convuls Ther. 1992;8(3):163-173</Citation><ArticleIdList><ArticleId IdType="pubmed">11941166</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1997 Jul-Aug;38(4):193-201</Citation><ArticleIdList><ArticleId IdType="pubmed">9202876</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2010 Sep-Oct;51(5):497-503</Citation><ArticleIdList><ArticleId IdType="pubmed">20728007</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Dec;5(6):421-33</Citation><ArticleIdList><ArticleId IdType="pubmed">14636365</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 2013;(441):1-47</Citation><ArticleIdList><ArticleId IdType="pubmed">23215963</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Sep;133(1-2):105-13</Citation><ArticleIdList><ArticleId IdType="pubmed">21514674</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2015 Sep;76(9):e1151-2</Citation><ArticleIdList><ArticleId IdType="pubmed">26455688</ArticleId></ArticleIdList></Reference><Reference><Citation>J ECT. 2016 Mar;32(1):23-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26172058</ArticleId></ArticleIdList></Reference><Reference><Citation>J ECT. 2010 Dec;26(4):278-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21155154</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2010 Jun;121(6):431-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19895623</ArticleId></ArticleIdList></Reference><Reference><Citation>J ECT. 2008 Sep;24(3):199-202</Citation><ArticleIdList><ArticleId IdType="pubmed">18772704</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Jul;116(1-2):106-12</Citation><ArticleIdList><ArticleId IdType="pubmed">19081638</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2014 Jan;129(1):4-16</Citation><ArticleIdList><ArticleId IdType="pubmed">23600771</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 May;11(3):289-97</Citation><ArticleIdList><ArticleId IdType="pubmed">19419386</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2009 Jun;23(4):346-88</Citation><ArticleIdList><ArticleId IdType="pubmed">19329543</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2003;17(1):9-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12467490</ArticleId></ArticleIdList></Reference><Reference><Citation>J ECT. 2016 Sep;32(3):149-50</Citation><ArticleIdList><ArticleId IdType="pubmed">27428478</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2007 Apr 26;356(17):1711-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17392295</ArticleId></ArticleIdList></Reference><Reference><Citation>Convuls Ther. 1986;2(4):231-237</Citation><ArticleIdList><ArticleId IdType="pubmed">11940870</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2010 Apr;67(4):339-47</Citation><ArticleIdList><ArticleId IdType="pubmed">20368510</ArticleId></ArticleIdList></Reference><Reference><Citation>J ECT. 2000 Mar;16(1):32-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10735329</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Jul;132(1-2):1-13</Citation><ArticleIdList><ArticleId IdType="pubmed">20858566</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2009;70 Suppl 4:1-46; quiz 47-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19686636</ArticleId></ArticleIdList></Reference><Reference><Citation>J ECT. 2007 Dec;23(4):233-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18090694</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2007;21(1):47-71</Citation><ArticleIdList><ArticleId IdType="pubmed">17190529</ArticleId></ArticleIdList></Reference><Reference><Citation>J ECT. 2011 Jun;27(2):123-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20559148</ArticleId></ArticleIdList></Reference><Reference><Citation>Postgrad Med. 2000 Apr;Spec No:1-104</Citation><ArticleIdList><ArticleId IdType="pubmed">10895797</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Dec;67(1-3):105-14</Citation><ArticleIdList><ArticleId IdType="pubmed">11869757</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 2011 Spring;23(2):223-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21677256</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 1997 Aug;42 Suppl 2:79S-86S</Citation><ArticleIdList><ArticleId IdType="pubmed">9288440</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2001 Jul;62(7):552-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11488367</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Mar 8;361(9360):799-808</Citation><ArticleIdList><ArticleId IdType="pubmed">12642045</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2008 Jan;23(1):53-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18191551</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Jun;159(6):1005-10</Citation><ArticleIdList><ArticleId IdType="pubmed">12042190</ArticleId></ArticleIdList></Reference><Reference><Citation>J ECT. 2000 Jun;16(2):183-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10868328</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6131496</PMID><DateCompleted><Year>1983</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0278-5846</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>4-6</Issue><PubDate><Year>1982</Year></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Current psychopharmacogenetic strategies in primary affective disorders.</ArticleTitle><Pagination><MedlinePgn>675-9</MedlinePgn></Pagination><Abstract><AbstractText>1. The evidence is substantial that primary affective disorders are genetically inherited. 2. Using pharmacological probes or strategies, biological markers of the gene(s) should be able to be ascertained or induced during remission of illness. 3. Genetic marker criteria are defined and are applied to the scanty existing data. 4. It is concluded that these strategies have yet to yield a clear marker of primary affective disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Waters</LastName><ForeName>B G</ForeName><Initials>BG</Initials></Author><Author ValidYN="Y"><LastName>Lapierre</LastName><ForeName>Y D</ForeName><Initials>YD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018377">Neurotransmitter Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017981">Receptors, Neurotransmitter</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="Y">Genetic Markers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018377" MajorTopicYN="N">Neurotransmitter Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017981" MajorTopicYN="N">Receptors, Neurotransmitter</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1982</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1982</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1982</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6131496</ArticleId><ArticleId IdType="pii">S0278-5846(82)80168-1</ArticleId><ArticleId IdType="doi">10.1016/s0278-5846(82)80168-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">5884005</PMID><DateCompleted><Year>1966</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-690X</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>4</Issue><PubDate><Year>1965</Year></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Family history, the electroencephalogram and perinatal factors in manic conditions.</ArticleTitle><Pagination><MedlinePgn>527-63</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>DalÃ©n</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001720" MajorTopicYN="N">Birth Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001722" MajorTopicYN="N">Birth Order</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001925" MajorTopicYN="N">Brain Damage, Chronic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008423" MajorTopicYN="N">Maternal Age</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1965</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1965</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1965</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">5884005</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.1965.tb06169.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11481160</PMID><DateCompleted><Year>2001</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>158</Volume><Issue>8</Issue><PubDate><Year>2001</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The familial aggregation of psychotic symptoms in bipolar disorder pedigrees.</ArticleTitle><Pagination><MedlinePgn>1258-64</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Symptomatic overlap between affective disorders and schizophrenia has long been noted. More recently, family and linkage studies have provided some evidence for overlapping genetic susceptibility between bipolar disorder and schizophrenia. If shared genes are responsible for the psychotic manifestations of both disorders, these genes may result in clustering of psychotic symptoms in some bipolar disorder pedigrees. The authors tested this hypothesis in families ascertained for a genetic study of bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Rates of psychotic symptoms-defined as hallucinations or delusions-during affective episodes were compared in families of 47 psychotic and 18 nonpsychotic probands with bipolar I disorder. The analysis included 202 first-degree relatives with major affective disorder.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Significantly more families of psychotic probands than families of nonpsychotic probands (64% versus 28%) contained at least one relative who had affective disorder with psychotic symptoms. Significantly more affectively ill relatives of psychotic probands than of nonpsychotic probands (34% versus 11%) had psychotic symptoms. An analysis of clustering of psychotic subjects across all families revealed significant familial aggregation. Clustering of psychosis was also apparent when only bipolar I disorder was considered the affected phenotype.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Psychotic bipolar disorder may delineate a subtype of value for genetic and biological investigations. Families with this subtype should be used to search for linkage in chromosomal regions 10p12-13, 13q32, 18p11.2, and 22q11-13, where susceptibility genes common to bipolar disorder and schizophrenia may reside. Putative schizophrenia-associated biological markers, such as abnormal evoked response, oculomotor, and neuroimaging measures, could similarly be explored in such families.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Potash</LastName><ForeName>J B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, The Johns Hopkins School of Medicine, 600 North Wolfe St., Baltimore, MD 21287, USA. jpotash@jhmi.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willour</LastName><ForeName>V L</ForeName><Initials>VL</Initials></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Y F</ForeName><Initials>YF</Initials></Author><Author ValidYN="Y"><LastName>Simpson</LastName><ForeName>S G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>MacKinnon</LastName><ForeName>D F</ForeName><Initials>DF</Initials></Author><Author ValidYN="Y"><LastName>Pearlson</LastName><ForeName>G D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><LastName>DePaulo</LastName><ForeName>J R</ForeName><Initials>JR</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>McInnis</LastName><ForeName>M G</ForeName><Initials>MG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-42243</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="Y">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>8</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>8</Month><Day>31</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>8</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11481160</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.158.8.1258</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8722243</PMID><DateCompleted><Year>1996</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2674</ISSN><JournalIssue CitedMedium="Print"><Volume>30</Volume><Issue>1</Issue><PubDate><MedlineDate>1996 Jan-Feb</MedlineDate></PubDate></JournalIssue><Title>Psychiatria polska</Title><ISOAbbreviation>Psychiatr Pol</ISOAbbreviation></Journal><ArticleTitle>[Pharmacotherapy of depression in patients with and without conversion from depression to mania in the course of bipolar affective disorder].</ArticleTitle><Pagination><MedlinePgn>99-111</MedlinePgn></Pagination><Abstract><AbstractText>To answer the question whether the kind and duration of the applied antidepressant therapy is a risk factor for the occurrence of mania directly after depression, the treatment of depression relapses in 30 patients with switch from depression to mania in the course of bipolar disease, and the treatment of 30 (appropriately selected) patients without this change was compared. No differences in treatment procedures were stated in comparable relapses, apart from more frequent application of lithium carbonate and carbamazepine in the patients with the switch from depression to mania. It was shown that long-term application of antidepressant drugs is not connected with the increased risk of such change.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koszewska</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Z II Kliniki Psychiatrycznej IPiN w Warszawie.</Affiliation></AffiliationInfo></Author></AuthorList><Language>pol</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Farmakoterapia nawrotÃ³w depresyjnych u chorych ze zmiana fazy depresyjnej w maniakalna i bez zmiany fazy w przebiegu choroby afektywnej dwubiegunowej.</VernacularTitle></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Psychiatr Pol</MedlineTA><NlmUniqueID>0103314</NlmUniqueID><ISSNLinking>0033-2674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000929">Antidepressive Agents, Tricyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000929" MajorTopicYN="N">Antidepressive Agents, Tricyclic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8722243</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19961811</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2010</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Comorbid substance use disorders among youth with bipolar disorder: opportunities for early identification and prevention.</ArticleTitle><Pagination><MedlinePgn>348-58</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.09r05222gry</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The burden of substance use disorders (SUDs) among adults with bipolar disorder is well documented. Comparatively less is known regarding comorbid SUD among youth with bipolar disorder. This article aims to integrate the extant literature on this topic and to suggest strategies for delaying or preventing SUD among youth with bipolar disorder.</AbstractText><AbstractText Label="DATA SOURCES AND STUDY SELECTION" NlmCategory="METHODS">Relevant studies in English were identified using PubMed and MEDLINE (1950-February 2009). Search terms were bipolar disorder cross-referenced with child, adolescent, or youth, and alcohol, drug, or substance, and abuse, dependence, or disorder. Articles were selected on the basis of containing data regarding both bipolar disorder and SUD. The search was supplemented by manually reviewing reference lists from the identified publications.</AbstractText><AbstractText Label="DATA SYNTHESIS" NlmCategory="RESULTS">Epidemiologic and clinical studies demonstrate that youth-onset bipolar disorder confers even greater risk of SUD in comparison with adult-onset bipolar disorder. Recent studies of youth with bipolar disorder have not identified childhood SUD (0%); however, the prevalence of SUD escalates during adolescence (16%-39%). Substance use disorder among bipolar youth is associated with legal and academic difficulties, pregnancy, and suicidality. Few studies have addressed interventions for this population, although studies are underway. Because bipolar disorder onset most commonly precedes SUD among youth (55%-83%), there is a window of opportunity for prevention.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Pending the results of ongoing treatment studies, several strategies are suggested for curtailing the burden of SUD in youth with bipolar disorder. These include screening for substance use among bipolar youth beginning at age 10 irrespective of other risk factors, education and intervention at the family level, and implementation of preventive interventions that have been successful in other populations.</AbstractText><CopyrightInformation>(c) 2010 Physicians Postgraduate Press, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Benjamin I</ForeName><Initials>BI</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, FG53, Toronto, Ontario, Canada. benjamin.goldstein@sunnybrook.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bukstein</LastName><ForeName>Oscar G</ForeName><Initials>OG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DA012414-06</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DA020036-01</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-077676-01A2</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019973" MajorTopicYN="N">Alcohol-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017831" MajorTopicYN="N">Diagnosis, Dual (Psychiatry)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>90</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>03</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>08</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19961811</ArticleId><ArticleId IdType="doi">10.4088/JCP.09r05222gry</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9647431</PMID><DateCompleted><Year>1998</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0096-882X</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>4</Issue><PubDate><Year>1998</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of studies on alcohol</Title><ISOAbbreviation>J Stud Alcohol</ISOAbbreviation></Journal><ArticleTitle>Overdiagnosis of major psychiatric disorders in individuals with substance use disorders and personality disorders: the downside of the Woodruff principle.</ArticleTitle><Pagination><MedlinePgn>477-8</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brim</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Stud Alcohol</MedlineTA><NlmUniqueID>7503813</NlmUniqueID><ISSNLinking>0096-882X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017831" MajorTopicYN="N">Diagnosis, Dual (Psychiatry)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9647431</ArticleId><ArticleId IdType="doi">10.15288/jsa.1998.59.477</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2517680</PMID><DateCompleted><Year>1990</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0048-7848</ISSN><JournalIssue CitedMedium="Print"><Volume>93</Volume><Issue>4</Issue><PubDate><MedlineDate>1989 Oct-Dec</MedlineDate></PubDate></JournalIssue><Title>Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi</Title><ISOAbbreviation>Rev Med Chir Soc Med Nat Iasi</ISOAbbreviation></Journal><ArticleTitle>[Lithium carbonate (Contemnol--Spofa). A clinical study].</ArticleTitle><Pagination><MedlinePgn>683-94</MedlinePgn></Pagination><Abstract><AbstractText>The estimation of the present day stage in the therapy with lithium salts allowed the authors some considerations on the mechanisms of action and pharmacodynamics of lithium ion, as well as on the indications and counterindications, side effects and therapeutical management. Thus, the authors have analysed the findings of a simple-blind clinical study on lithium carbonate (Contemnol--Spofa) in a series of 15 inpatients. The research methodology included the thorough examination of the patients, blood lithium screening, psychological investigations and laboratory tests on the basis of an itemized investigation card. The analysis of the results confirmed the efficacy of this substance in bipolar hyperthymic psychosyndromes, depressions and hyperthymic psychosyndromes with dissociative elements, its tolerance and low incidence of side effects. The selection of the cases, the clinical and paraclinical examinations, the observance of the indications and counterindications permit the administration of this substance as a curative and prophylactic treatment, providing the blood lithium is screened and clinical control and biological investigations are carried out.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pirozynski</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>ChiriÅ£Ä</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Cosmovici</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Berlescu</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Luchian</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gafencu</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>BÄlÅ£atu</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>rum</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Carbonatul de litiu (Contemnol--Spofa). Studiu clinic.</VernacularTitle></Article><MedlineJournalInfo><Country>Romania</Country><MedlineTA>Rev Med Chir Soc Med Nat Iasi</MedlineTA><NlmUniqueID>0413735</NlmUniqueID><ISSNLinking>0048-7848</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013607">Tablets</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="N">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004341" MajorTopicYN="N">Drug Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2517680</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12904975</PMID><DateCompleted><Year>2003</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0940-1334</ISSN><JournalIssue CitedMedium="Print"><Volume>253</Volume><Issue>3</Issue><PubDate><Year>2003</Year><Month>Jun</Month></PubDate></JournalIssue><Title>European archives of psychiatry and clinical neuroscience</Title><ISOAbbreviation>Eur Arch Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Lithium in the long-term treatment of bipolar disorders.</ArticleTitle><Pagination><MedlinePgn>120-5</MedlinePgn></Pagination><Abstract><AbstractText>Usefulness of lithium in the prophylaxis of bipolar disorders has been challenged for five major reasons. The authors review the empirical basis of these criticisms and come to the following conclusions. 1. Lithium efficacy is high and beyond reasonable doubt in classic manic-depressive illness. Bipolar patients presenting atypical features show a much poorer response rate to lithium. 2. There is no empirical evidence for a loss of lithium efficacy over time. 3. There is little evidence for discontinuation-induced refractoriness to lithium. 4. Lithium withdrawal phenomena are well established but seem to be rather specific to certain subgroups. Withdrawal phenomena seem to be common in atypical bipolar disorder but rare in fully stabilized classic manic-depressive illness. 5. Other factors limiting lithium efficacy in clinical practice (e. g., non-compliance) are not specific to lithium. In conclusion, prophylactic lithium does have major drawbacks and there is a clear need for more efficacious alternatives in non-classic bipolars. Compared to existing alternatives, lithium currently is to be considered the golden standard. This status might, however, be challenged by major alternative mood-stabilizers that are presently under clinical investigation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kleindienst</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Psychiatric Hospital, University of Munich, Nussbaumstr. 7, 80336, Munich, Germany. nikolaus.kleindienst@psy.med.uni-muenchen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greil</LastName><ForeName>W</ForeName><Initials>W</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur Arch Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9103030</NlmUniqueID><ISSNLinking>0940-1334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013375" MajorTopicYN="N">Substance Withdrawal Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="Y">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>75</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2003</Year><Month>05</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>9</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12904975</ArticleId><ArticleId IdType="doi">10.1007/s00406-003-0429-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16319409</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>187</Volume><PubDate><Year>2005</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>559-67</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chisholm</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Health System Financing, Evidence and Information for Policy (EIP), World Health Organization, 1211 Geneva, Switzerland. ChisholmD@who.int</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Ommeren</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ayuso-Mateos</LastName><ForeName>Jose-Luis</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Saxena</LastName><ForeName>Shekhar</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003156" MajorTopicYN="N">Community Mental Health Services</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="Y">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018803" MajorTopicYN="N">Models, Economic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="N">Social Support</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16319409</ArticleId><ArticleId IdType="pii">S0007125000168801</ArticleId><ArticleId IdType="doi">10.1192/bjp.187.6.559</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24306631</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1757-790X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2013</Volume><PubDate><Year>2013</Year><Month>Dec</Month><Day>04</Day></PubDate></JournalIssue><Title>BMJ case reports</Title><ISOAbbreviation>BMJ Case Rep</ISOAbbreviation></Journal><ArticleTitle>Quetiapine-induced manic episode: a paradox for contemplation.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1136/bcr-2013-201761</ELocationID><ELocationID EIdType="pii" ValidYN="Y">bcr2013201761</ELocationID><Abstract><AbstractText>A 24-year-old man with bipolar disorder who was started on quetiapine as an adjunct to valproate (mood stabiliser) after a depressive episode switched to a manic episode while on the drug. The manic episode resolved following the withdrawal of quetiapine. This case illustrates the rare possibility of quetiapine emergent manic episode which a clinician needs to be aware of in the context of the management of bipolar disorders. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gnanavel</LastName><ForeName>Sundar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>AIIMS, New Delhi, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Case Rep</MedlineTA><NlmUniqueID>101526291</NlmUniqueID><ISSNLinking>1757-790X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24306631</ArticleId><ArticleId IdType="pii">bcr-2013-201761</ArticleId><ArticleId IdType="doi">10.1136/bcr-2013-201761</ArticleId><ArticleId IdType="pmc">PMC3863048</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eur Neuropsychopharmacol. 2001 Apr;11(2):105-10</Citation><ArticleIdList><ArticleId IdType="pubmed">11313155</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2008 Sep;33(10):2303-12</Citation><ArticleIdList><ArticleId IdType="pubmed">18059438</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 2011 Winter;23(1):E5-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21304129</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Jul;162(7):1351-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15994719</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 1981 Aug;30(2):239-45</Citation><ArticleIdList><ArticleId IdType="pubmed">7249508</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19188536</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3636</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Influence of genes and environment on brain volumes in twin pairs concordant and discordant for bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>142-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archgenpsychiatry.2008.541</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Structural neuroimaging studies suggest the presence of subtle abnormalities in the brains of patients with bipolar disorder. The influence of genetic and/or environmental factors on these brain abnormalities is unknown.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the contribution of genetic and environmental factors on brain volume in bipolar disorder.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Magnetic resonance imaging (1.5 T) brain scans of monozygotic (MZ) or dizygotic (DZ) twins concordant and discordant for bipolar disorder were compared with healthy twin pairs.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Subjects were recruited from the population, the Netherlands Twin Register, and the twin pair cohort at the University Medical Center Utrecht, Utrecht, The Netherlands.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">A total of 234 subjects including 50 affected twin pairs (9 MZ concordant; 15 MZ discordant; 4 DZ concordant; 22 DZ discordant) and 67 healthy twin pairs (39 MZ and 28 DZ) were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Volumes of the intracranium, cerebrum, cerebellum, lateral and third ventricle, and gray and white matter from the cerebrum and frontal, parietal, temporal, and occipital lobes, both with and without correction for lithium use. To estimate the influence of additive genetic, common, and unique environmental factors, structural equation modeling was applied.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bipolar disorder was associated with a decrease in total cortical volume. Decreases in white matter were related to the genetic risk of developing bipolar disorder (bivariate heritability, 77%; 95% confidence interval, 38% to 100%). Significant environmental correlations were found for cortical gray matter. These relationships all became more pronounced when data were corrected for lithium use.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Focusing on genes controlling white matter integrity may be a fruitful strategy in the quest to discover genes implicated in bipolar disorder. Elucidating the mechanism by which lithium attenuates brain matter loss may lead to the development of neuroprotective drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van der Schot</LastName><ForeName>Astrid C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vonk</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Brans</LastName><ForeName>Rachel G H</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>van Haren</LastName><ForeName>Neeltje E M</ForeName><Initials>NE</Initials></Author><Author ValidYN="Y"><LastName>Koolschijn</LastName><ForeName>P CÃ©dric M P</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Nuboer</LastName><ForeName>Valerie</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Schnack</LastName><ForeName>Hugo G</ForeName><Initials>HG</Initials></Author><Author ValidYN="Y"><LastName>van Baal</LastName><ForeName>G Caroline M</ForeName><Initials>GC</Initials></Author><Author ValidYN="Y"><LastName>Boomsma</LastName><ForeName>Dorret I</ForeName><Initials>DI</Initials></Author><Author ValidYN="Y"><LastName>Nolen</LastName><ForeName>Willem A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Hulshoff Pol</LastName><ForeName>Hilleke E</ForeName><Initials>HE</Initials></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>RenÃ© S</ForeName><Initials>RS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D018486">Twin Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004200" MajorTopicYN="N">Diseases in Twins</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="Y">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="Y">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021621" MajorTopicYN="Y">Imaging, Three-Dimensional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012931" MajorTopicYN="Y">Social Environment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014429" MajorTopicYN="N">Twins, Dizygotic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014430" MajorTopicYN="N">Twins, Monozygotic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19188536</ArticleId><ArticleId IdType="pii">66/2/142</ArticleId><ArticleId IdType="doi">10.1001/archgenpsychiatry.2008.541</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7367331</PMID><DateCompleted><Year>1980</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0032-3756</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><Issue>3</Issue><PubDate><Year>1980</Year><Month>Jan</Month><Day>21</Day></PubDate></JournalIssue><Title>Polski tygodnik lekarski (Warsaw, Poland : 1960)</Title><ISOAbbreviation>Pol Tyg Lek</ISOAbbreviation></Journal><ArticleTitle>[Study of lithium transport through cell membrane in bipolar affective disorder on the model of red cell].</ArticleTitle><Pagination><MedlinePgn>103-5</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rybakowski</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>pol</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Badanie transportu litu przez bÅone komÃ³rkowa w chorobie afektywnej dwubiegunowej na modelu krwinki czerwonej.</VernacularTitle></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Pol Tyg Lek</MedlineTA><NlmUniqueID>9705468</NlmUniqueID><ISSNLinking>0032-3756</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004910" MajorTopicYN="N">Erythrocyte Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004912" MajorTopicYN="N">Erythrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1980</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1980</Year><Month>1</Month><Day>21</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1980</Year><Month>1</Month><Day>21</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7367331</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3116362</PMID><DateCompleted><Year>1987</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0730-725X</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>4</Issue><PubDate><Year>1987</Year></PubDate></JournalIssue><Title>Magnetic resonance imaging</Title><ISOAbbreviation>Magn Reson Imaging</ISOAbbreviation></Journal><ArticleTitle>An NMR study of lithium responding manic depressive patients.</ArticleTitle><Pagination><MedlinePgn>273-7</MedlinePgn></Pagination><Abstract><AbstractText>Manic depressive patients on long-term prophylactic therapy with lithium carbonate are examined by nuclear magnetic resonance imaging of the brain. Their ventricular brain ratios and cerebral grey and white matter spin lattice relaxation times (T1) are within normal limits. The implication of these findings in the light of previous studies using other techniques is discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Besson</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Mental Health, University of Aberdeen, Foresterhill, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>J G</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Foreman</LastName><ForeName>E I</ForeName><Initials>EI</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>F W</ForeName><Initials>FW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Magn Reson Imaging</MedlineTA><NlmUniqueID>8214883</NlmUniqueID><ISSNLinking>0730-725X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002552" MajorTopicYN="N">Cerebral Ventricles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3116362</ArticleId><ArticleId IdType="pii">0730-725X(87)90004-X</ArticleId><ArticleId IdType="doi">10.1016/0730-725x(87)90004-x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1245143</PMID><DateCompleted><Year>1976</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0012-3714</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>2</Issue><PubDate><Year>1976</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Diseases of the nervous system</Title><ISOAbbreviation>Dis Nerv Syst</ISOAbbreviation></Journal><ArticleTitle>Lithium carbonate in juvenile manic-depressive illness.</ArticleTitle><Pagination><MedlinePgn>90-2</MedlinePgn></Pagination><Abstract><AbstractText>A case of juvenile manic-depressive illness associated with mental retardation is reported having been treated successfully with lithium carbonate. During four years of maintenance treatment with daily doses of 600 mgs. to 900 mgs. per day of lithium carbonate, disruptive manic behavior has been controlled and a subjective leveling out of mood has allowed that patient to develop more fully her cognitive and psychomotor capacities. There was one exascerbation of disruptive behavior during the first year of treatment that was easily controlled with haloperidol together with continued lithium carbonate maintenance treatment. No measurable adverse developmental or thyroid effects have been noted. The Shaffer acquiescence scale of the MMPI correctly predicted that the patient would be a positive responder to lithium carbonate treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>J T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Buegel</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Nerv Syst</MedlineTA><NlmUniqueID>0370666</NlmUniqueID><ISSNLinking>0012-3714</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008607" MajorTopicYN="N">Intellectual Disability</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1976</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1976</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1976</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1245143</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22398509</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2012</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-033X</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>3</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>Psychopathology</Title><ISOAbbreviation>Psychopathology</ISOAbbreviation></Journal><ArticleTitle>Role of substance abuse comorbidity and personality on the outcome of depression in bipolar disorder: harm avoidance influences medium-term treatment outcome.</ArticleTitle><Pagination><MedlinePgn>174-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000330364</ELocationID><Abstract><AbstractText>Comorbid conditions are frequent in bipolar disorder (BD) and may complicate the treatment and course of illness. We investigated the role of substance use disorder (SUD), axis II personality disorders (PD) and continuous personality traits on the medium-term outcome (6 months) of treatment for bipolar depression. One hundred and thirty-nine BD patients meeting criteria for a depressive episode were included in the study. SUD and PD were diagnosed according to structured interviews. Personality dimensions were evaluated by the Temperament and Character Inventory. Depressive severity over time was evaluated by the Hamilton Rating Scale for Depression. Neither PD nor SUD influenced the outcome of depression. Variables independently associated with a poor outcome were a high baseline severity and high scores for the temperamental trait of Harm Avoidance. Though several limitations characterize the present study, neurotic personality traits seem to be associated with a slower recovery from depressive symptoms in BD, independently from their initial severity.</AbstractText><CopyrightInformation>Copyright Â© 2012 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mandelli</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Bologna, Bologna, Italy. laura.mandelli@unibo.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazza</LastName><ForeName>Marianna</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Di Nicola</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zaninotto</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Harnic</LastName><ForeName>Desiree</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Catalano</LastName><ForeName>Valeria</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Tedeschi</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Martinotti</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bria</LastName><ForeName>Pietro</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Janiri</LastName><ForeName>Luigi</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Serretti</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychopathology</MedlineTA><NlmUniqueID>8401537</NlmUniqueID><ISSNLinking>0254-4962</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040261" MajorTopicYN="Y">Harm Reduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="Y">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>09</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22398509</ArticleId><ArticleId IdType="pii">000330364</ArticleId><ArticleId IdType="doi">10.1159/000330364</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14977462</PMID><DateCompleted><Year>2004</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1044-5463</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Season>Winter</Season></PubDate></JournalIssue><Title>Journal of child and adolescent psychopharmacology</Title><ISOAbbreviation>J Child Adolesc Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Patterns of comorbidity and dysfunction in clinically referred preschool and school-age children with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>495-505</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Despite its common onset in preschool years, few studies have examined the characteristics of bipolar disorder (BPD) in preschoolers. This study reports on the clinical characteristics, psychiatric comorbidity, and functioning of preschoolers identified with BPD who were referred to a pediatric psychiatric clinic.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Structured psychiatric interviews assessing lifetime psychopathology by Diagnostic and Statistical Manual of Mental Disorders (third edition, revised) criteria were completed with parents about their children and confirmed by clinical interview of the child. Family, social, and overall functioning were also assessed at intake. Findings from preschoolers ages 4 to 6 years were compared with a group of children ages 7 to 9 years (school age).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 44 preschoolers and 29 consecutively ascertained school-age youth with BPD. Preschoolers had similar rates of comorbid psychopathology compared to school-age youth with BPD. Preschoolers and school-age children with BPD typically manifest symptoms of mania and major depression simultaneously (mixed states). Both preschoolers and school-age children had substantial impairment in school, social, and overall functioning.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results suggest that clinically referred preschoolers with BPD share with school-age children with BPD high rates of comorbid psychopathology and impaired functioning. Follow-up of these clinically referred preschoolers with BPD evaluating the stability of their diagnoses, treatment response, and their long-term outcome is necessary.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wilens</LastName><ForeName>Timothy E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Johnson and Johnson Center for the Study of Pediatric Psychopathology, Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA. twilens@partners.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biederman</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Forkner</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ditterline</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Mathew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Hadley</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Galdo</LastName><ForeName>Maribel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Spencer</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Wozniak</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DA12945</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Child Adolesc Psychopharmacol</MedlineTA><NlmUniqueID>9105358</NlmUniqueID><ISSNLinking>1044-5463</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012919" MajorTopicYN="N">Social Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>2</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>3</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>2</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14977462</ArticleId><ArticleId IdType="doi">10.1089/104454603322724887</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2748874</PMID><DateCompleted><Year>1989</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0278-5846</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>3-4</Issue><PubDate><Year>1989</Year></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Transmembrane lithium distribution and hypertension in manic depressive patients.</ArticleTitle><Pagination><MedlinePgn>525-30</MedlinePgn></Pagination><Abstract><AbstractText>1. The association of hypertension and depression has long been recognized. The purpose of this study was to explore the relationship between RBC level/plasma level of lithium (Li), blood pressure (BP) and weight in bipolar affective disorder patients. 2. All patients were evaluated by the same examiner using DSM-III Diagnostic Criteria. Measurement of patients' Li values, BP and weight were carried out on the same day or within 24 hours. 3. We evaluated 103 bipolar patients treated with lithium (mean age: 44 years, mean duration of Li treatment, 6 years). Ten percent of these patients were hypertensive. 4. No significant difference was found between hypertensive (H) and non-hypertensive (NH) patients with respect to their RBC, plasma or RBC/plasma Li ratio. This finding was consistent in patients treated with Li alone or Li combined with other neuroleptics. 5. Our study did not confirm previous findings (McCoy et al, 1982) indicating that there is a correlation between low Li ratio (less than 0.30) and hypertension in bipolar affective disorder patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghadirian</LastName><ForeName>A M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Douglas Hospital Center, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nair</LastName><ForeName>N P</ForeName><Initials>NP</Initials></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>J6292F8L3D</RegistryNumber><NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance></Chemical><Chemical><RegistryNumber>U42B7VYA4P</RegistryNumber><NameOfSubstance UI="D002746">Chlorpromazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002746" MajorTopicYN="N">Chlorpromazine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004912" MajorTopicYN="N">Erythrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2748874</ArticleId><ArticleId IdType="doi">10.1016/0278-5846(89)90141-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2497949</PMID><DateCompleted><Year>1989</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0706-7437</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>3</Issue><PubDate><Year>1989</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Canadian journal of psychiatry. Revue canadienne de psychiatrie</Title><ISOAbbreviation>Can J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Tourette disorder and bipolar symptomatology in childhood and adolescence.</ArticleTitle><Pagination><MedlinePgn>230-3</MedlinePgn></Pagination><Abstract><AbstractText>Three boys with an early history of attention deficit disorder with hyperactivity developed Tourette disorder. At 13, 12 and eight years of age, respectively, each met DSM-III criteria for a manic episode or bipolar disorder. Each of the boys had a family history of affective or affective spectrum disorder. Lithium carbonate in a range of 0.8 to 1.2 meq/L markedly improved their bipolar symptomatology with Tourette symptoms improving in two patients. Further study is suggested to determine the significance of these findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kerbeshian</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of North Dakota School of Medicine, Grand Forks.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burd</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Psychiatry</MedlineTA><NlmUniqueID>7904187</NlmUniqueID><ISSNLinking>0706-7437</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1HIZ4DL86F</RegistryNumber><NameOfSubstance UI="D010868">Pimozide</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010868" MajorTopicYN="N">Pimozide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005879" MajorTopicYN="N">Tourette Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2497949</ArticleId><ArticleId IdType="doi">10.1177/070674378903400313</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29672741</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1745-1701</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>03</Month><Day>07</Day></PubDate></JournalIssue><Title>Schizophrenia bulletin</Title><ISOAbbreviation>Schizophr Bull</ISOAbbreviation></Journal><ArticleTitle>Multimodal Brain Changes in First-Episode Mania: A Voxel-Based Morphometry, Functional Magnetic Resonance Imaging, and Connectivity Study.</ArticleTitle><Pagination><MedlinePgn>464-473</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/schbul/sby047</ELocationID><Abstract><AbstractText Label="BACKGROUND">Brain structural and functional changes in bipolar disorder (BD) are well-established findings, but it is uncertain whether these changes are already present in first episode mania (FEM).</AbstractText><AbstractText Label="METHODS">We compared 31 FEM subjects, with 31 healthy individuals matched for age, sex, and premorbid IQ. Whole-brain voxel-wise morphometry, functional magnetic resonance imaging during the n-back task, and a functional connectivity analysis were performed.</AbstractText><AbstractText Label="RESULTS">There were no volumetric differences between the 2 groups. During the 2-back task, FEM patients did not perform differently from controls and activated similar regions, but they showed less deactivation in the ventromedial prefrontal cortex (vmPFC), the anterior hub of the default mode network (DMN). They showed preserved functional connectivity between the vmPFC and other regions of the DMN, but increased connectivity with the superior frontal gyrus.</AbstractText><AbstractText Label="CONCLUSIONS">The absence of volumetric changes in FEM patients suggests that these changes could be related to progression of the illness. On the other hand, the failure of deactivation of the anterior hub of the DMN is present from the onset of the illness and may represent a core pathophysiological feature of BD.</AbstractText><CopyrightInformation>Â© The Author(s) 2018. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goikolea</LastName><ForeName>JosÃ© M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Barcelona Bipolar Disorders Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dima</LastName><ForeName>Danai</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychology, School of Arts and Social Sciences, City University London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LandÃ­n-Romero</LastName><ForeName>RamÃ³n</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>FIDMAG Germanes HospitalÃ ries Research Foundation, Benito Menni Complex Assistencial en Salut Mental, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Imma</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Barcelona Bipolar Disorders Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DelVecchio</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>ValentÃ­</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Barcelona Bipolar Disorders Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amann</LastName><ForeName>Benedikt L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>FIDMAG Germanes HospitalÃ ries Research Foundation, Benito Menni Complex Assistencial en Salut Mental, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>BonnÃ­n</LastName><ForeName>Caterina Mar</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Barcelona Bipolar Disorders Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKenna</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>FIDMAG Germanes HospitalÃ ries Research Foundation, Benito Menni Complex Assistencial en Salut Mental, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pomarol-Clotet</LastName><ForeName>Edith</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>FIDMAG Germanes HospitalÃ ries Research Foundation, Benito Menni Complex Assistencial en Salut Mental, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frangou</LastName><ForeName>Sophia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Barcelona Bipolar Disorders Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Schizophr Bull</MedlineTA><NlmUniqueID>0236760</NlmUniqueID><ISSNLinking>0586-7614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="Y">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063132" MajorTopicYN="N">Connectome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="Y">Nerve Net</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="Y">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">magnetic resonance imaging</Keyword><Keyword MajorTopicYN="Y">mania</Keyword><Keyword MajorTopicYN="Y">neuroimaging</Keyword><Keyword MajorTopicYN="Y">pathophysiology</Keyword><Keyword MajorTopicYN="Y">whole-brain statistical analysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29672741</ArticleId><ArticleId IdType="pii">4973660</ArticleId><ArticleId IdType="doi">10.1093/schbul/sby047</ArticleId><ArticleId IdType="pmc">PMC6403052</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mol Psychiatry. 2015 Feb;20(1):23-31</Citation><ArticleIdList><ArticleId IdType="pubmed">25048003</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2016 Sep;18(6):502-510</Citation><ArticleIdList><ArticleId IdType="pubmed">27759213</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2012 Mar 30;36(2):231-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22119745</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Dec;11(8):807-14</Citation><ArticleIdList><ArticleId IdType="pubmed">19922551</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2009 Apr 1;45(2):319-32</Citation><ArticleIdList><ArticleId IdType="pubmed">19110062</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2010 Jun 1;67(11):1097-105</Citation><ArticleIdList><ArticleId IdType="pubmed">20303066</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Apr 1;73(7):652-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23158114</ArticleId></ArticleIdList></Reference><Reference><Citation>Encephale. 2010 Mar;36 Suppl 3:S71-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21095396</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2012 Dec;13(8):605-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21812622</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2006 Nov-Dec;47(6):433-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17067865</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Mar 15;61(6):776-81</Citation><ArticleIdList><ArticleId IdType="pubmed">17027928</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2010 Jan;167(1):78-85</Citation><ArticleIdList><ArticleId IdType="pubmed">19952077</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2008 Aug;38(8):1185-93</Citation><ArticleIdList><ArticleId IdType="pubmed">18507885</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2014 Sep;158(1-3):85-90</Citation><ArticleIdList><ArticleId IdType="pubmed">25043264</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2010 Apr 30;182(1):22-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20227857</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2018 Apr;23(4):932-942</Citation><ArticleIdList><ArticleId IdType="pubmed">28461699</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2012 Dec;13(8):616-26</Citation><ArticleIdList><ArticleId IdType="pubmed">21604958</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Jul;156(7):1091-3</Citation><ArticleIdList><ArticleId IdType="pubmed">10401458</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2005 Nov 15;67(5):403-12</Citation><ArticleIdList><ArticleId IdType="pubmed">16216687</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):313-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22631617</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Sep 15;184:116-22</Citation><ArticleIdList><ArticleId IdType="pubmed">26074021</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2012 Dec;16(12):584-92</Citation><ArticleIdList><ArticleId IdType="pubmed">23142417</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2008 Jun;38(6):771-85</Citation><ArticleIdList><ArticleId IdType="pubmed">17922938</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2015 Feb;206(2):136-44</Citation><ArticleIdList><ArticleId IdType="pubmed">25497296</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Feb;13(1):28-40</Citation><ArticleIdList><ArticleId IdType="pubmed">21320250</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2001 Oct;2(10):685-94</Citation><ArticleIdList><ArticleId IdType="pubmed">11584306</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2013 Jan;43(1):143-53</Citation><ArticleIdList><ArticleId IdType="pubmed">22583916</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2010 Jul 30;183(1):59-68</Citation><ArticleIdList><ArticleId IdType="pubmed">20553873</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Aug;61(8):781-92</Citation><ArticleIdList><ArticleId IdType="pubmed">15289277</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Clin Psychol. 2012;8:49-76</Citation><ArticleIdList><ArticleId IdType="pubmed">22224834</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2004 Nov;23(3):921-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15528092</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 1997 Oct;6(3):218-29</Citation><ArticleIdList><ArticleId IdType="pubmed">9344826</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1979 Apr;134:382-9</Citation><ArticleIdList><ArticleId IdType="pubmed">444788</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Nov;9(7):693-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17988358</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1987;13(2):261-76</Citation><ArticleIdList><ArticleId IdType="pubmed">3616518</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Jul;65(7):746-60</Citation><ArticleIdList><ArticleId IdType="pubmed">18606948</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Nov;159(11):1841-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12411217</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9673-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15976020</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Psychol. 2012;63:1-29</Citation><ArticleIdList><ArticleId IdType="pubmed">21961947</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Jun;148(2-3):170-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22854099</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2013 Mar;37(3):418-35</Citation><ArticleIdList><ArticleId IdType="pubmed">23318228</ArticleId></ArticleIdList></Reference><Reference><Citation>Early Interv Psychiatry. 2008 Nov;2(4):225-33</Citation><ArticleIdList><ArticleId IdType="pubmed">19190727</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1279-84</Citation><ArticleIdList><ArticleId IdType="pubmed">19164577</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2008 Jun;23(4):300-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17656073</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2015 Feb;40(3):658-66</Citation><ArticleIdList><ArticleId IdType="pubmed">25139065</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2014;204:290-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24434074</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Mar;14(2):135-45</Citation><ArticleIdList><ArticleId IdType="pubmed">22420589</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12788-93</Citation><ArticleIdList><ArticleId IdType="pubmed">22807481</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2005 May;25(1):46-59</Citation><ArticleIdList><ArticleId IdType="pubmed">15846822</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 2013;68(2):63-70</Citation><ArticleIdList><ArticleId IdType="pubmed">23881005</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Struct Funct. 2014 Jul;219(4):1463-72</Citation><ArticleIdList><ArticleId IdType="pubmed">23700105</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2008 Mar;1124:1-38</Citation><ArticleIdList><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2005 Jul 1;26(3):839-51</Citation><ArticleIdList><ArticleId IdType="pubmed">15955494</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Sep;65(9):1017-32</Citation><ArticleIdList><ArticleId IdType="pubmed">18762588</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2011 May;128(1-3):175-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21144711</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10584760</PMID><DateCompleted><Year>1999</Year><Month>12</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>60</Volume><Issue>11</Issue><PubDate><Year>1999</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A history of substance abuse complicates remission from acute mania in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>733-40</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Substance abuse frequently complicates the course of bipolar illness, promotes mixed states, and contributes to poor outcome in mania. Preliminary open trials suggest that anticonvulsant mood stabilizers may enhance remission rates and outcome for bipolar patients with substance abuse. This study compared remission patterns for mixed or pure manic episodes among bipolar inpatients with or without substance abuse histories.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Hospital records were retrospectively reviewed for 204 DSM-III-R bipolar I inpatients. Clinical features were compared for those with or without substance abuse/dependence histories predating the index manic episode. Time until remission was analyzed by Kaplan-Meier survival analysis. Naturalistic treatment outcome with lithium or anticonvulsant mood stabilizers was compared for those with or without past substance abuse.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Past substance abuse was evident in 34% of the bipolar sample and comprised most often alcoholism (82%), followed by cocaine (30%), marijuana (29%), sedative-hypnotic or amphetamine (21%), and opiate (13%) abuse. Substance abuse was more common among men (p &lt; .05) and those with mixed rather than pure mania (p &lt; .05). Remission during hospitalization was less likely among patients with prior substance abuse (p &lt; .05), especially alcohol or marijuana abuse, and among mixed manic patients with past substance abuse (p &lt; .05). Bipolar patients with substance abuse histories who received divalproex or carbamazepine remitted during hospitalization more often than did those who received lithium as the sole mood stabilizer (p &lt; .05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings support previous reports suggesting that bipolar patients with past substance abuse have poorer naturalistic treatment outcomes, but may show a better response to anticonvulsant mood stabilizers than lithium.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>J F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Payne Whitney Clinic, New York Presbyterian Hospital and Weill Medical College of Cornell University, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garno</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Leon</LastName><ForeName>A C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Kocsis</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Portera</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017831" MajorTopicYN="N">Diagnosis, Dual (Psychiatry)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>12</Month><Day>10</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>12</Month><Day>10</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10584760</ArticleId><ArticleId IdType="doi">10.4088/jcp.v60n1103</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11000914</PMID><DateCompleted><Year>2001</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1055-0496</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Season>Summer</Season></PubDate></JournalIssue><Title>The American journal on addictions</Title><ISOAbbreviation>Am J Addict</ISOAbbreviation></Journal><ArticleTitle>Is bipolar disorder a risk for cigarette smoking in ADHD youth?</ArticleTitle><Pagination><MedlinePgn>187-95</MedlinePgn></Pagination><Abstract><AbstractText>Despite emerging literature linking juvenile bipolar disorder (BPD) and substance abuse, little is known about a link between BPD and cigarette smoking. To this end, we evaluated the association between BPD and cigarette smoking in youth. Subjects were 31 bipolar adolescents derived from a cohort of boys with DSM-III-R ADHD (N = 128) and non-ADHD comparisons (N = 109) followed prospectively for 4 years into mid-adolescence. Information on cigarette smoking was obtained in a standardized manner blind to the proband's clinical status. Logistic regression models were used to determine risk for smoking at follow-up. BPD was associated with a higher risk for cigarette smoking in mid-adolescence, which was largely accounted for by conduct disorder. The developmental onset of BPD in adolescence (age 13-18 years) conferred a greater risk for cigarette smoking compared to those youths with the onset of their BPD prepubertally (&lt; or = 12 years; odds ratio = 10.8, p &lt; 0.01), even after controlling for conduct disorder and other confounds. The naturalistic treatment of BPD with combined counseling and pharmacotherapy appeared to reduce the risk for cigarette smoking. BPD, particularly when it onsets in adolescence, is a significant risk factor for the early initiation of cigarette smoking in these ADHD youths. These data coupled with the literature strongly suggest that juveniles with BPD need to be carefully monitored for the early initiation of cigarette smoking and substance abuse.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wilens</LastName><ForeName>T E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston 02114, USA. wilens@helix.mgh.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biederman</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Milberger</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hahesy</LastName><ForeName>A L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wozniak</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Spencer</LastName><ForeName>T J</ForeName><Initials>TJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01DA00029402</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HD36317A02</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R29DA11315</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Addict</MedlineTA><NlmUniqueID>9208821</NlmUniqueID><ISSNLinking>1055-0496</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000294" MajorTopicYN="N">Adolescent Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012907" MajorTopicYN="N">Smoking</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>9</Month><Day>23</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>9</Month><Day>23</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11000914</ArticleId><ArticleId IdType="doi">10.1080/10550490050148017</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4566490</PMID><DateCompleted><Year>1973</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0066-4219</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><PubDate><Year>1972</Year></PubDate></JournalIssue><Title>Annual review of medicine</Title><ISOAbbreviation>Annu Rev Med</ISOAbbreviation></Journal><ArticleTitle>Lithium salts in the management of the manic-depressive syndrome.</ArticleTitle><Pagination><MedlinePgn>439-52</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gershon</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Annu Rev Med</MedlineTA><NlmUniqueID>2985151R</NlmUniqueID><ISSNLinking>0066-4219</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002395">Catecholamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>OGG85SX4E4</RegistryNumber><NameOfSubstance UI="D007099">Imipramine</NameOfSubstance></Chemical><Chemical><RegistryNumber>U42B7VYA4P</RegistryNumber><NameOfSubstance UI="D002746">Chlorpromazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002395" MajorTopicYN="N">Catecholamines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002746" MajorTopicYN="N">Chlorpromazine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003919" MajorTopicYN="N">Diabetes Insipidus</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006042" MajorTopicYN="N">Goiter</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007099" MajorTopicYN="N">Imipramine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>74</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1972</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1972</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1972</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4566490</ArticleId><ArticleId IdType="doi">10.1146/annurev.me.23.020172.002255</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21216014</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2011</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>189</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Aug</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with second generation antipsychotics.</ArticleTitle><Pagination><MedlinePgn>21-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2010.11.021</ELocationID><Abstract><AbstractText>There is accumulating evidence for an increased prevalence of metabolic syndrome (MetS) in bipolar patients, which is comparable to the prevalence of MetS in patients with schizophrenia. Hyperhomocysteinaemia has emerged as an independent and graded risk factor for the development of cardiovascular disease (CVD), which is, at the same time, the primary clinical outcome of MetS. The aim of this study was to ascertain if the presence of MetS was associated with hyperhomocysteinaemia in patients with bipolar disorder (N=36) and schizophrenia (N=46) treated with second-generation antipsychotics (SGA). MetS was defined according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP-III) criteria and the cut-off point for hyperhomocysteinaemia was set up at 15 Î¼moll(-1). Results of the study indicated that the presence of the MetS is statistically significantly associated with the elevated serum homocysteine in all participants. As hyperhomocysteinaemia has emerged as an independent risk factor for psychiatric disorder and CVD, it could be useful to include fasting homocysteine serum determination in the diagnostic panels of psychiatric patients to obtain a better assessment of their metabolic risk profile.</AbstractText><CopyrightInformation>Copyright Â© 2010 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vuksan-Äusa</LastName><ForeName>Bjanka</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>University Hospital Zagreb, Psychiatric Clinic, KiÅ¡patiÄeva Street, Zagreb, Croatia. bjanka.vuksan@inet.hr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>JakovljeviÄ</LastName><ForeName>Miro</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sagud</LastName><ForeName>Marina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>MihaljeviÄ PeleÅ¡</LastName><ForeName>Alma</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>MarÄinko</LastName><ForeName>Darko</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>TopiÄ</LastName><ForeName>Radmila</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>MihaljeviÄ</LastName><ForeName>Sanea</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>SertiÄ</LastName><ForeName>Jadranka</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>462-10-2</RegistryNumber><NameOfSubstance UI="D006711">Homocystine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006711" MajorTopicYN="N">Homocystine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008659" MajorTopicYN="N">Metabolic Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018962" MajorTopicYN="N">Phlebotomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="Y">Schizophrenia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>12</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21216014</ArticleId><ArticleId IdType="pii">S0165-1781(10)00713-4</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2010.11.021</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26037879</PMID><DateCompleted><Year>2015</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2015</Year><Month>06</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7222</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Season>Fall</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Hyponatremia masquerading as panic symptoms in bipolar affective disorder.</ArticleTitle><Pagination><MedlinePgn>E3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.neuropsych.13080174</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Li-Fen</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Dept. of Psychiatry, Tri-Service General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, National Defense Medical Center, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dept. of Nursing, Taipei Tzuchi Hospital, The Buddhist Medical Foundation, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Tzu-Chi University, Hualien, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dept. of Psychiatry, Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Tzu Chi University, Hualien, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi</LastName><ForeName>Hsin-Chang</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Dept. of Psychiatry, Tri-Service General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, National Defense Medical Center, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dept. of Nursing, Taipei Tzuchi Hospital, The Buddhist Medical Foundation, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Tzu-Chi University, Hualien, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dept. of Psychiatry, Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Tzu Chi University, Hualien, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Ching-En</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Dept. of Psychiatry, Tri-Service General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, National Defense Medical Center, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dept. of Nursing, Taipei Tzuchi Hospital, The Buddhist Medical Foundation, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Tzu-Chi University, Hualien, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dept. of Psychiatry, Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Tzu Chi University, Hualien, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014151">Anti-Anxiety Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0DHU5B8D6V</RegistryNumber><NameOfSubstance UI="D015283">Citalopram</NameOfSubstance></Chemical><Chemical><RegistryNumber>36S3EQV54C</RegistryNumber><NameOfSubstance UI="D004949">Estazolam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014151" MajorTopicYN="N">Anti-Anxiety Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015283" MajorTopicYN="N">Citalopram</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004949" MajorTopicYN="N">Estazolam</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007010" MajorTopicYN="N">Hyponatremia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016584" MajorTopicYN="N">Panic Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26037879</ArticleId><ArticleId IdType="doi">10.1176/appi.neuropsych.13080174</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">28068616</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>210</Volume><PubDate><Year>2017</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Residual depressive symptoms, sleep disturbance and perceived cognitive impairment as determinants of functioning in patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>280-286</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(16)31905-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2016.12.054</ELocationID><Abstract><AbstractText Label="BACKGROUND">Many patients with bipolar disorder (BD) experience residual symptoms during their inter-episodic periods. The study aimed to analyse the relationship between residual depressive symptoms, sleep disturbances and self-reported cognitive impairment as determinants of psychosocial functioning in a large sample of euthymic BD patients.</AbstractText><AbstractText Label="METHODS">This was a cross-sectional study of 468 euthymic BD outpatients. We evaluated the residual depressive symptoms with the Bipolar Depression Rating Scale, the sleep disturbances with the Pittsburgh Sleep Quality Index, the perceived cognitive performance using visual analogic scales and functioning with the Functioning Assessment Short Test. Structural equation modelling (SEM) was used to describe the relationships among the residual depressive symptoms, sleep disturbances, perceived cognitive performance and functioning.</AbstractText><AbstractText Label="RESULTS">SEM showed good fit with normed chi square=2.46, comparative fit index=0.94, root mean square error of approximation=0.05 and standardized root mean square residuals=0.06. This model revealed that residual depressive symptoms (path coefficient =0.37) and perceived cognitive performance (path coefficient=0.27) were the most important features significantly related to psychosocial functioning. Sleep disturbances were indirectly associated with functioning via residual depressive symptoms and perceived cognitive performance (path coefficient=0.23).</AbstractText><AbstractText Label="CONCLUSIONS">This study contributes to a better understanding of the determinants of psychosocial functioning during the inter-episodic periods of BD patients. These findings should facilitate decision-making in therapeutics to improve the functional outcomes of BD during this period.</AbstractText><CopyrightInformation>Copyright Â© 2017 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Samalin</LastName><ForeName>Ludovic</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CHU Clermont-Ferrand, Department of Psychiatry, EA 7280, University of Auvergne, Clermont-Ferrand, France; Bipolar Disorder Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain; Fondation FondaMental, CrÃ©teil, France. Electronic address: lsamalin@chu-clermontferrand.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyer</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Aix-Marseille University, EA 3279, Public Health, Chronic Diseases and Quality of Life research Unit, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murru</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacchiarotti</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinares</LastName><ForeName>MarÃ­a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonnin</LastName><ForeName>Caterina Mar</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torrent</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verdolini</LastName><ForeName>Norma</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain; Division of Psychiatry, Clinical Psychology and Rehabilitation, Department of Medicine, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pancheri</LastName><ForeName>Corinna</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Policlinico Umberto I of Rome, La Sapienza University of Roma, Department of Neurology and Psychiatry, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Chazeron</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>CHU Clermont-Ferrand, Department of Psychiatry, EA 7280, University of Auvergne, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boucekine</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Aix-Marseille University, EA 3279, Public Health, Chronic Diseases and Quality of Life research Unit, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geoffroy</LastName><ForeName>Pierre-Alexis</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Fondation FondaMental, CrÃ©teil, France; Inserm U1144, Paris, France; UniversitÃ© Paris Diderot, Sorbonne Paris CitÃ©, UMR-S 1144, Paris, France; AP-HP, GH Saint-Louis - LariboisiÃ©re - F. Widal,Widal, PÃ´le de Psychiatrie et de MÃ©decine Addictologique, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellivier</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Fondation FondaMental, CrÃ©teil, France; Inserm U1144, Paris, France; UniversitÃ© Paris Diderot, Sorbonne Paris CitÃ©, UMR-S 1144, Paris, France; AP-HP, GH Saint-Louis - LariboisiÃ©re - F. Widal,Widal, PÃ´le de Psychiatrie et de MÃ©decine Addictologique, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llorca</LastName><ForeName>Pierre-Michel</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>CHU Clermont-Ferrand, Department of Psychiatry, EA 7280, University of Auvergne, Clermont-Ferrand, France; Fondation FondaMental, CrÃ©teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="N">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007398" MajorTopicYN="N">Interpersonal Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058992" MajorTopicYN="N">Social Participation</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Cognitive functioning</Keyword><Keyword MajorTopicYN="Y">Functioning</Keyword><Keyword MajorTopicYN="Y">Residual depressive symptoms</Keyword><Keyword MajorTopicYN="Y">Sleep disturbances</Keyword><Keyword MajorTopicYN="Y">Structural equation modelling</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>12</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28068616</ArticleId><ArticleId IdType="pii">S0165-0327(16)31905-X</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2016.12.054</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2136079</PMID><DateCompleted><Year>1992</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0895-0172</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>2</Issue><PubDate><Year>1990</Year><Season>Spring</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Limbic lesions in a patient with recurrent mania.</ArticleTitle><Pagination><MedlinePgn>235-6</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berthier</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Starkstein</LastName><ForeName>S E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>R G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Leiguarda</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001925" MajorTopicYN="N">Brain Damage, Chronic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002538" MajorTopicYN="N">Intracranial Arteriovenous Malformations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008032" MajorTopicYN="N">Limbic System</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019965" MajorTopicYN="N">Neurocognitive Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2136079</ArticleId><ArticleId IdType="doi">10.1176/jnp.2.2.235</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32458698</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2158-0022</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>09</Month></PubDate></JournalIssue><Title>Brain connectivity</Title><ISOAbbreviation>Brain Connect</ISOAbbreviation></Journal><ArticleTitle>Resting-State Network Patterns Underlying Cognitive Function in Bipolar Disorder: A Graph Theoretical Analysis.</ArticleTitle><Pagination><MedlinePgn>355-367</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/brain.2019.0709</ELocationID><Abstract><AbstractText><b><i>Background:</i></b> Synchronous and antisynchronous activity between neural elements at rest reflects the physiological processes underlying complex cognitive ability. Regional and pairwise connectivity investigations suggest that perturbations in these activity patterns may relate to widespread cognitive impairments seen in bipolar disorder (BD). Here we take a network-based perspective to more meaningfully capture interactions among distributed brain regions compared to focal measurements and examine network-cognition relationships across a range of commonly affected cognitive domains in BD in relation to healthy controls. <b><i>Methods:</i></b> Resting-state networks were constructed as matrices of correlation coefficients between regionally averaged resting-state time series from 86 cortical/subcortical brain regions (FreeSurferv5.3.0). Cognitive performance measured using the Wechsler Adult Intelligence Scale, Cambridge Automated Neuropsychological Test Battery (CANTAB), and Reading the Mind in the Eyes tests was examined in relation to whole-brain connectivity measures and patterns of connectivity using a permutation-based statistical approach. <b><i>Results:</i></b> Faster response times in controls (<i>n</i>â=â49) related to synchronous activity between frontal, parietal, cingulate, temporal, and occipital regions, while a similar response times in BD (<i>n</i>â=â35) related to antisynchronous activity between regions of this subnetwork. Across all subjects, antisynchronous activity between the frontal, parietal, temporal, occipital, cingulate, insula, and amygdala regions related to improved memory performance. No resting-state subnetworks related to intelligence, executive function, short-term memory, or social cognition performance in the overall sample or in a manner that would explain deficits in these facets in BD. <b><i>Conclusions:</i></b> Our results demonstrate alterations in the intrinsic connectivity patterns underlying response timing in BD that are not specific to performance or errors on the same tasks. Across all individuals, no strong effects of resting-state global topology on cognition are found, while distinct functional networks supporting episodic and spatial memory highlight intrinsic inhibitory influences present in the resting state that facilitate memory processing. Impact Statement Regional and pairwise-connectivity investigations suggest altered interactions between brain areas may contribute to impairments in cognition that are observed in bipolar disorder. However, the distributed nature of these interactions across the brain remains poorly understood. Using recent advances in network neuroscience, we examine functional connectivity patterns associated with multiple cognitive domains in individuals with and without bipolar disorder. We discover distinct patterns of connectivity underlying response-timing performance uniquely in bipolar disorder and, independent of diagnosis, inhibitory interactions that relate to memory performance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McPhilemy</LastName><ForeName>Genevieve</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Neuroimaging &amp; Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nabulsi</LastName><ForeName>Leila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for Neuroimaging &amp; Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kilmartin</LastName><ForeName>Liam</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>College of Science and Engineering, National University of Ireland Galway, Galway, Republic of Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whittaker</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Cardiff University Brain Research Imaging Centre (CUBRIC), School of Physics and Astronomy, Cardiff University, Cardiff, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martyn</LastName><ForeName>Fiona M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Centre for Neuroimaging &amp; Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hallahan</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre for Neuroimaging &amp; Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Colm</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Neuroimaging &amp; Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cardiff University Brain Research Imaging Centre (CUBRIC), School of Physics and Astronomy, Cardiff University, Cardiff, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cannon</LastName><ForeName>Dara M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Centre for Neuroimaging &amp; Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Brain Connect</MedlineTA><NlmUniqueID>101550313</NlmUniqueID><ISSNLinking>2158-0014</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007360" MajorTopicYN="N">Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012146" MajorTopicYN="N">Rest</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014888" MajorTopicYN="N">Wechsler Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">cognition</Keyword><Keyword MajorTopicYN="Y">graph theory</Keyword><Keyword MajorTopicYN="Y">network analysis</Keyword><Keyword MajorTopicYN="Y">resting state</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32458698</ArticleId><ArticleId IdType="doi">10.1089/brain.2019.0709</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19394086</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>120</Volume><Issue>1-3</Issue><PubDate><Year>2010</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Higher psychological pain during a major depressive episode may be a factor of vulnerability to suicidal ideation and act.</ArticleTitle><Pagination><MedlinePgn>226-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2009.03.013</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">It has been suggested that psychological pain ("psychache") is a key factor in the suicidal process. In addition, suicidal acts may be best understood within a stress-vulnerability model. We hypothesized that more intense psychache during a major depressive episode would be a factor of vulnerability to suicidal behavior.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients hospitalized for a major depressive episode, including 87 individuals with a recent history of suicidal acts, 61 individuals with a past history of suicidal acts, and 62 individuals without any suicidal history, were assessed at admission using several Visual Analog scales to measure levels of psychache, physical pain and suicidal ideation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with a recent or past history of suicide attempts expressed significantly higher levels of current psychological pain, and a higher intensity and frequency of current suicidal ideation than patients without any history of suicidal acts. The level of current psychache was significantly and positively associated with intensity and frequency of suicidal ideation. There were no between-group differences for physical pain.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Medication status was not controlled. A lack of statistical power may have masked an association between physical pain and suicidal ideation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Higher psychological pain during a major depressive episode may be a factor of vulnerability to suicidal behavior, by increasing the propensity to suicidal ideation. Measuring and taking care of psychache during a depressive episode should be a major therapeutic target during crisis intervention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>OliÃ©</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>UniversitÃ© Montpellier 1, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillaume</LastName><ForeName>SÃ©bastien</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Jaussent</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Courtet</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Jollant</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003419" MajorTopicYN="N">Crisis Intervention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012907" MajorTopicYN="N">Smoking</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013850" MajorTopicYN="Y">Thinking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>01</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>03</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>03</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19394086</ArticleId><ArticleId IdType="pii">S0165-0327(09)00126-8</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2009.03.013</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9395150</PMID><DateCompleted><Year>1998</Year><Month>01</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-690X</ISSN><JournalIssue CitedMedium="Print"><Volume>96</Volume><Issue>5</Issue><PubDate><Year>1997</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Electroconvulsive therapy vs. paroxetine in treatment-resistant depression -- a randomized study.</ArticleTitle><Pagination><MedlinePgn>334-42</MedlinePgn></Pagination><Abstract><AbstractText>Failure to respond to adequate pharmacological treatment for major depression is now the most common indication for the use of electroconvulsive therapy (ECT). The advantages of ECT with respect to both speed and quality of response are clinically important issues, but surprisingly few studies have examined the efficacy of ECT in relation to newer antidepressant agents such as selective serotonin reuptake inhibitors (SSRIs). A total of 39 subjects with major depression and with at least two failed antidepressant trials (mean 4.9 trials) were randomized to either paroxetine treatment (n=18) or right unilateral (RUL) ECT (n=21). Up to the end of the study treatment we found a reduction in the HAMD score of 59% for the ECT group and of 29% for the paroxetine group (P&lt;0.001 paired t-test). In the ECT group, 71% of subjects fulfilled the response criteria (at least a 50% decrease in total HAMD score). The present study found ECT to be superior to paroxetine in medication-resistant major depression, in terms of both degree and speed of response.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Folkerts</LastName><ForeName>H W</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of MÃ¼nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michael</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>TÃ¶lle</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Schonauer</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>MÃ¼cke</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Schulze-MÃ¶nking</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical><Chemical><RegistryNumber>41VRH5220H</RegistryNumber><NameOfSubstance UI="D017374">Paroxetine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="Y">Electroconvulsive Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017374" MajorTopicYN="N">Paroxetine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019233" MajorTopicYN="N">Retreatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>12</Month><Day>12</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>12</Month><Day>12</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9395150</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.1997.tb09926.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15319029</PMID><DateCompleted><Year>2004</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1044-5463</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>2</Issue><PubDate><Year>2004</Year><Season>Summer</Season></PubDate></JournalIssue><Title>Journal of child and adolescent psychopharmacology</Title><ISOAbbreviation>J Child Adolesc Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Divalproex for the treatment of aggression associated with adolescent mania.</ArticleTitle><Pagination><MedlinePgn>325-8</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>DelBello</LastName><ForeName>Melissa P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Caleb</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Strakowski</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Child Adolesc Psychopharmacol</MedlineTA><NlmUniqueID>9105358</NlmUniqueID><ISSNLinking>1044-5463</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014754" MajorTopicYN="N">Violence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>10</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15319029</ArticleId><ArticleId IdType="doi">10.1089/1044546041649101</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8615426</PMID><DateCompleted><Year>1996</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>153</Volume><Issue>5</Issue><PubDate><Year>1996</Year><Month>May</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Treatment of dysphoric mania with nefazodone.</ArticleTitle><Pagination><MedlinePgn>732-3</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Worthington</LastName><ForeName>J J</ForeName><Initials>JJ</Initials><Suffix>3rd</Suffix></Author><Author ValidYN="Y"><LastName>Pollack</LastName><ForeName>M H</ForeName><Initials>MH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014230">Triazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>59H4FCV1TF</RegistryNumber><NameOfSubstance UI="C051752">nefazodone</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8615426</ArticleId><ArticleId IdType="doi">10.1176/ajp.153.5.732b</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10073390</PMID><DateCompleted><Year>1999</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>60 Suppl 2</Volume><PubDate><Year>1999</Year></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Suicide attempts in major affective disorder patients with comorbid substance use disorders.</ArticleTitle><Pagination><MedlinePgn>63-9; discussion 75-6, 113-6</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The widely accepted impression that substance abuse and dependence are associated with increased suicidal risk was evaluated by literature review and with new data.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Previous research on this association was reviewed, and clinical data on suicide attempts and substance use in 504 mood disorder patients hospitalized in 4 psychiatric units in Sardinia affiliated with the Italian mental health system were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The literature supports associations of alcohol and drug use comorbidity with major affective disorders, and of some substances (polyabuse, alcohol, heroin, cocaine, and even tobacco, but perhaps not marijuana or hallucinogens) with suicidal behavior. Our new findings generally supported these 2-way associations. Suicidal risks were similar in hospitalized men and women but were associated with bipolar II, bipolar I (mainly mixed), and unipolar depressive disorders as well as substance abuse, with little effect of type of agent. Substance abuse was more common in nonmixed bipolar disorders, men, and age below 30.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The tendency for bipolar I, mainly nonmixed patients, to have a relatively high risk of substance abuse and low risk of suicide attempts indicates that mainly depressive or dysphoric (bipolar II, nonbipolar, and bipolar I, mainly mixed) mood disorders may be especially lethal. Differences in risks of substance abuse and suicidal behavior in men and in bipolar I patients further suggest that substance abuse and mood disorders may contribute to suicidal risk with at least partial independence or additivity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tondo</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>International Consortium for Research on Bipolar Disorders; the Department of Psychiatry, Harvard Medical School, Boston, Mass, USA. ltondo@aol.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldessarini</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Hennen</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Minnai</LastName><ForeName>G P</ForeName><Initials>GP</Initials></Author><Author ValidYN="Y"><LastName>Salis</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Scamonatti</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Masia</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ghiani</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mannu</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-47370</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006778" MajorTopicYN="N">Hospitals, Psychiatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>60</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>3</Month><Day>12</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>3</Month><Day>12</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10073390</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21677206</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7222</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Season>Spring</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Use of transcranial magnetic stimulation in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>E12-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.neuropsych.23.2.E12</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Agarkar</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mahgoub</LastName><ForeName>Nahla</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K02 MH067028</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="N">Transcranial Magnetic Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21677206</ArticleId><ArticleId IdType="pii">23/2/E12</ArticleId><ArticleId IdType="doi">10.1176/jnp.23.2.jnpe12</ArticleId><ArticleId IdType="pmc">PMC4102108</ArticleId><ArticleId IdType="mid">NIHMS597535</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bipolar Disord. 2009 Feb;11(1):76-81</Citation><ArticleIdList><ArticleId IdType="pubmed">19133969</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2008 Feb;11(1):119-30</Citation><ArticleIdList><ArticleId IdType="pubmed">17335643</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005;7 Suppl 1:38-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15762867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002;4 Suppl 1:94-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12479689</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 Nov;155(11):1608-10</Citation><ArticleIdList><ArticleId IdType="pubmed">9812128</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Mar;78(3):253-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15013251</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neurophysiol. 2009 Dec;120(12):2008-2039</Citation><ArticleIdList><ArticleId IdType="pubmed">19833552</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Oct;117(3):146-50</Citation><ArticleIdList><ArticleId IdType="pubmed">19178948</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Feb;5(1):40-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12656937</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Neurophysiol. 2002 Aug;19(4):344-60</Citation><ArticleIdList><ArticleId IdType="pubmed">12436089</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 2007 Spring;19(2):198-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17431073</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2009 Dec;11(6):447-52</Citation><ArticleIdList><ArticleId IdType="pubmed">19909666</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Feb;5(1):36-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12656936</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2004;20(2):98-100</Citation><ArticleIdList><ArticleId IdType="pubmed">15390210</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2004 Sep 30;128(2):199-202</Citation><ArticleIdList><ArticleId IdType="pubmed">15488963</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10073389</PMID><DateCompleted><Year>1999</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2005</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>60 Suppl 2</Volume><PubDate><Year>1999</Year></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Suicide risk in patients with major depressive disorder.</ArticleTitle><Pagination><MedlinePgn>57-62; discussion 75-6, 113-6</MedlinePgn></Pagination><Abstract><AbstractText>Understanding the origins of suicide is the first step in preventing it. Review of the current literature has revealed only limited data from general practice and community samples; most research has been performed on inpatient psychiatric populations, and extended follow-ups are rare. Mood disorders were found to be highly associated with suicide, especially in patients with major depressive disorder. Depression is an important factor in suicides of adolescents and the elderly, but those with late-onset depression are at higher risk. Both comorbidity with other disorders, such as anxiety and agitation, and rapid changes in the depressive state, for instance after release from the hospital, increase the risk for suicide.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Angst</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Zurich University Psychiatric Hospital, Switzerland. nthommen@bli.unizh.ch</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angst</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Stassen</LastName><ForeName>H H</ForeName><Initials>HH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010351" MajorTopicYN="N">Patient Discharge</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013557" MajorTopicYN="N" Type="Geographic">Switzerland</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>56</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>3</Month><Day>12</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>3</Month><Day>12</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10073389</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18355924</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2009</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>111</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Impact of depressive mixed state in an emergency psychiatry setting: a marker of bipolar disorder and a possible risk factor for emergency hospitalization.</ArticleTitle><Pagination><MedlinePgn>52-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2008.02.009</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Depressive mixed state (DMX) has been reported to be one of the most useful clinical markers for bipolar II disorder (BP-II) in the outpatient setting. However, the significance of DMX in emergency psychiatry has not been well studied.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A chart review study of 139 patients who were hospitalized in an emergency psychiatric ward with an initial diagnosis of major depressive disorder (MDD).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In 42 (30.2%) patients, the diagnosis was changed to bipolar disorder after a median observation period of 189 days from hospitalization, and of these, 34 were diagnosed as having BP-II. DMX was observed in 56 (40.3%) patients at the time of hospitalization. Compared with patients who remained in MDD, significantly more patients who later developed bipolar disorder had experienced DMX (59.5% vs. 32.0%, p = 0.0044). In multivariate analysis, DMX was one of the independent predictors of conversion to bipolar disorder (OR 2.45, p = 0.037), and the independent predictors for DMX were chronic depression and atypical features (OR 2.85, p = 0.010; OR 3.67, p = 0.046, respectively). In addition, DMX was significantly more frequently observed at emergency hospitalization than at non-emergency hospitalization (48.6% vs. 29.1%, p = 0.0065).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">A single reviewer evaluated DMX by chart review.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">DMX is a useful marker of bipolar disorder (mainly BP-II) in the emergency psychiatric setting and is closely related to emergency hospitalization for mood disorders. To confirm these findings, a prospective study that systematically evaluates DMX is needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takeshima</LastName><ForeName>Minoru</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Ishikawa Prefectural Takamatsu Hospital, Ya-36, Uchi-Takamatsu, Kahoku City, Japan. min-take@p2.tcnet.ne.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitamura</LastName><ForeName>Tatsuru</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kitamura</LastName><ForeName>Maki</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kidani</LastName><ForeName>Tomokazu</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tochimoto</LastName><ForeName>Shin-Ichi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Muramori</LastName><ForeName>Fumihiko</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Kosaka</LastName><ForeName>Kazuto</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Mitsuru</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ueno</LastName><ForeName>Katsuhiko</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hamahara</LastName><ForeName>Syouni</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kurata</LastName><ForeName>Kouichi</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>03</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004636" MajorTopicYN="N">Emergency Service, Hospital</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004637" MajorTopicYN="N">Emergency Services, Psychiatric</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>03</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>01</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>02</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18355924</ArticleId><ArticleId IdType="pii">S0165-0327(08)00069-4</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2008.02.009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20598752</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>127</Volume><Issue>1-3</Issue><PubDate><Year>2010</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Differences in white matter abnormalities between bipolar I and II disorders.</ArticleTitle><Pagination><MedlinePgn>309-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2010.05.026</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although patients with bipolar I and II disorders exhibit heterogeneous clinical presentations and cognitive functions, it remains unclear whether these two subtypes have distinct neural substrates. This study aimed to differentiate the fiber abnormalities between bipolar I and II patients using diffusion tensor images.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Fourteen bipolar I patients, thirteen bipolar II patients, and twenty-one healthy subjects were recruited. Fractional anisotropy (FA) values calculated from diffusion tensor images were compared among groups using two-sample t-test analysis in a voxel-wise manner. Correlations between the mean FA value of each survived area and the clinical characteristics as well as the scores of neuropsychological tests were further analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients of both subtypes manifested fiber impairments in the thalamus, anterior cingulate, and inferior frontal areas, whereas the bipolar II patients showed more fiber alterations in the temporal and inferior prefrontal regions. The FA values of the subgenual anterior cingulate cortices for both subtypes correlated with the performance of working memory. The FA values of the right inferior frontal area of bipolar I and the left middle temporal area of bipolar II both correlated with executive function. For bipolar II patients, the left middle temporal and inferior prefrontal FA values correlated with the scores of YMRS and hypomanic episodes, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings suggest distinct neuropathological substrates between bipolar I and II subtypes. The fiber alterations observed in the bipolar I patients were majorly associated with cognitive dysfunction, whereas those in the bipolar II patients were related to both cognitive and emotional processing.</AbstractText><CopyrightInformation>Copyright Â© 2010 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jia-Xiu</ForeName><Initials>JX</Initials><AffiliationInfo><Affiliation>Department of Computer Science, National Chiao Tung University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong-Sheng</ForeName><Initials>YS</Initials></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Jen-Chuen</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Tung-Ping</ForeName><Initials>TP</Initials></Author><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Tzu-Chen</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Li-Fen</ForeName><Initials>LF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038524" MajorTopicYN="Y">Diffusion Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004292" MajorTopicYN="N">Dominance, Cerebral</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006179" MajorTopicYN="N">Gyrus Cinguli</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056784" MajorTopicYN="N">Leukoencephalopathies</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009412" MajorTopicYN="N">Nerve Fibers</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013788" MajorTopicYN="N">Thalamus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>03</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>05</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20598752</ArticleId><ArticleId IdType="pii">S0165-0327(10)00411-8</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2010.05.026</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20171792</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2777</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>6</Issue><PubDate><Year>2010</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Medical hypotheses</Title><ISOAbbreviation>Med Hypotheses</ISOAbbreviation></Journal><ArticleTitle>Possible testable correlations between passive smoking and bipolar/cyclothymic disorder, depression and ADD/ADHD.</ArticleTitle><Pagination><MedlinePgn>1084-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mehy.2010.01.040</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gracia</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Hypotheses</MedlineTA><NlmUniqueID>7505668</NlmUniqueID><ISSNLinking>0306-9877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014028">Tobacco Smoke Pollution</NameOfSubstance></Chemical><Chemical><RegistryNumber>6M3C89ZY6R</RegistryNumber><NameOfSubstance UI="D009538">Nicotine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008960" MajorTopicYN="N">Models, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009538" MajorTopicYN="N">Nicotine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012201" MajorTopicYN="N">Reward</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014028" MajorTopicYN="N">Tobacco Smoke Pollution</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>01</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>01</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20171792</ArticleId><ArticleId IdType="pii">S0306-9877(10)00056-3</ArticleId><ArticleId IdType="doi">10.1016/j.mehy.2010.01.040</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26047808</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-244X</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2015</Year><Month>Jun</Month><Day>06</Day></PubDate></JournalIssue><Title>BMC psychiatry</Title><ISOAbbreviation>BMC Psychiatry</ISOAbbreviation></Journal><ArticleTitle>An exploratory randomised controlled trial of a web-based integrated bipolar parenting intervention (IBPI) for bipolar parents of young children (aged 3-10).</ArticleTitle><Pagination><MedlinePgn>122</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12888-015-0505-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Communication, impulse control and motivation can all be affected by Bipolar Disorder (BD) making consistent parenting more difficult than for parents without mental health problems. Children of parents with BD (CPB) are at significantly increased risk of a range of mental health issues including Attention Deficit Hyperactivity Disorder (ADHD), anxiety, depression, substance use, and sleep disorders. Furthermore, CPB are also at elevated risk for BD compared to the general population. This paper describes the rationale and protocol for a pilot randomised controlled trial (RCT) designed to assess the feasibility and acceptability of a new online intervention providing interactive psychoeducational information and parenting support for parents with BD.</AbstractText><AbstractText Label="METHODS AND DESIGN" NlmCategory="METHODS">This article describes a single-blind randomised controlled trial comparing an Integrated Bipolar Parenting Intervention (IBPI) in addition to treatment as usual (TAU) with TAU alone. Participants will be recruited from across the UK from mental health services and through self-referral. The primary outcome of the study is the feasibility and acceptability of IBPI as indicated by recruitment to target, use of the intervention site, and retention to follow-up. Parents with BD allocated to the IBPI condition will have access to the intervention for 16 weeks. Effect size estimates will be obtained with respect to child behaviour, parenting skills and measures of parental mental health using measures taken at baseline (0), and at 16, 24, 36, and 48 weeks post randomization.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">This is the first randomised controlled trial of an integrated bipolar disorder parenting intervention. The benefits and challenges of delivering this online intervention, and evaluation using online RCT methodology are discussed.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Current Controlled Trials ISRCTN75279027 Registered 12 August 2013.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Spectrum Centre for Mental Health Research, Faculty of Health and Medicine, Lancaster University, LA1 4YT, Lancaster, UK. s.jones7@lancaster.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wainwright</LastName><ForeName>Laura D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Spectrum Centre for Mental Health Research, Faculty of Health and Medicine, Lancaster University, LA1 4YT, Lancaster, UK. l.wainwright@lancaster.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jovanoska</LastName><ForeName>Jelena</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Spectrum Centre for Mental Health Research, Faculty of Health and Medicine, Lancaster University, LA1 4YT, Lancaster, UK. jovanosk@exchange.lancs.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vincent</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Spectrum Centre for Mental Health Research, Faculty of Health and Medicine, Lancaster University, LA1 4YT, Lancaster, UK. h.vincent@lancaster.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diggle</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>CHICAS, Faculty of Health and Medicine Lancaster University, Lancaster, LA1 4YT, UK. p.diggle@lancaster.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calam</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Psychological Sciences, University of Manchester, Manchester, M13 9PL, UK. rachel.calam@manchester.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Rob</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Spectrum Centre for Mental Health Research, Faculty of Health and Medicine, Lancaster University, LA1 4YT, Lancaster, UK. r.j.parker@lancaster.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Rita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Spectrum Centre for Mental Health Research, Faculty of Health and Medicine, Lancaster University, LA1 4YT, Lancaster, UK. r.long2@lancaster.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayes</LastName><ForeName>Debbie</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Spectrum Centre for Mental Health Research, Faculty of Health and Medicine, Lancaster University, LA1 4YT, Lancaster, UK. d.mayes@lancaster.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanders</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Parenting and Family Support Centre, School of Psychology, University of Queensland, Brisbane, QLD 4072, Australia. matts@psy.uq.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lobban</LastName><ForeName>Fiona</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Spectrum Centre for Mental Health Research, Faculty of Health and Medicine, Lancaster University, LA1 4YT, Lancaster, UK. f.lobban@lancaster.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName><AccessionNumberList><AccessionNumber>ISRCTN75279027</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>MR/J011886/1</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Psychiatry</MedlineTA><NlmUniqueID>100968559</NlmUniqueID><ISSNLinking>1471-244X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002652" MajorTopicYN="N">Child Behavior</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002985" MajorTopicYN="Y">Clinical Protocols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020407" MajorTopicYN="Y">Internet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="N">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016487" MajorTopicYN="N">Parenting</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013813" MajorTopicYN="Y">Therapy, Computer-Assisted</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>05</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26047808</ArticleId><ArticleId IdType="doi">10.1186/s12888-015-0505-y</ArticleId><ArticleId IdType="pii">10.1186/s12888-015-0505-y</ArticleId><ArticleId IdType="pmc">PMC4456784</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Affect Disord. 2014 Dec;169:21-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25129531</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2008 Oct;28(7):1083-95</Citation><ArticleIdList><ArticleId IdType="pubmed">18433958</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1987 Jun;44(6):540-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3579500</ArticleId></ArticleIdList></Reference><Reference><Citation>J Youth Adolesc. 1991 Apr;20(2):149-66</Citation><ArticleIdList><ArticleId IdType="pubmed">24265004</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1991 Sep;48(9):807-12</Citation><ArticleIdList><ArticleId IdType="pubmed">1929771</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Ment Health Nurs. 2011 Apr;18(3):257-64</Citation><ArticleIdList><ArticleId IdType="pubmed">21395917</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2009 Feb;194(2):146-51</Citation><ArticleIdList><ArticleId IdType="pubmed">19182176</ArticleId></ArticleIdList></Reference><Reference><Citation>J Fam Psychol. 2008 Aug;22(4):506-17</Citation><ArticleIdList><ArticleId IdType="pubmed">18729665</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Med Inform Assoc. 2013 May 1;20(3):568-76</Citation><ArticleIdList><ArticleId IdType="pubmed">23065196</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2014 Feb;204(2):122-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24262817</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Psychol. 2008 Sep;47(Pt 3):355-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18257975</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2001 Sep 15;50(6):468-71</Citation><ArticleIdList><ArticleId IdType="pubmed">11566165</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Cogn Psychother. 2014 May;42(3):283-96</Citation><ArticleIdList><ArticleId IdType="pubmed">23544953</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 2008 Sep;49(9):924-32</Citation><ArticleIdList><ArticleId IdType="pubmed">18492040</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 2000 Aug;68(4):624-40</Citation><ArticleIdList><ArticleId IdType="pubmed">10965638</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Dec;9(8):828-38</Citation><ArticleIdList><ArticleId IdType="pubmed">18076532</ArticleId></ArticleIdList></Reference><Reference><Citation>Addiction. 2009 Mar;104(3):378-88</Citation><ArticleIdList><ArticleId IdType="pubmed">19207345</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>J Appl Psychol. 1997 Apr;82(2):293-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9109287</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Child Fam Psychol Rev. 2008 Sep;11(3):114-44</Citation><ArticleIdList><ArticleId IdType="pubmed">18509758</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 2006 Feb;15(1):25-37</Citation><ArticleIdList><ArticleId IdType="pubmed">16411028</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2001 Nov;40(11):1337-45</Citation><ArticleIdList><ArticleId IdType="pubmed">11699809</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 1978 Jun;17(6):430-1</Citation><ArticleIdList><ArticleId IdType="pubmed">673161</ArticleId></ArticleIdList></Reference><Reference><Citation>Australas Psychiatry. 2006 Dec;14(4):399-402</Citation><ArticleIdList><ArticleId IdType="pubmed">17116080</ArticleId></ArticleIdList></Reference><Reference><Citation>Child Maltreat. 2008 Nov;13(4):347-61</Citation><ArticleIdList><ArticleId IdType="pubmed">18641169</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2009 Mar;66(3):287-96</Citation><ArticleIdList><ArticleId IdType="pubmed">19255378</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Dec 10;141(2-3):204-12</Citation><ArticleIdList><ArticleId IdType="pubmed">22472729</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Perspect Psychol Sci. 2011 Jan;6(1):21-37</Citation><ArticleIdList><ArticleId IdType="pubmed">26162113</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004 Oct;65(10):1343-51</Citation><ArticleIdList><ArticleId IdType="pubmed">15491237</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6107049</PMID><DateCompleted><Year>1980</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>137</Volume><Issue>9</Issue><PubDate><Year>1980</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A comparison of unipolar and bipolar depressive illness.</ArticleTitle><Pagination><MedlinePgn>1084-7</MedlinePgn></Pagination><Abstract><AbstractText>In a study of 40 consecutively hospitalized patients with research diagnoses of endogenous depression, the authors found no difference between unipolar and bipolar depressive patients in the risk for affective disorder in first-degree relatives, proportion of EEG or neuropsychological abnormalities, clinical evidence of the depressive syndrome, or response to doctor's choice of treatment. Bipolar patients had an earlier age of onset and displayed more manic symptoms that did unipolar patients. The authors conclude that the two forms of depressive illness are clinically and genetically homogeneous, are without identifying EEG or cognitive differences, and have an equally good response to somatic treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abrams</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1980</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1980</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1980</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6107049</ArticleId><ArticleId IdType="doi">10.1176/ajp.137.9.1084</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25841077</PMID><DateCompleted><Year>2015</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>179</Volume><PubDate><Year>2015</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Collaborative care for patients with bipolar disorder: Effects on functioning and quality of life.</ArticleTitle><Pagination><MedlinePgn>14-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2015.03.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(15)00132-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Functioning and quality of life are impaired in bipolar patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Collaborative Care (CC) is a multi-component intervention, provided by a multidisciplinary team, in which a nurse-care manager plays a central role. Effects on functioning and quality of life were tested in a clinical trial. We also investigated the mediating role of depression severity on these outcome variables.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients randomized to CC showed more improvement in overall functioning compared to patients in the control group who obtained care as usual (CAU), with a small effect size (ES=0.3, z=-2.5, p=0.01). In the domains of autonomy and leisure time, a medium effect was found in favor of CC (autonomy: ES=0.5, z=-2.9, p=0.004; leisure-time: ES=0.4, z=-2.4, p=0.02). No differences between conditions were found in the other domains of functioning. Concerning quality of life, patients in CC improved more in the domain physical health (ES=0.4, z=2.5, p=0.01), if compared to CAU. No differences were found in overall quality of life. Half of the effects on functioning are mediated through the effects of CC on depression severity.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">At baseline, differences on the main outcomes existed between conditions. Two teams stopped participation in the experimental condition after randomization. Sample size was limited.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Besides effects on depressive symptoms, CC seems to have direct beneficial effects on both level of functioning and aspects of quality of life.</AbstractText><CopyrightInformation>Copyright Â© 2015 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van der Voort</LastName><ForeName>Trijntje Y G</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>VU University Medical Center, Department of Psychiatry, Amsterdam, The Netherlands; Inholland University of Applied Sciences, Department of Health, Sports &amp; Welfare/Cluster Nursing, Research Group Mental Health Nursing, Amsterdam, The Netherlands. Electronic address: nienke.vandervoort2@inholland.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Meijel</LastName><ForeName>Berno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VU University Medical Center, Department of Psychiatry, Amsterdam, The Netherlands; Inholland University of Applied Sciences, Department of Health, Sports &amp; Welfare/Cluster Nursing, Research Group Mental Health Nursing, Amsterdam, The Netherlands; Parnassia Psychiatric Institute, Parnassia Academy, The Hague, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoogendoorn</LastName><ForeName>Adriaan W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>VU University Medical Center, Department of Psychiatry, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goossens</LastName><ForeName>Peter J J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Dimence Mental Health, Deventer, The Netherlands; Radboud University Medical Center, Nijmegen, The Netherlands; GGZVS, Institute for the Education of Clinical Nurse Specialists in Mental Health, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beekman</LastName><ForeName>Aartjan T F</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>VU University Medical Center, Department of Psychiatry, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kupka</LastName><ForeName>Ralph W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>VU University Medical Center, Department of Psychiatry, Amsterdam, The Netherlands; Altrecht Mental Health, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007899" MajorTopicYN="Y">Leisure Activities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010348" MajorTopicYN="N">Patient Care Team</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026684" MajorTopicYN="Y">Personal Autonomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Collaborative Care</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Functioning</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>03</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>03</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25841077</ArticleId><ArticleId IdType="pii">S0165-0327(15)00132-9</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2015.03.005</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12078030</PMID><DateCompleted><Year>2002</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-2804</ISSN><JournalIssue CitedMedium="Print"><Volume>73</Volume><Issue>5</Issue><PubDate><Year>2002</Year><Month>May</Month></PubDate></JournalIssue><Title>Der Nervenarzt</Title><ISOAbbreviation>Nervenarzt</ISOAbbreviation></Journal><ArticleTitle>[Mental incapacity and incapacity to make a decision and their status for determining legal guardianship].</ArticleTitle><Pagination><MedlinePgn>478-80</MedlinePgn></Pagination><Abstract><AbstractText>The juridical guidelines for legal capacity demand the distinction between continuous and temporary mental disorders. A case report illustrates the problematic nature of this distinction. In addition the parallels to legal requirements for guardianship are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Habermeyer</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Klinik fÃ¼r Psychiatrie und Psychotherapie, RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen. EHabermeye@aol.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sass</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>GeschÃ¤ftsunfÃ¤higkeit bzw. Nichtigkeit einer WillenserklÃ¤rung und ihre Stellung zu Bestimmungen des Betreuungsrechtes.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nervenarzt</MedlineTA><NlmUniqueID>0400773</NlmUniqueID><ISSNLinking>0028-2804</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nervenarzt. 2002 Nov;73(11):1119-20; author reply 1121-2</RefSource><PMID Version="1">12528663</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005104" MajorTopicYN="N">Expert Testimony</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007872" MajorTopicYN="Y">Legal Guardians</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016365" MajorTopicYN="N">Liability, Legal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016743" MajorTopicYN="N">Mental Competency</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>6</Month><Day>25</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>6</Month><Day>25</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12078030</ArticleId><ArticleId IdType="doi">10.1007/s001150101188</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7081502</PMID><DateCompleted><Year>1982</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>139</Volume><Issue>6</Issue><PubDate><Year>1982</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Failure to find evidence of schizophrenia in first-degree relatives of schizophrenic probands.</ArticleTitle><Pagination><MedlinePgn>826-8</MedlinePgn></Pagination><Abstract><AbstractText>The first-degree relatives (N = 199) of DSM-III schizophrenic probands (N = 39) were diagnosed from chart data by a rater who was blind to proband diagnosis. No cases of even "possible" schizophrenia were found. This augments the growing evidence that the genetic component in schizophrenia may be less than was formerly suspected.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pope</LastName><ForeName>H G</ForeName><Initials>HG</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Jonas</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>B M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Lipinski</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1982</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1982</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7081502</ArticleId><ArticleId IdType="doi">10.1176/ajp.139.6.826</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">500576</PMID><DateCompleted><Year>1980</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>12</Issue><PubDate><Year>1979</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Prospective use of saliva lithium determinations to monitor lithium therapy.</ArticleTitle><Pagination><MedlinePgn>525-6</MedlinePgn></Pagination><Abstract><AbstractText>A mathematical equation (y = 2.27x -0.45) relating saliva (y) to plasma (x) lithium concentrations was previously determined by one of the authors. A prospective study is reported here in which the correlation coefficient between the predicted and the observed plasma concentrations in a new group of 25 patients was r = 0.89 (p less than 0.001). The study demonstrates that saliva lithium determinations can be safely used to monitor lithium therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Othmer</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Piziak</LastName><ForeName>V K</ForeName><Initials>VK</Initials></Author><Author ValidYN="Y"><LastName>Preskorn</LastName><ForeName>S H</ForeName><Initials>SH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012463" MajorTopicYN="N">Saliva</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1979</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1979</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1979</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">500576</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11333068</PMID><DateCompleted><Year>2001</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>2</Issue><PubDate><Year>2001</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Neuropsychological frontal lobe tests indicate that bipolar depressed patients are more impaired than unipolar.</ArticleTitle><Pagination><MedlinePgn>88-94</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to compare the neuropsychological performance of patients with bipolar or unipolar mood disorders during acute episodes of depression using intelligence and frontal lobe tests.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Fifteen patients with bipolar depression (BP) and 30 with unipolar depression (UP) were studied. For the neuropsychological assessment, the following tests: the Wechsler Adult Intelligence Scale-Revised (WAIS-R), the Trail Making Test (TMT), the Stroop test, the verbal fluency test and the Wisconsin Card Sorting Test (WCST) were used.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean intensity of depression and mean duration of illness were similar in both groups. Patients in the BP group achieved significantly lower levels of performance in the non-verbal part of WAIS-R, in both parts of the Stroop test, in the verbal fluency test and also showed a tendency to achieve poorer results in TMT-B than those in the UP group. Bipolar depressed patients also produced significantly poorer results with the WCST as they made twice as many perseverative errors and only completed half of the correct categories compared with the UP patients. The results of the TMT-A tests, which measure psychomotor slowness, were similar in BP and UP patients. No differences between the results of male and female patients were noted in either group. Deterioration of the results associated with duration of the illness was only observed in the UP patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A higher degree of cognitive dysfunction connected with frontal lobe activity during an acute depressive episode was found in bipolar compared with unipolar depressed patients. These results may corroborate other findings pointing to pathogenic distinctions between bipolar and unipolar affective illness and to some similarities between bipolar illness and schizophrenia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Borkowska</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University School of Medical Science, Bydgoszcz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rybakowski</LastName><ForeName>J K</ForeName><Initials>JK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011596" MajorTopicYN="N">Psychomotor Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>5</Month><Day>3</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>9</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>5</Month><Day>3</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11333068</ArticleId><ArticleId IdType="doi">10.1034/j.1399-5618.2001.030207.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4887671</PMID><DateCompleted><Year>1969</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>125</Volume><Issue>11</Issue><PubDate><Year>1969</Year><Month>May</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Toward a biology of depression: some suggestions from neurophysiology.</ArticleTitle><Pagination><MedlinePgn>1491-500</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Whybrow</LastName><ForeName>P C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Mendels</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002395">Catecholamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013256">Steroids</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>9NEZ333N27</RegistryNumber><NameOfSubstance UI="D012964">Sodium</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001143" MajorTopicYN="N">Arousal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002395" MajorTopicYN="N">Catecholamines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005071" MajorTopicYN="N">Evoked Potentials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009132" MajorTopicYN="N">Muscles</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012964" MajorTopicYN="N">Sodium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013256" MajorTopicYN="N">Steroids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014882" MajorTopicYN="N">Water-Electrolyte Balance</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>66</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1969</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1969</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1969</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4887671</ArticleId><ArticleId IdType="doi">10.1176/ajp.125.11.1491</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3520803</PMID><DateCompleted><Year>1986</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0586-7614</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>1986</Year></PubDate></JournalIssue><Title>Schizophrenia bulletin</Title><ISOAbbreviation>Schizophr Bull</ISOAbbreviation></Journal><ArticleTitle>Season of birth: schizophrenia and bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>173-86</MedlinePgn></Pagination><Abstract><AbstractText>Studies investigating the association between the risk of schizophrenia and season of birth are reviewed and the association clearly established. This association cannot be explained on the basis of age-incidence or age-prevalence artifacts. Other studies suggest there may be an association between bipolar disorder and season of birth. The leading theory in explaining the season of birth phenomenon is that a seasonal factor (such as viral infection, malnutrition, vitamin deficiency, prenatal or obstetrical complications, or ambient temperature) can damage an infant's brain and thereby predispose the child to later development of psychosis. Evidence suggests that the seasonal effect is associated with a subgroup of schizophrenics who have early onset of psychosis, less genetic loading than other schizophrenics, and better prognosis. Case-control studies are needed comparing winterborn to nonwinter-born schizophrenics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boyd</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Pulver</LastName><ForeName>A E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>W</ForeName><Initials>W</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Schizophr Bull</MedlineTA><NlmUniqueID>0236760</NlmUniqueID><ISSNLinking>0586-7614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001925" MajorTopicYN="N">Brain Damage, Chronic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005306" MajorTopicYN="N">Fertilization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="Y">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012923" MajorTopicYN="N">Social Class</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>51</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3520803</ArticleId><ArticleId IdType="doi">10.1093/schbul/12.2.173</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27405742</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-960X</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>08</Month></PubDate></JournalIssue><Title>Evidence-based mental health</Title><ISOAbbreviation>Evid Based Ment Health</ISOAbbreviation></Journal><ArticleTitle>Prevalence, impact and treatment of generalised anxiety disorder in bipolar disorder: a systematic review and meta-analysis.</ArticleTitle><Pagination><MedlinePgn>73-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/eb-2016-102412</ELocationID><Abstract><AbstractText Label="QUESTION">Recent data suggest that anxiety disorders are as often comorbid with bipolar disorder (BD) as with unipolar depression; however, less attention has been paid to comorbidity of anxiety disorders with BD. Generalised anxiety disorder (GAD) is one of the most prevalent anxiety disorders that is highly comorbid with other mental disorders. We carried out a systematic review and meta-analysis to assess the degree of comorbidity between GAD and BD.</AbstractText><AbstractText Label="STUDY SELECTION AND ANALYSIS">We searched for all studies, which included primary data concerning the existence of GAD in patients with BD. The literature search strategy, selection of publications and the reporting of results have been conducted with PRISMA guidelines. The meta-analysis calculated prevalence estimates using the variance-stabilising Freeman-Tukey double arcsine transformation. We applied the inverse variance method using both fixed-effects and random-effects models to estimate summary effects for all combined studies. Heterogeneity was assessed and measured with Cochran's Q and I(2) statistics, respectively.</AbstractText><AbstractText Label="FINDINGS">The current meta-analysis analysed data from 28 independent studies and a total of 2975 patients from point prevalence studies and 4919 patients from lifetime studies. The overall random-effects point prevalence of GAD in patients with BD was 12.2% (95% CI 10.9% to 13.5%) and the overall random-effects lifetime estimate was 15.1% (95% CI 9.7% to 21.5%). Both estimates reported significant heterogeneity (94.0% and 94.7%, respectively).</AbstractText><AbstractText Label="CONCLUSIONS">Published studies report prevalence rates with high heterogeneity and consistently higher than those typically reported in the general population. It is believed that comorbid GAD might be associated with a more severe BD course and increased suicidality, and it is unknown how best to treat such conditions. The current meta-analysis confirms that GAD is highly prevalent in BD and the rate is higher in comparison to those in the general population.</AbstractText><CopyrightInformation>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Preti</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genneruxi Medical Center, Cagliari, Italy Center for Consultation-Liaison Psychiatry and Psychosomatics, University Hospital of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vrublevska</LastName><ForeName>Jelena</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Narcology, Riga Stradins University, Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veroniki</LastName><ForeName>Areti Angeliki</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huedo-Medina</LastName><ForeName>Tania B</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>Department of Allied Health Sciences, University of Connecticut, Storrs, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fountoulakis</LastName><ForeName>Konstantinos N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>3rd Department of Psychiatry, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Evid Based Ment Health</MedlineTA><NlmUniqueID>100883413</NlmUniqueID><ISSNLinking>1362-0347</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>06</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>06</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27405742</ArticleId><ArticleId IdType="pii">eb-2016-102412</ArticleId><ArticleId IdType="doi">10.1136/eb-2016-102412</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31981272</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2850</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of psychiatric and mental health nursing</Title><ISOAbbreviation>J Psychiatr Ment Health Nurs</ISOAbbreviation></Journal><ArticleTitle>Patients' experiences of cognitive functioning in recurrent depression: A qualitative study.</ArticleTitle><Pagination><MedlinePgn>321-329</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jpm.12603</ELocationID><Abstract><AbstractText>WHAT IS KNOWN ON THE SUBJECT?: Recurrent depressive episodes involve significant morbidity, suicide risk and recurrent hospitalizations. In both major depressive disorder and bipolar disorder, there are significant impairments in functioning following resolution of acute symptoms. WHAT THIS PAPER ADDS TO EXISTING KNOWLEDGE?: This paper provides an in-depth qualitative understanding of the subjective experience of cognitive impairment following a depressive episode in a recurrent mood disorder. It identifies descriptions of two types of experience (being stuck and being preoccupied with one's thoughts) that led to impairments in concentration, memory, organization and decision-making. WHAT ARE THE IMPLICATIONS FOR PRACTICE?: Mental health nurses need to develop an awareness of the impact of cognitive difficulties in the process of recovery from recurrent mood disorders. Mental health nurses need to provide knowledgeable reassurance, information and interventions to people who experience cognitive difficulties to provide a framework of understanding that promotes recovery. ABSTRACT: Introduction People who experience recurrent depressive episodes often have ongoing cognitive problems that impact on their functional recovery. These cognitive difficulties have been identified as impacting on social, interpersonal and occupational functioning and can result in vulnerability to relapse. Aim The aim of this qualitative study was to explore participants' subjective experiences of cognitive impairment after discharge from mental health services following treatment for recurrent depression. Methods The study was designed as a qualitative study in order to best capture participants' subjective experiences. Data were collected by semi-structured interviews and were analysed using a process of thematic analysis. Results Twenty participants took part in this study. All participants described experiences of either 1) "being stuck"; or 2) "being preoccupied with own thoughts"; however, all participants described the experiences in the third theme: "it stops you living to your potential." Implications for practice In order to promote recovery in a meaningful way, mental health nurses need to provide information about and strategies for managing cognitive difficulties associated with recurrent mood disorders.</AbstractText><CopyrightInformation>Â© 2020 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Crowe</LastName><ForeName>Marie</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-7220-8658</Identifier><AffiliationInfo><Affiliation>Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porter</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Douglas</LastName><ForeName>Katie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inder</LastName><ForeName>Maree</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacey</LastName><ForeName>Cameron</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jordan</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-4699-6301</Identifier><AffiliationInfo><Affiliation>Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wells</LastName><ForeName>Hayley</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>New Zealand Lottery Grants Board</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Ment Health Nurs</MedlineTA><NlmUniqueID>9439514</NlmUniqueID><ISSNLinking>1351-0126</ISSNLinking></MedlineJournalInfo><CitationSubset>N</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010351" MajorTopicYN="N">Patient Discharge</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036301" MajorTopicYN="N">Qualitative Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">cognitive functioning</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">functional impairment</Keyword><Keyword MajorTopicYN="N">patient experience</Keyword><Keyword MajorTopicYN="N">qualitative research</Keyword><Keyword MajorTopicYN="N">recovery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>01</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>01</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31981272</ArticleId><ArticleId IdType="doi">10.1111/jpm.12603</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Baldessarini, R. J., Faedda, G. L., Offidani, E., Vazquez, G. H., Marangoni, C., Serra, G., &amp; Tondo, L. (2013). Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: A review. Journal of Affective Disorders, 148(1), 129-135. https://doi.org/10.1016/j.jad.2012.10.033</Citation></Reference><Reference><Citation>Baune, B. T., &amp; Malhi, G. S. (2015). A review on the impact of cognitive dysfunction on social, occupational, and general functional outcomes in bipolar disorder. Bipolar Disorders, 17(Suppl 2), 41-55. https://doi.org/10.1111/bdi.12341</Citation></Reference><Reference><Citation>Bora, E., Harrison, B. J., Yucel, M., &amp; Pantelis, C. (2013). Cognitive impairment in euthymic major depressive disorder: A meta-analysis. Psychological Medicine, 43(10), 2017-2026. https://doi.org/10.1017/S0033291712002085</Citation></Reference><Reference><Citation>Bourne, C., Aydemir, Ã., BalanzÃ¡-MartÃ­nez, V., Bora, E., Brissos, S., Cavanagh, J. T. O., â¦ Goodwin, G. M. (2013). Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: An individual patient data meta-analysis. Acta Psychiatrica Scandinavica, 128(3), 149-162. https://doi.org/10.1111/acps.12133</Citation></Reference><Reference><Citation>Bowie, C. R., Gupta, M., &amp; Holshausen, K. (2013). Cognitive remediation therapy for mood disorders: Rationale, early evidence, and future directions. Canadian Journal of Psychiatry, 58(6), 319-325. https://doi.org/10.1177/070674371305800603</Citation></Reference><Reference><Citation>Braun, V., &amp; Clarke, V. (2006). Using thematic analysis in psychology. Qualitative Research in Psychology, 3(2), 77-101. https://doi.org/10.1191/1478088706qp063oa</Citation></Reference><Reference><Citation>Brebion, G., Smith, M. J., &amp; Allilaire, J. F. (1995). Psychometric characteristics of ideational retardation in depressives. British Journal of Clinical Psychology, 34, 371-381. https://doi.org/10.1111/j.2044-8260.1995.tb01472.x</Citation></Reference><Reference><Citation>Bui, E., &amp; Fava, M. (2017). From depression to anxiety, and back. Acta Psychiatrica Scandinavica, 136(4), 341-342. https://doi.org/10.1111/acps.12801</Citation></Reference><Reference><Citation>Burdick, K. E., Gunawardane, N., Goldberg, J. F., Halperin, J. M., Garno, J. L., &amp; Malhotra, A. K. (2009). Attention and psychomotor functioning in bipolar depression. Psychiatry Research, 166(2-3), 192-200. https://doi.org/10.1016/j.psychres.2008.03.006</Citation></Reference><Reference><Citation>Clarke, V., &amp; Braun, V. (2018). Using thematic analysis in counselling and psychotherapy research: A critical reflection. Counselling and Psychotherapy Research, 18(2), 107-110. https://doi.org/10.1002/capr.12165</Citation></Reference><Reference><Citation>Conradi, H. J., Ormel, J., &amp; de Jonge, P. (2011). Presence of individual (residual) symptoms during depressive episodes and periods of remission: A 3-year prospective study. Psychological Medicine, 41(6), 1165-1174. https://doi.org/10.1017/S0033291710001911</Citation></Reference><Reference><Citation>Crowe, M. (2017). Recovery and mood disorders. Journal of Psychiatric and Mental Health Nursing, 24(8), 561-562. https://doi.org/10.1111/jpm.12418</Citation></Reference><Reference><Citation>Crowe, M., Inder, M., &amp; Porter, R. (2015). Conducting qualitative research in mental health: Thematic and content analyses. Australian and New Zealand Journal of Psychiatry, 49(7), 616-623. https://doi.org/10.1177/0004867415582053</Citation></Reference><Reference><Citation>Cuijpers, P. (2011). The patient perspective in research on major depression. BMC Psychiatry, 11, 89. https://doi.org/10.1186/1471-244X-11-89</Citation></Reference><Reference><Citation>Ebert, B., Miskowiak, K., Kloster, M., Johansen, J., Eckholm, C., Waerner, T., â¦ Bruun, L. M. (2017). An ethnographic study of the effects of cognitive symptoms in patients with major depressive disorder: The IMPACT study. BMC Psychiatry, 17(1), 370. https://doi.org/10.1186/s12888-017-1523-8</Citation></Reference><Reference><Citation>Frank, E. (2005). Treating Bipolar Disorder: A clinician's guide to interpersonal and social rhythm therapy. New York, NY: Guilford Press.</Citation></Reference><Reference><Citation>Gitlin, M. J., &amp; Miklowitz, D. J. (2017). The difficult lives of individuals with bipolar disorder: A review of functional outcomes and their implications for treatment. Journal of Affective Disorders, 209, 147-154. https://doi.org/10.1016/j.jad.2016.11.021</Citation></Reference><Reference><Citation>Goodwin, F. K., &amp; Jamison, K. R. (2007). Manic-depressive illness - Bipolar disorders and recurrent depression (2nd ed.). New York: Oxford University Press.</Citation></Reference><Reference><Citation>Gutierrez-Rojas, L., Gurpegui, M., Ayuso-Mateos, J. L., Gutierrez-Ariza, J. A., Ruiz-Veguilla, M., &amp; Jurado, D. (2008). Quality of life in bipolar disorder patients: A comparison with a general population sample. Bipolar Disorders, 10(5), 625-634. https://doi.org/10.1111/j.1399-5618.2008.00604.x</Citation></Reference><Reference><Citation>Hasking, P., Boyes, M. E., Finlay-Jones, A., McEvoy, P. M., &amp; Rees, C. S. (2019). Common pathways to NSSI and suicide ideation: The roles of rumination and self-compassion. Archives of Suicide Research, 23(2), 247-260. https://doi.org/10.1080/13811118.2018.1468836</Citation></Reference><Reference><Citation>Horwitz, A. G., Czyz, E. K., Berona, J., &amp; King, C. A. (2019). Rumination, brooding, and reflection: Prospective associations with suicide ideation and suicide attempts. Suicide and Life-Threatening Behavior, 49(4), 1085-1093. https://doi.org/10.1111/sltb.12507</Citation></Reference><Reference><Citation>Judd, L. L., Akiskal, H. S., Schettler, P., Endicott, J., Leon, A., Solomon, D. A., â¦ Keller, M. (2005). Psychosocial disability in the course of bipolar I and bipolar II disorders: A prospective, comparative, longitudinal study. Archives of General Psychiatry, 62(12), 1322-1330.</Citation></Reference><Reference><Citation>Kallio, H., Pietila, A. M., Johnson, M., &amp; Kangasniemi, M. (2016). Systematic methodological review: Developing a framework for a semi-structured qualitative interview guide. Journal of Advanced Nursing, 72, 2954-2965.</Citation></Reference><Reference><Citation>Keizer, I., Piguet, C., Favre, S., Aubry, J. M., Dayer, A., Gervasoni, N., â¦ Bertschy, G. (2014). Subjective experience of thought overactivation in mood disorders: Beyond racing and crowded thoughts. Psychopathology, 47(3), 174-184. https://doi.org/10.1159/000354781</Citation></Reference><Reference><Citation>Knight, M. J., Lyrtzis, E., &amp; Baune, B. T. (2019). The association of cognitive deficits with mental and physical quality of life in major depressive disorder. Comprehensive Psychiatry, 97, 152147. https://doi.org/10.1016/j.comppsych.2019.152147</Citation></Reference><Reference><Citation>Koch, T. (2006). Establishing rigour in qualitative research: The decision trail. Journal of Advanced Nursing, 53, 91-100. https://doi.org/10.1111/j.1365-2648.2006.03681.x</Citation></Reference><Reference><Citation>McAllister-Williams, R. H., Bones, K., Goodwin, G. M., Harrison, J., Katona, C., Rasmussen, J., â¦ Young, A. H. (2017). Analysing UK clinicians' understanding of cognitive symptoms in major depression: A survey of primary care physicians and psychiatrists. Journal of Affective Disorders, 207, 346-352. https://doi.org/10.1016/j.jad.2016.09.036</Citation></Reference><Reference><Citation>McIntyre, R. S., Cha, D. S., Soczynska, J. K., Woldeyohannes, H. O., Gallaugher, L. A., Kudlow, P., â¦ Baskaran, A. (2013). Cognitive deficits and functional outcomes in major depressive disorder: Determinants, substrates, and treatment interventions. Depress Anxiety, 30(6), 515-527. https://doi.org/10.1002/da.22063</Citation></Reference><Reference><Citation>Moreno, C., Hasin, D. S., Arango, C., Oquendo, M. A., Vieta, E., Liu, S., â¦ Blanco, C. (2012). Depression in bipolar disorder versus major depressive disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Bipolar Disorders, 14(3), 271-282. https://doi.org/10.1111/j.1399-5618.2012.01009.x</Citation></Reference><Reference><Citation>Nolen-Hoeksema, S., Wisco, B. E., &amp; Lyubomirsky, S. (2008). Rethinking rumination. Perspectives on Psychological Science, 3(5), 400-424. https://doi.org/10.1111/j.1745-6924.2008.00088.x</Citation></Reference><Reference><Citation>Ott, C. V., Bjertrup, A. J., Jensen, J. H., Ullum, H., Sjaelland, R., Purdon, S. E., â¦ Miskowiak, K. W. (2016). Screening for cognitive dysfunction in unipolar depression: Validation and evaluation of objective and subjective tools. Journal of Affective Disorders, 190, 607-615. https://doi.org/10.1016/j.jad.2015.10.059</Citation></Reference><Reference><Citation>Papageorgiou, C., &amp; Wells, A. e. (2004). Depressive Rumination: Nature, theory and treatment. West Sussex, England: John Wiley.</Citation></Reference><Reference><Citation>Parker, G., Bassett, D., Outhred, T., Morris, G., Hamilton, A., Das, P., â¦ Malhi, G. S. (2017). Defining melancholia: A core mood disorder. Bipolar Disorders, 19(3), 235-237. https://doi.org/10.1111/bdi.12501</Citation></Reference><Reference><Citation>Petersen, J. Z., Porter, R. J., &amp; Miskowiak, K. W. (2018). Clinical characteristics associated with the discrepancy between subjective and objective cognitive impairment in depression. Journal of Affective Disorders, 246, 763-774. https://doi.org/10.1016/j.jad.2018.12.105</Citation></Reference><Reference><Citation>Porter, R. J., Bowie, C. R., Jordan, J., &amp; Malhi, G. S. (2013). Cognitive remediation as a treatment for major depression: A rationale, review of evidence and recommendations for future research. Australian and New Zealand Journal of Psychiatry, 47(12), 1165-1175. https://doi.org/10.1177/0004867413502090</Citation></Reference><Reference><Citation>Porter, R. J., Inder, M., Douglas, K. M., Moor, S., Carter, J., Frampton, C. M., &amp; Crowe, M. (2019). Improvement in cognitive function in young people with bipolar disorder: Results from participants in an 18-month randomised controlled trial of adjunctive psychotherapy. Australian and New Zealand Journal of Psychiatry. https://doi.org/10.1177/0004867419887794. [Epub ahead of print].</Citation></Reference><Reference><Citation>Roca, M., LÃ³pez-Navarro, E., MonzÃ³n, S., Vives, M., GarcÃ­a-Toro, M., GarcÃ­a-Campayo, J., â¦ Gili, M. (2015). Cognitive impairment in remitted and non-remitted depressive patients: A follow-up comparison between first and recurrent episodes. European Neuropsychopharmacology, 25(11), 1991-1998. https://doi.org/10.1016/j.euroneuro.2015.07.020</Citation></Reference><Reference><Citation>Samalin, L., Bellivier, F., Giordana, B., Yon, L., Milhiet, V., El-Hage, W., â¦ Llorca, P. M. (2014). Patients' perspectives on residual symptoms in bipolar disorder a focus group study. Journal of Nervous and Mental Disease, 202(7), 550-555. https://doi.org/10.1097/Nmd.0000000000000157</Citation></Reference><Reference><Citation>Sim, K., Lau, W., Sim, J., Min, Y. S., &amp; Baldessarini, R. J. (2016). Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials. Journal of Neuropsychopharmacology, 19, pyv076. https://doi.org/10.1093/ijnp/pyv076</Citation></Reference><Reference><Citation>Strine, T. W., Kroenke, K., Dhingra, S., Balluz, L. S., Gonzalez, O., Berry, J. T., &amp; Mokdad, A. H. (2009). The associations between depression, health-related quality of life, social support, life satisfaction, and disability in community-dwelling US adults. The Journal of Nervous and Mental Disease, 197(1), 61-64. https://doi.org/10.1097/NMD.0b013e3181924ad8</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24557044</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0216</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>2-3</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Neuroimmunomodulation</Title><ISOAbbreviation>Neuroimmunomodulation</ISOAbbreviation></Journal><ArticleTitle>The immunology of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>117-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000356539</ELocationID><Abstract><AbstractText>Bipolar disorder (BD) is a psychiatric condition associated with elevated frequency of clinical comorbidities and cognitive impairment. The neurobiology of BD is not completely understood. Recent evidence has implicated immune dysfunction in its physiopathology. Here, we review several data supporting the presence of immunological dysfunction in BD: (i) increased frequency of autoimmune diseases; (ii) distinct immune cell profile; (iii) release of/altered cytokines by stimulated mononuclear cells; (iv) elevated levels of circulating immune markers, and (v) inflammatory changes in the central nervous system. We also discuss the interplay between immunological dysfunction and neuroprogression in BD.</AbstractText><CopyrightInformation>Â© 2014 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barbosa</LastName><ForeName>Izabela GuimarÃ£es</ForeName><Initials>IG</Initials><AffiliationInfo><Affiliation>LaboratÃ³rio Interdisciplinar de InvestigaÃ§Ã£o MÃ©dica da Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machado-Vieira</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Soares</LastName><ForeName>Jair C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Teixeira</LastName><ForeName>Antonio L</ForeName><Initials>AL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z99 MH999999</GrantID><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neuroimmunomodulation</MedlineTA><NlmUniqueID>9422763</NlmUniqueID><ISSNLinking>1021-7401</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24557044</ArticleId><ArticleId IdType="pii">000356539</ArticleId><ArticleId IdType="doi">10.1159/000356539</ArticleId><ArticleId IdType="pmc">PMC4041530</ArticleId><ArticleId IdType="mid">NIHMS571217</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aust N Z J Psychiatry. 2012 Jul;46(7):684-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22735640</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2013 Sep;47(9):1119-33</Citation><ArticleIdList><ArticleId IdType="pubmed">23768870</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2009 Jun 15;61(6):822-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19479699</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2007 Jun 21;421(1):33-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17548157</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2007 May-Jun;17(6-7):394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17140771</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pract Epidemiol Ment Health. 2009 Jan 23;5:3</Citation><ArticleIdList><ArticleId IdType="pubmed">19166608</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2002 Feb 15;51(4):305-11</Citation><ArticleIdList><ArticleId IdType="pubmed">11958781</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2011 Mar;261(2):139-43</Citation><ArticleIdList><ArticleId IdType="pubmed">20446090</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2011 Jan;35(3):804-17</Citation><ArticleIdList><ArticleId IdType="pubmed">20934453</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2013 Mar;263(2):159-65</Citation><ArticleIdList><ArticleId IdType="pubmed">22584806</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Nov;9(7):743-53</Citation><ArticleIdList><ArticleId IdType="pubmed">17988365</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Oct 15;82(2):309-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15488263</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Dec;8(6):740-50</Citation><ArticleIdList><ArticleId IdType="pubmed">17156159</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Jul 1;74(1):15-25</Citation><ArticleIdList><ArticleId IdType="pubmed">23419545</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2013 Jul;18(7):767-73</Citation><ArticleIdList><ArticleId IdType="pubmed">22801413</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2010 Aug;64(4):442-3</Citation><ArticleIdList><ArticleId IdType="pubmed">20653912</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Dec;104(1-3):91-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17434599</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Psychopharmacol. 2008 Mar;23(2):87-94</Citation><ArticleIdList><ArticleId IdType="pubmed">18172906</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 Sep;12(6):638-46</Citation><ArticleIdList><ArticleId IdType="pubmed">20868462</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Open. 2012 Feb 22;2(1):e000643</Citation><ArticleIdList><ArticleId IdType="pubmed">22357572</ArticleId></ArticleIdList></Reference><Reference><Citation>Mult Scler. 2004 Oct;10(5):575-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15471376</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med. 2013 Mar 18;11:74</Citation><ArticleIdList><ArticleId IdType="pubmed">23506529</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Apr;65(4):395-407</Citation><ArticleIdList><ArticleId IdType="pubmed">18391128</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2012 Mar;46(3):389-93</Citation><ArticleIdList><ArticleId IdType="pubmed">22137759</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Apr;15(4):384-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19488045</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2013 May;38(5):667-76</Citation><ArticleIdList><ArticleId IdType="pubmed">22989476</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2013 Mar;53:52-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23064447</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 2005 Jun 15;80(6):789-97</Citation><ArticleIdList><ArticleId IdType="pubmed">15884015</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2011 Mar;36(2):114-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21138659</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 1993 Nov;17(6):971-84</Citation><ArticleIdList><ArticleId IdType="pubmed">8278606</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2012 Sep;37(9):1397-416</Citation><ArticleIdList><ArticleId IdType="pubmed">22525700</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 2004 May;150(1-2):116-22</Citation><ArticleIdList><ArticleId IdType="pubmed">15081255</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Aug;15(8):784-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20351717</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2001 Nov;79(4):826-34</Citation><ArticleIdList><ArticleId IdType="pubmed">11723175</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Nov 15;74(10):e29-30</Citation><ArticleIdList><ArticleId IdType="pubmed">23601849</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2011 Dec;45(12):1608-16</Citation><ArticleIdList><ArticleId IdType="pubmed">21889167</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2011 Aug 30;193(2):71-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21676596</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2009 May;12(4):561-78</Citation><ArticleIdList><ArticleId IdType="pubmed">19224657</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2011 Aug;25(6):1206-13</Citation><ArticleIdList><ArticleId IdType="pubmed">21443944</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2009 Jan;43(3):181-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18582900</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2013 Nov;34:47-55</Citation><ArticleIdList><ArticleId IdType="pubmed">23876746</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Jan;136(1-2):110-116</Citation><ArticleIdList><ArticleId IdType="pubmed">21962564</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1988 Sep;25(3):243-51</Citation><ArticleIdList><ArticleId IdType="pubmed">3186859</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Mar;137(1-3):151-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22252095</ArticleId></ArticleIdList></Reference><Reference><Citation>Egypt J Immunol. 2006;13(1):79-85</Citation><ArticleIdList><ArticleId IdType="pubmed">17974152</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24237345</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1480-3321</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>10</Issue><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Genome</Title><ISOAbbreviation>Genome</ISOAbbreviation></Journal><ArticleTitle>Family-based exome-sequencing approach identifies rare susceptibility variants for lithium-responsive bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>634-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1139/gen-2013-0081</ELocationID><Abstract><AbstractText>Bipolar disorder (BD) is a psychiatric condition characterized by the occurrence of at least two episodes of clinically disturbed mood including mania and depression. A vast literature describing BD studies suggests that a strong genetic contribution likely underlies this condition; heritability is estimated to be as high as 80%. Many studies have identified BD susceptibility loci, but because of the genetic and phenotypic heterogeneity observed across individuals, very few loci were subsequently replicated. Research in BD genetics to date has consisted of classical linkage or genome-wide association studies, which have identified candidate genes hypothesized to present common susceptibility variants. Although the observation of such common variants is informative, they can only explain a small fraction of the predicted BD heritability, suggesting a considerable contribution would come from rare and highly penetrant variants. We are seeking to identify such rare variants, and to increase the likelihood of being successful, we aimed to reduce the phenotypic heterogeneity factor by focusing on a well-defined subphenotype of BD: excellent response to lithium monotherapy. Our group has previously shown positive response to lithium therapy clusters in families and has a consistent clinical presentation with minimal comorbidity. To identify such rare variants, we are using a targeted exome capture and high-throughput DNA sequencing approach, and analyzing the entire coding sequences of BD affected individuals from multigenerational families. We are prioritizing rare variants with a frequency of less than 1% in the population that segregate with affected status within each family, as well as being potentially highly penetrant (e.g., protein truncating, missense, or frameshift) or functionally relevant (e.g., 3'UTR, 5'UTR, or splicing). By focusing on rare variants in a familial cohort, we hope to explain a significant portion of the missing heritability in BD, as well as to narrow our current insight on the key biochemical pathways implicated in this complex disorder. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cruceanu</LastName><ForeName>Cristiana</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>a Department of Human Genetics, McGill University, MontrÃ©al, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ambalavanan</LastName><ForeName>Amirthagowri</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Spiegelman</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>LafreniÃ¨re</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Dion</LastName><ForeName>Patrick A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Alda</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Turecki</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Rouleau</LastName><ForeName>Guy A</ForeName><Initials>GA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Genome</MedlineTA><NlmUniqueID>8704544</NlmUniqueID><ISSNLinking>0831-2796</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059472" MajorTopicYN="Y">Exome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059014" MajorTopicYN="Y">High-Throughput Nucleotide Sequencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24237345</ArticleId><ArticleId IdType="doi">10.1139/gen-2013-0081</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16730333</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2007</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>60</Volume><Issue>9</Issue><PubDate><Year>2006</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Impact of neurocognitive function on academic difficulties in pediatric bipolar disorder: A clinical translation.</ArticleTitle><Pagination><MedlinePgn>951-6</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous research has demonstrated that academic and neuropsychological functions are compromised in pediatric bipolar disorder (PBD). Investigation of the degree to which neuropsychological deficits might contribute to those academic problems is needed to aid in the recognition and intervention for school achievement difficulties in PBD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A sample of 55 children and adolescents with PBD with and without attention-deficit/hyperactivity disorder (ADHD) (PBD group, n = 28; PBD+ADHD group, n = 27) were tested with a computerized neurocognitive battery and standardized neuropsychological tests. Age range of subjects was 7-17 years, with the mean age of 11.97 (3.18) years. Parents completed a structured questionnaire on school and academic functioning.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Logistic regression analyses indicated that executive function, attention, working memory, and verbal memory scores were poorer in those with a history of reading/writing difficulties. A separate logistic regression analysis found that attentional dysfunction predicted math difficulties. These relationships between neuropsychological function and academic difficulties were not different in those with PBD+ADHD than in those with PBD alone.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In PBD neuropsychological deficits in the areas of attention, working memory, and organization/problem solving skills all contribute to academic difficulties. Early identification and intervention for these difficulties might help prevent lower academic achievement in PBD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pavuluri</LastName><ForeName>Mani N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois, USA. mpavuluri@psych.uic.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Megan Marlow</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Harral</LastName><ForeName>Erin M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sweeney</LastName><ForeName>John A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 EE018638-01</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002658" MajorTopicYN="N">Developmental Disabilities</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010372" MajorTopicYN="Y">Pediatrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014477" MajorTopicYN="Y">Underachievement</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>11</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>03</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>03</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16730333</ArticleId><ArticleId IdType="pii">S0006-3223(06)00403-3</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2006.03.027</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3054622</PMID><DateCompleted><Year>1988</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0302-282X</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>1988</Year></PubDate></JournalIssue><Title>Neuropsychobiology</Title><ISOAbbreviation>Neuropsychobiology</ISOAbbreviation></Journal><ArticleTitle>Therapeutic effect of maprotiline and chlorimipramine: controlled study.</ArticleTitle><Pagination><MedlinePgn>20-4</MedlinePgn></Pagination><Abstract><AbstractText>A study was done on 40 outpatients suffering from major affective disorders (uni- and bipolar). Chlorimipramine or maprotiline was administered alternatively (means = 116.25 and 116.75 mg/day, respectively). The therapeutic effect of both antidepressive drugs is very similar, but maprotiline improves the gastrointestinal somatic symptoms faster and seems to be more effective in bipolar patients. It also produces less side effects than chlorimipramine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Montejo-Iglesias</LastName><ForeName>M L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Hospital Clinico San Carlos, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos-Brieva</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neuropsychobiology</MedlineTA><NlmUniqueID>7512895</NlmUniqueID><ISSNLinking>0302-282X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000873">Anthracenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>2U1W68TROF</RegistryNumber><NameOfSubstance UI="D008376">Maprotiline</NameOfSubstance></Chemical><Chemical><RegistryNumber>NUV44L116D</RegistryNumber><NameOfSubstance UI="D002997">Clomipramine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000873" MajorTopicYN="N">Anthracenes</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002997" MajorTopicYN="N">Clomipramine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008376" MajorTopicYN="N">Maprotiline</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="N">Psychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3054622</ArticleId><ArticleId IdType="pii">118428</ArticleId><ArticleId IdType="doi">10.1159/000118428</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">22085804</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>136</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Effects of comorbidity and early age of onset in young people with Bipolar Disorder on self harming behaviour and suicide attempts.</ArticleTitle><Pagination><MedlinePgn>1212-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2011.10.018</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The age of the first episode of illness in Bipolar Disorder has been shown to be an important predictor of outcome with early onset, particularly onset before puberty, associated with greater comorbidity, a poorer quality of life and greatest impairment in functioning.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Baseline data from a psychotherapy study was used to examine the prevalence of other comorbid psychiatric conditions and the impact of onset at an early age on both self harming behaviour and suicide attempts in young people with Bipolar Disorder.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">This study of 100 adolescents and young adults (aged 15-36 years) with Bipolar Disorder showed that comorbid conditions were very common, even at the start of their bipolar illness. Comorbidity increased as the age of onset decreased with very early onset (&lt;13 years) patients bearing the greatest burden of disease. Greater comorbidity also significantly increased the risk of having self harmed and attempted suicide with high lethal intent. Self harming behaviour was predicted by having a lifetime diagnoses of Borderline Personality Disorder and Panic Disorder along with an early age of onset of Bipolar Disorder. In contrast, previous suicide attempts were predicted by greater comorbidity and not by very early (&lt;13 years) age of onset.</AbstractText><CopyrightInformation>Copyright Â© 2011 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moor</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, University of Otago, Christchurch, New Zealand. stephanie.moor@otago.ac.nz</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowe</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Luty</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Joyce</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Affect Disord. 2016 Jan 15;190:894</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016584" MajorTopicYN="N">Panic Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016728" MajorTopicYN="N">Self-Injurious Behavior</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>02</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22085804</ArticleId><ArticleId IdType="pii">S0165-0327(11)00667-7</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2011.10.018</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20000279</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0279-3695</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>12</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of psychosocial nursing and mental health services</Title><ISOAbbreviation>J Psychosoc Nurs Ment Health Serv</ISOAbbreviation></Journal><ArticleTitle>Pediatric bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>22-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3928/02793695-20091103-02</ELocationID><Abstract><AbstractText>Pediatric bipolar disorder differs from the adult form of the disorder, marked by longer episodes, rapid cycling, prominent irritability, and high rates of comorbid attention-deficit/hyperactivity disorder and anxiety disorders. A careful assessment by families of children's symptoms, including their duration and intensity, helps with accurate diagnosis. After the diagnosis is made and careful psychopharmacological intervention is initiated, psychiatric nursing treatment of children and adolescents with pediatric bipolar disorder should involve child-and family-focused cognitive-behavioral therapies, family support, and psychoeducation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carbray</LastName><ForeName>M Julie A</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Pediatric Mood Disorder Clinic, Institute for Juvenile Research, University of Illinois at Chicago, Chicago, IL 60608, USA. jcarbray@psych.uic.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGuinness</LastName><ForeName>Teena</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychosoc Nurs Ment Health Serv</MedlineTA><NlmUniqueID>8200911</NlmUniqueID><ISSNLinking>0279-3695</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>N</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002665" MajorTopicYN="N">Child Psychiatry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="N">Cognitive Behavioral Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009730" MajorTopicYN="N">Nursing Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010290" MajorTopicYN="N">Parents</DescriptorName><QualifierName UI="Q000193" MajorTopicYN="N">education</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011568" MajorTopicYN="N">Psychiatric Nursing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="N">Social Support</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20000279</ArticleId><ArticleId IdType="doi">10.3928/02793695-20091103-02</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8461272</PMID><DateCompleted><Year>1993</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0920-9964</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>1993</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>A comparative study of obstetric history in schizophrenics, bipolar patients and normal subjects.</ArticleTitle><Pagination><MedlinePgn>67-9</MedlinePgn></Pagination><Abstract><AbstractText>Information on pregnancy and birth complications was collected for 46 patients with DSM-IIIR schizophrenia or bipolar disorder and for 23 normal controls. Pregnancy complications were more frequent and birth complications more frequent and more severe in schizophrenics than in bipolar patients or in normal controls. In contrast with other findings in the literature, more obstetric complications (OCs) were found in female than male schizophrenic patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Verdoux</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourgeois</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001720" MajorTopicYN="N">Birth Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001925" MajorTopicYN="N">Brain Damage, Chronic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011248" MajorTopicYN="N">Pregnancy Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8461272</ArticleId><ArticleId IdType="pii">0920-9964(93)90011-7</ArticleId><ArticleId IdType="doi">10.1016/0920-9964(93)90011-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16251165</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1067-3229</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>5</Issue><PubDate><MedlineDate>2005 Sep-Oct</MedlineDate></PubDate></JournalIssue><Title>Harvard review of psychiatry</Title><ISOAbbreviation>Harv Rev Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Bipolar depression: issues in diagnosis and treatment.</ArticleTitle><Pagination><MedlinePgn>257-71</MedlinePgn></Pagination><Abstract><AbstractText>Although bipolar affective disorder is defined by the history of manic or hypomanic episodes, depression is arguably a more important facet of the illness. Depressive episodes, on average, are more numerous and last longer than manic or hypomanic episodes, and most suicides occur during these periods. Misdiagnosis of major depressive disorder delays initiation of appropriate therapy, further worsening prognosis. Distinguishing features of bipolar depression include earlier age of onset, a family history of bipolar disorder, presence of psychotic or reverse neurovegetative features, and antidepressant-induced switching. Bipolar I depressions should initially be treated with a mood stabilizer (carbamazapine, divalproex, lamotrigine, lithium, or an atypical antipsychotic); antidepressant monotherapy is contraindicated. More severe or "breakthrough" episodes often require a concomitant antidepressant, such as bupropion or a selective serotonin reuptake inhibitor (SSRI). The first treatment specifically approved for bipolar depression is a combination of the SSRI fluoxetine and the atypical antipsychotic olanzapine. For refractory depressive episodes, venlafaxine, the monoamine oxidase inhibitor tranylcypromine, and ECT are most widely recommended. The optimal duration of maintenance antidepressant therapy has not been established empirically and, until better evidence-based guidelines are established, should be determined on a case-by-case basis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thase</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA. thaseme@upmc.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH80001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Harv Rev Psychiatry</MedlineTA><NlmUniqueID>9312789</NlmUniqueID><ISSNLinking>1067-3229</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>152</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16251165</ArticleId><ArticleId IdType="pii">G85760441U5TH326</ArticleId><ArticleId IdType="doi">10.1080/10673220500326425</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16401162</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>66</Volume><Issue>12</Issue><PubDate><Year>2005</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A retrospective analysis of risk and protective factors for natural death in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1586-91</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Many of the prior mortality studies on bipolar disorder have emerged primarily from the larger health service groups, with a tendency to focus on suicide alone. This study examines personal and clinical characteristics of bipolar patients in Taiwan in order to identify the factors associated with early natural death.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Bipolar patients admitted to a psychiatric hospital in Taiwan between 1987 and 2002 were retrospectively followed through record linkage for cause of death. One living bipolar individual was matched to each deceased patient as a control subject for age, gender, and date of index admission. Clinical data and the results of laboratory examinations during the last period of hospitalization were obtained through a review of medical records.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In a total of 60 natural deaths, the principal cause was circulatory disease (33.3%). Conditional logistic regressions revealed that the variables most strongly associated with natural deaths were years of antipsychotic treatment prior to the last visit (95% CI for odds ratio [OR] = 0.77 to 0.98), serum alanine aminotransferase levels (95% CI for OR = 1.02 to 1.25), and leukocyte counts (95% CI for OR = 1.01 to 2.50). Years of lithium treatment (95% CI for OR = 0.74 to 0.97) may be substituted for antipsychotic treatment as a protective factor.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Systemic inflammation and nonhepatic tissue damage during the acute phase of bipolar disorder may be risk factors for early natural death. Psychiatric treatment, including medication with antipsychotics or lithium, could be a factor in protecting against early natural death.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Shang-Ying</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Taipei Medical University School of Medicine, Medical University Hospital, 252 Wu-Hsing Street, Taipei 110, Taiwan. tmcpsyts@tmu.edu.tw</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chao-Hsien</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Kuo</LastName><ForeName>Chian-Jue</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chiao-Chicy</ForeName><Initials>CC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.6.1.2</RegistryNumber><NameOfSubstance UI="D000410">Alanine Transaminase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000410" MajorTopicYN="N">Alanine Transaminase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="Y">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004363" MajorTopicYN="N">Drug Utilization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007958" MajorTopicYN="N">Leukocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013624" MajorTopicYN="N" Type="Geographic">Taiwan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16401162</ArticleId><ArticleId IdType="doi">10.4088/jcp.v66n1215</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11958781</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>51</Volume><Issue>4</Issue><PubDate><Year>2002</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure.</ArticleTitle><Pagination><MedlinePgn>305-11</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We assessed the prevalence of thyroperoxidase antibodies (TPO-Abs) and thyroid failure in outpatients with bipolar disorder compared with two control groups.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The TPO-Abs of outpatients with DSM-IV bipolar disorder (n = 226), a population control group (n = 252), and psychiatric inpatients of any diagnosis (n = 3190) were measured. Thyroid failure was defined as a raised thyroid stimulating hormone level, previously diagnosed hypothyroidism, or both. Subjects were compared with attention to age, gender, and exposure to lithium.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The TPO-Abs were more prevalent in bipolar patients (28%) than population and psychiatric controls (3-18%). The presence of TPO-Abs in bipolar patients was associated with thyroid failure, but not with age, gender, mood state, rapid cycling, or lithium exposure. Thyroid failure was present in 17% of bipolar patients and more prevalent in women. It was associated with lithium exposure, especially in the presence of TPO-Abs, but not with current rapid cycling, although an association may have been masked by thyroid hormone replacement.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Thyroid autoimmunity was highly prevalent in this sample of outpatients with bipolar disorder and not associated with lithium treatment. These variables appear to be independent risk factors for the development of hypothyroidism, especially in women with bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kupka</LastName><ForeName>Ralph W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Altrecht Centre for Mental Health Care and University Medical Centre Utrecht, Vrouwjuttenhof 18, 3512 PZ Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nolen</LastName><ForeName>Willem A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Post</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>McElroy</LastName><ForeName>Susan L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Altshuler</LastName><ForeName>Lori L</ForeName><Initials>LL</Initials></Author><Author ValidYN="Y"><LastName>Denicoff</LastName><ForeName>Kirk D</ForeName><Initials>KD</Initials></Author><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Keck</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Leverich</LastName><ForeName>Gabriele S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Rush</LastName><ForeName>A John</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Suppes</LastName><ForeName>Trisha</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Pollio</LastName><ForeName>Chad</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Drexhage</LastName><ForeName>Hemmo A</ForeName><Initials>HA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-71-5</RegistryNumber><NameOfSubstance UI="D013972">Thyrotropin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013967" MajorTopicYN="N">Thyroiditis, Autoimmune</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013972" MajorTopicYN="N">Thyrotropin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>31</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11958781</ArticleId><ArticleId IdType="pii">S0006322301012173</ArticleId><ArticleId IdType="doi">10.1016/s0006-3223(01)01217-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10883915</PMID><DateCompleted><Year>2000</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3085</ISSN><JournalIssue CitedMedium="Print"><Volume>93</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of neurosurgery</Title><ISOAbbreviation>J Neurosurg</ISOAbbreviation></Journal><ArticleTitle>Efficacy of unilateral deep brain stimulation of the thalamic ventralis intermedius nucleus in a patient with bipolar disorder associated with Klinefelter syndrome and essential tremor. Case report.</ArticleTitle><Pagination><MedlinePgn>127-8</MedlinePgn></Pagination><Abstract><AbstractText>Deep brain stimulation (DBS) of the ventralis intermedius nucleus (Vim) is a safe and effective treatment for essential tremor. Bipolar disorder and essential tremor had each been reported to occur in association with Klinefelter syndrome but the three diseases have been reported to occur together in only one patient. The genetic basis and natural history of these disorders are not completely understood and may be related rather than coincidental. The authors report on a 23-year-old man with Klinefelter syndrome (47,XXY) and bipolar disorder who was treated successfully with unilateral DBS of the thalamic Vim for essential tremor.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Telfeian</LastName><ForeName>A E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Pennsylvania Neurological Institute at Pennsylvania Hospital, Hospital of the University of Pennsylvania, Philadelphia 19104, USA. Telfeian@mail.med.upenn.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boockvar</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Simuni</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Jaggi</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Skolnick</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Baltuch</LastName><ForeName>G H</ForeName><Initials>GH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosurg</MedlineTA><NlmUniqueID>0253357</NlmUniqueID><ISSNLinking>0022-3085</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004599" MajorTopicYN="Y">Electric Stimulation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020329" MajorTopicYN="N">Essential Tremor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007713" MajorTopicYN="N">Klinefelter Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020651" MajorTopicYN="N">Ventral Thalamic Nuclei</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>7</Month><Day>7</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>25</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>7</Month><Day>7</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10883915</ArticleId><ArticleId IdType="doi">10.3171/jns.2000.93.1.0127</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">32936715</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-4673</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Issues in mental health nursing</Title><ISOAbbreviation>Issues Ment Health Nurs</ISOAbbreviation></Journal><ArticleTitle>The Meaning of Recovery: The Lived Experience of Patients with Bipolar Disorder in Turkey.</ArticleTitle><Pagination><MedlinePgn>573-580</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/01612840.2020.1818015</ELocationID><Abstract><AbstractText>Recovery in mental illness refers to a process with many aspects, steps and meanings. This study aims to provide a deeper understanding of the lived experience of recovery of patients with bipolar disorder. A qualitative approach with 28 participants was performed. Data were collected through semi-structured interviews. The experiences of the individuals regarding the recovery processes were themed with the journey metaphor: the beginning of the journey, the route of the journey, a stop in the journey, the meaning of the journey. This study suggests ways clinicians must be aware of and adopted contemporary approach which recovery is defined as a process beyond treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Durgu</LastName><ForeName>Nihan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>aFaculty of Health Science, Department of Nursing, Mental Health and Psychiatry Nursing, Manisa Celal Bayar University, Yunusemre/Manisa, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dulgerler</LastName><ForeName>Seyda</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Nursing, Mental Health and Psychiatry Nursing, Ege University Faculty of Nursing Bornova/Ä°zmir, Ege University, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Issues Ment Health Nurs</MedlineTA><NlmUniqueID>7907126</NlmUniqueID><ISSNLinking>0161-2840</ISSNLinking></MedlineJournalInfo><CitationSubset>N</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036301" MajorTopicYN="N">Qualitative Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014421" MajorTopicYN="N" Type="Geographic">Turkey</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>16</Day><Hour>17</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32936715</ArticleId><ArticleId IdType="doi">10.1080/01612840.2020.1818015</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24170252</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1433-0407</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>9</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Der Nervenarzt</Title><ISOAbbreviation>Nervenarzt</ISOAbbreviation></Journal><ArticleTitle>[Pharmaceutical treatment of bipolar depression. Evidence from clinical guidelines and treatment recommendations].</ArticleTitle><Pagination><MedlinePgn>1075-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00115-013-3919-0</ELocationID><Abstract><AbstractText>Treatment of bipolar depression requires complex treatment decisions in daily routine care. The best evidence for pharmacological treatment is given for quetiapine and with limitations also in off-label use for lamotrigine, especially in combination with lithium, carbamazepine and olanzapine. Effectiveness and recommendation of antidepressants in treatment of bipolar depression remain controversial because of insufficient data. Initially, in depressive episodes a phase prophylactic treatment should be initiated or (if already existing) optimized and more severe episodes should be treated with the substances described before. In case of non-response, the combination of lithium and lamotrigine or antidepressants in combination with lithium, antiepileptics or atypical antipsychotics may be necessary. If depressive episodes occur in the course of pharmacological treatment with prophylactic agents, combination therapies of different substances, even with antidepressants, are necessary. In case of treatment-resistant depressive episodes, complex treatment strategies (e.g. combination therapies and MAO inhibitors) should be considered. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>KÃ¶hler</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Klinik fÃ¼r Psychiatrie und Psychotherapie, CharitÃ© - UniversitÃ¤tsmedizin Berlin, Campus Mitte, CharitÃ©platz 1, 10117, Berlin, Deutschland, stephan.koehler@charite.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bschor</LastName><ForeName>T</ForeName><Initials>T</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Pharmakologische Behandlung der bipolaren Depression. Evidenz aus klinischen Leitlinien und Behandlungsempfehlungen.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nervenarzt</MedlineTA><NlmUniqueID>0400773</NlmUniqueID><ISSNLinking>0028-2804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038622" MajorTopicYN="N">Internationality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009462" MajorTopicYN="N">Neurology</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="Y">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24170252</ArticleId><ArticleId IdType="doi">10.1007/s00115-013-3919-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Affect Disord. 2006 Jul;93(1-3):13-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16650901</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2011 Oct;72(10):1413-22</Citation><ArticleIdList><ArticleId IdType="pubmed">21672493</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2009 Jan;194(1):4-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19118318</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Feb 15;57(4):430-2</Citation><ArticleIdList><ArticleId IdType="pubmed">15705360</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2012 Jun 1;71(11):939-46</Citation><ArticleIdList><ArticleId IdType="pubmed">22297150</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Nov;60(11):1079-88</Citation><ArticleIdList><ArticleId IdType="pubmed">14609883</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Dec;135(1-3):389-94</Citation><ArticleIdList><ArticleId IdType="pubmed">21719110</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 2010 Feb;22(1):3-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20196977</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Apr;122(1-2):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19926140</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2010 Feb;71(2):163-74</Citation><ArticleIdList><ArticleId IdType="pubmed">20122366</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2010 Oct;71(10):1363-70</Citation><ArticleIdList><ArticleId IdType="pubmed">20673554</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2000 May;57(5):481-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10807488</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2010 Jan 30;375(9712):385-95</Citation><ArticleIdList><ArticleId IdType="pubmed">20092882</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2012 Nov;201(5):376-82</Citation><ArticleIdList><ArticleId IdType="pubmed">22918966</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2010 Mar;11(2):81-109</Citation><ArticleIdList><ArticleId IdType="pubmed">20148751</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2008 Feb;28(1):13-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18204335</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Jul;162(7):1351-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15994719</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Dec 15;142(1-3):45-52</Citation><ArticleIdList><ArticleId IdType="pubmed">22954812</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Jun;11(4):391-400</Citation><ArticleIdList><ArticleId IdType="pubmed">19500092</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2003;(1):CD004052</Citation><ArticleIdList><ArticleId IdType="pubmed">12535506</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2008 Apr;28(2):171-81</Citation><ArticleIdList><ArticleId IdType="pubmed">18344727</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2007 Apr-Jun;41(3-4):360-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16081106</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Aug;124(3):228-34</Citation><ArticleIdList><ArticleId IdType="pubmed">20044142</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2010 Oct;167(10):1194-201</Citation><ArticleIdList><ArticleId IdType="pubmed">20713498</ArticleId></ArticleIdList></Reference><Reference><Citation>Harv Rev Psychiatry. 2010 May-Jun;18(3):143-57</Citation><ArticleIdList><ArticleId IdType="pubmed">20415631</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Aug;164(8):1242-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17671288</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2010 Jun;121(6):404-14</Citation><ArticleIdList><ArticleId IdType="pubmed">19958306</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2011 Feb;72(2):156-67</Citation><ArticleIdList><ArticleId IdType="pubmed">21034686</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Mar;2(1):47-55</Citation><ArticleIdList><ArticleId IdType="pubmed">11254020</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2008 May;192(5):388-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18450667</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Dec;111(2-3):334-43</Citation><ArticleIdList><ArticleId IdType="pubmed">18358540</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Mar;63(1-3):79-83</Citation><ArticleIdList><ArticleId IdType="pubmed">11246083</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2013 May;127(5):355-64</Citation><ArticleIdList><ArticleId IdType="pubmed">23121222</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Jul 1;56(1):54-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15219473</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2010 Feb;13(1):5-14</Citation><ArticleIdList><ArticleId IdType="pubmed">19638254</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacopsychiatry. 2011 Jan;44(1):21-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21031345</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 Feb;12(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20148862</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2011 Jan 6;364(1):51-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21208108</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2013 Aug;16(7):1673-85</Citation><ArticleIdList><ArticleId IdType="pubmed">23428003</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2007 Dec;68(12):1840-4</Citation><ArticleIdList><ArticleId IdType="pubmed">18162014</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2007 Apr 26;356(17):1711-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17392295</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Oct;63(10):1121-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17015814</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 1989 Oct;4(4):313-22</Citation><ArticleIdList><ArticleId IdType="pubmed">2607128</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Mar;161(3):564-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14992985</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 Feb;15(1):1-44</Citation><ArticleIdList><ArticleId IdType="pubmed">23237061</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Apr;85(3):259-66</Citation><ArticleIdList><ArticleId IdType="pubmed">15780695</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999 Feb;60(2):79-88</Citation><ArticleIdList><ArticleId IdType="pubmed">10084633</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 May;14 Suppl 2:37-50</Citation><ArticleIdList><ArticleId IdType="pubmed">22510035</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2006 Dec;26(6):600-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17110817</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Oct;162(10):1805-19</Citation><ArticleIdList><ArticleId IdType="pubmed">16199826</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23998447</PMID><DateCompleted><Year>2014</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1944-7930</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>87</Issue><PubDate><Year>2013</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Discovery medicine</Title><ISOAbbreviation>Discov Med</ISOAbbreviation></Journal><ArticleTitle>Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations.</ArticleTitle><Pagination><MedlinePgn>113-22</MedlinePgn></Pagination><Abstract><AbstractText>An increasing focus on personalized medicine is driving a renewed effort to understand the impact of ethnic and genetic background on treatment outcomes. Since responses to psychopharmacological treatments continue to be sub-optimal, there is a pressing need to identify markers of tolerability and efficacy. Pharmacogenomic studies aim to find such markers within the human genome, and have made some progress in recent years. Progress has been slower in populations with diverse racial and ethnic backgrounds. Here we review 10 genome-wide association studies (GWAS) that assessed outcomes after antidepressant, antipsychotic, or mood stabilizer treatment. These studies used samples collected by the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), Sequenced Treatment Alternatives to Relieve Depression (STAR*D), and Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) studies. We highlight findings from African American and European American participants since they are the largest groups studied, but we also address issues related to Asian and Hispanic groups. None of the GWAS we reviewed identified individual genetic markers at genome-wide significance, probably due to limited sample sizes. However, all the studies found poorer outcomes among African American participants. Some of this disparity seems to be explained by psychosocial and economic disadvantages, but at least 2 studies found that widespread genetic differences between participants of European and African ancestry also play an important role. Non-European groups are underrepresented in these studies, but the differences that are evident so far suggest that poorer outcomes among African Americans are not inevitable and may be particularly suited to pharmacogenomic strategies. The vision of more personalized psychopharmacology may critically depend on larger studies in more diverse human populations. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Eleanor</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Human Genetics Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA. eleanor.murphy@nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMahon</LastName><ForeName>Francis J</ForeName><Initials>FJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K22 MD006140</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Discov Med</MedlineTA><NlmUniqueID>101250006</NlmUniqueID><ISSNLinking>1539-6509</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="Y">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="Y">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010597" MajorTopicYN="N">Pharmacogenetics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23998447</ArticleId><ArticleId IdType="pmc">PMC6011657</ArticleId><ArticleId IdType="mid">NIHMS973530</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>N Engl J Med. 2005 Sep 22;353(12):1209-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16172203</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2006 May;78(5):804-814</Citation><ArticleIdList><ArticleId IdType="pubmed">16642436</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2009 Aug;14(8):755-63</Citation><ArticleIdList><ArticleId IdType="pubmed">19488044</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2012 Oct 23;2:e180</Citation><ArticleIdList><ArticleId IdType="pubmed">23092984</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2008 Aug;22(6):673-80</Citation><ArticleIdList><ArticleId IdType="pubmed">18308818</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2010 Jan 15;67(2):133-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19846067</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2011 Mar;16(3):321-32</Citation><ArticleIdList><ArticleId IdType="pubmed">20195266</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2006 Jan 26;354(4):408-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16436773</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2007 Sep;81(3):559-75</Citation><ArticleIdList><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2007 Nov;45(11):1043-51</Citation><ArticleIdList><ArticleId IdType="pubmed">18049344</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2012 Jun;42(6):1151-62</Citation><ArticleIdList><ArticleId IdType="pubmed">22041458</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 1991 Sep;50(3):308-13</Citation><ArticleIdList><ArticleId IdType="pubmed">1680593</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2011 Feb;36(3):616-26</Citation><ArticleIdList><ArticleId IdType="pubmed">21107309</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Pharmacol. 1985;28(1):79-83</Citation><ArticleIdList><ArticleId IdType="pubmed">3987789</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 1986 Oct;40(4):387-94</Citation><ArticleIdList><ArticleId IdType="pubmed">3757401</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2010 Feb;61(2):164-72</Citation><ArticleIdList><ArticleId IdType="pubmed">20123822</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Aug;164(8):1189-97</Citation><ArticleIdList><ArticleId IdType="pubmed">17671281</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Jun;13(6):570-84</Citation><ArticleIdList><ArticleId IdType="pubmed">18347602</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2003;29(1):33-43</Citation><ArticleIdList><ArticleId IdType="pubmed">12908659</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2007;68 Suppl 14:20-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18284274</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Fam Med. 1997 Jul-Aug;6(4):371-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9225711</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9362-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19474294</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuromolecular Med. 2010 Sep;12(3):237-42</Citation><ArticleIdList><ArticleId IdType="pubmed">19937159</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):217-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16449474</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2003;29(1):15-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12908658</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacogenet Genomics. 2013 Feb;23(2):69-77</Citation><ArticleIdList><ArticleId IdType="pubmed">23241943</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacogenomics J. 2012 Apr;12(2):165-72</Citation><ArticleIdList><ArticleId IdType="pubmed">20921969</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp Community Psychiatry. 1986 Jan;37(1):50-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2867967</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Toxicol. 1988 May;7(3):273-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3391625</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2009 Jan;43(3):215-29</Citation><ArticleIdList><ArticleId IdType="pubmed">18586274</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2009 Nov;60(11):1446-57</Citation><ArticleIdList><ArticleId IdType="pubmed">19880459</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2013 Sep;47(9):1157-65</Citation><ArticleIdList><ArticleId IdType="pubmed">23726668</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Jan;163(1):28-40</Citation><ArticleIdList><ArticleId IdType="pubmed">16390886</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2011 Mar 24;364(12):1126-33</Citation><ArticleIdList><ArticleId IdType="pubmed">21428768</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Jun 1;53(11):1028-42</Citation><ArticleIdList><ArticleId IdType="pubmed">12788248</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Jun;166(6):718-25</Citation><ArticleIdList><ArticleId IdType="pubmed">19448189</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2011 Apr;156B(3):370-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21305692</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Genomics Proteomics. 2010 Aug 03;2010:159761</Citation><ArticleIdList><ArticleId IdType="pubmed">20981231</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Exp Toxicol. 1991 May;10(3):175-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1678945</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2006 Aug;38(8):904-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16862161</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2007 Mar;12(3):247-57</Citation><ArticleIdList><ArticleId IdType="pubmed">17146470</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2013 Nov;30(11):1137-44</Citation><ArticleIdList><ArticleId IdType="pubmed">23723044</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Nov;163(11):1905-17</Citation><ArticleIdList><ArticleId IdType="pubmed">17074942</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacogenomics J. 2006 May-Jun;6(3):162-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16415920</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2013 Jun;64(6):570-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23494108</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18271906</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Chronotype distribution in bipolar I disorder and schizophrenia in a Korean sample.</ArticleTitle><Pagination><MedlinePgn>271-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2007.00573.x</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Although a broad range of circadian rhythm variations have been reported, analyses of chronotypes in bipolar I disorder (BDI) and schizophrenia are rare. The present study aimed to investigate specific chronotype patterns in BDI and schizophrenia compared with healthy subjects.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">All patients were clinically stable and recruited from the outpatient clinics of Seoul National University Hospital. They were diagnosed according to DSM-IV criteria. 'Morningness/eveningness', a chronotype correlated with circadian phase, was evaluated using the Composite Scale of Morningness (CSM) among 92 patients with BDI, 113 patients with schizophrenia (SZ), and 95 control individuals.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The CSM scores were significantly correlated with age in the control group, but a significant correlation with age was not observed in the schizophrenia or BDI groups. After controlling for age, there were significant differences between the BDI and control groups. The SZ patients did not differ from the BDI or control groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this Korean sample, patients with BDI showed a significantly greater preference for 'eveningness' (including delayed sleep timing) than control individuals. The influences of pharmacotherapy or clinical status on CSM scores need to be clarified.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Yong Min</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Science and Institute of Human Behavioral Medicine, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Jaeseung</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Joo</LastName><ForeName>Yeon Ho</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seong Chan</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kyu Young</ForeName><Initials>KY</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yong Sik</ForeName><Initials>YS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044466" MajorTopicYN="N">Asian Continental Ancestry Group</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021081" MajorTopicYN="N">Chronobiology Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18271906</ArticleId><ArticleId IdType="pii">BDI573</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2007.00573.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1528958</PMID><DateCompleted><Year>1992</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0176-3679</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>4</Issue><PubDate><Year>1992</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Pharmacopsychiatry</Title><ISOAbbreviation>Pharmacopsychiatry</ISOAbbreviation></Journal><ArticleTitle>Bipolar illness, lithium prophylaxis, and pregnancy.</ArticleTitle><Pagination><MedlinePgn>187-91</MedlinePgn></Pagination><Abstract><AbstractText>In advising bipolar patients wishing to become pregnant, Weinstein's guidelines were extended to seven stages: contraceptive measures; genetic counseling; discontinuing lithium in the first trimester or prescribing alternatives; ultrasound scanning for congenital anomalies, low lithium levels during pregnancy; discontinuing lithium at the end of pregnancy; starting immediately after birth, no breast feeding, observation of the neonate in the neonatal ward; and close observation of the patient in the follow-up year. Of the 15 bipolar patients, 11 gave birth to healthy children (five of them twice). Most patients knew nothing about the inheritance of bipolar illness. Four made no further attempt to become pregnant: two in view of a serious possibility of inheritance, the other two after a severe relapse. Three patients chose an alternative to lithium medication (carbamazepine and haloperidol). Postpartum, 27% of the patients who used medication relapsed and 60% of the patients who used none relapsed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Gent</LastName><ForeName>E M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Willem Arntsz Huis, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhoeven</LastName><ForeName>W M</ForeName><Initials>WM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Pharmacopsychiatry</MedlineTA><NlmUniqueID>8402938</NlmUniqueID><ISSNLinking>0176-3679</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011248" MajorTopicYN="N">Pregnancy Complications</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1528958</ArticleId><ArticleId IdType="doi">10.1055/s-2007-1014404</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30279458</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>9</Issue><PubDate><Year>2019</Year><Month>09</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Connectomics of bipolar disorder: a critical review, and evidence for dynamic instabilities within interoceptive networks.</ArticleTitle><Pagination><MedlinePgn>1296-1318</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41380-018-0267-2</ELocationID><Abstract><AbstractText>The notion that specific cognitive and emotional processes arise from functionally distinct brain regions has lately shifted toward a connectivity-based approach that emphasizes the role of network-mediated integration across regions. The clinical neurosciences have likewise shifted from a predominantly lesion-based approach to a connectomic paradigm-framing disorders as diverse as stroke, schizophrenia (SCZ), and dementia as "dysconnection syndromes". Here we position bipolar disorder (BD) within this paradigm. We first summarise the disruptions in structural, functional and effective connectivity that have been documented in BD. Not surprisingly, these disturbances show a preferential impact on circuits that support emotional processes, cognitive control and executive functions. Those at high risk (HR) for BD also show patterns of connectivity that differ from both matched control populations and those with BD, and which may thus speak to neurobiological markers of both risk and resilience. We highlight research fields that aim to link brain network disturbances to the phenotype of BD, including the study of large-scale brain dynamics, the principles of network stability and control, and the study of interoception (the perception of physiological states). Together, these findings suggest that the affective dysregulation of BD arises from dynamic instabilities in interoceptive circuits which subsequently impact on fear circuitry and cognitive control systems. We describe the resulting disturbance as a "psychosis of interoception".</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>Alistair</ForeName><Initials>A</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-0794-1538</Identifier><AffiliationInfo><Affiliation>QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. perry@mpib-berlin.mpg.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Max Planck UCL Centre for Computational Psychiatry and Ageing Research, Berlin/London, Germany. perry@mpib-berlin.mpg.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Lifespan Psychology, Max Planck Institute for Human Development, Lentzeallee 94, 14195, Berlin, Germany. perry@mpib-berlin.mpg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Gloria</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Psychiatry, University of New South Wales, Randwick, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Black Dog Institute, Prince of Wales Hospital, Randwick, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Philip B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>School of Psychiatry, University of New South Wales, Randwick, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Black Dog Institute, Prince of Wales Hospital, Randwick, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breakspear</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-4943-3969</Identifier><AffiliationInfo><Affiliation>QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. michael.breakspear@qimrberghofer.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Metro North Mental Health Service, Brisbane, QLD, Australia. michael.breakspear@qimrberghofer.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Mol Psychiatry. 2019 Jan 4;:</RefSource><PMID Version="1">30610200</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063132" MajorTopicYN="N">Connectome</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>05</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>09</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>08</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30279458</ArticleId><ArticleId IdType="doi">10.1038/s41380-018-0267-2</ArticleId><ArticleId IdType="pii">10.1038/s41380-018-0267-2</ArticleId><ArticleId IdType="pmc">PMC6756092</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Biol Psychiatry. 2013 Jul 1;74(1):55-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23245750</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 May;60(5):497-502</Citation><ArticleIdList><ArticleId IdType="pubmed">12742871</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2013 Jun;73:239-54</Citation><ArticleIdList><ArticleId IdType="pubmed">22846632</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2010 Jul 14;30(28):9477-87</Citation><ArticleIdList><ArticleId IdType="pubmed">20631176</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Comput Biol. 2008 Oct;4(10):e1000196</Citation><ArticleIdList><ArticleId IdType="pubmed">18846206</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2011 Jan;12(1):43-56</Citation><ArticleIdList><ArticleId IdType="pubmed">21170073</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2014 Dec;17(12):1661-3</Citation><ArticleIdList><ArticleId IdType="pubmed">25383900</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):2035-40</Citation><ArticleIdList><ArticleId IdType="pubmed">19188601</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage Clin. 2018 Mar 27;19:71-81</Citation><ArticleIdList><ArticleId IdType="pubmed">30035004</ArticleId></ArticleIdList></Reference><Reference><Citation>Neural Comput. 1995 Sep;7(5):889-904</Citation><ArticleIdList><ArticleId IdType="pubmed">7584891</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2012 Jan 10;2:75</Citation><ArticleIdList><ArticleId IdType="pubmed">22291663</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1995 Nov;52(11):947-59</Citation><ArticleIdList><ArticleId IdType="pubmed">7487343</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2008 Nov;29(11):1265-75</Citation><ArticleIdList><ArticleId IdType="pubmed">17894392</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2015 Oct 01;6:8414</Citation><ArticleIdList><ArticleId IdType="pubmed">26423222</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2015 Mar;29(3):221-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25711483</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2011 May 12;473(7346):167-73</Citation><ArticleIdList><ArticleId IdType="pubmed">21562557</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):340-55</Citation><ArticleIdList><ArticleId IdType="pubmed">22631619</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neurosci. 1995;3(2):89-97</Citation><ArticleIdList><ArticleId IdType="pubmed">7583624</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Sep;13(9):829, 833-57</Citation><ArticleIdList><ArticleId IdType="pubmed">18574483</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1998 Jun 4;393(6684):440-2</Citation><ArticleIdList><ArticleId IdType="pubmed">9623998</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2007 Jul 04;2(7):e597</Citation><ArticleIdList><ArticleId IdType="pubmed">17611629</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2012 May 15;71(10):881-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22401986</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Oct 15;82(2):191-201</Citation><ArticleIdList><ArticleId IdType="pubmed">15488247</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2018 Oct;48(14):2277-2284</Citation><ArticleIdList><ArticleId IdType="pubmed">29478431</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1999 Mar;56(3):254-60</Citation><ArticleIdList><ArticleId IdType="pubmed">10078503</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Brain Res. 1993 Oct 21;57(1):53-61</Citation><ArticleIdList><ArticleId IdType="pubmed">8292255</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2015 Jan;30(1):82-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24853295</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2005 Nov;187:431-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16260818</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Mar;14(2):162-74</Citation><ArticleIdList><ArticleId IdType="pubmed">22420592</ArticleId></ArticleIdList></Reference><Reference><Citation>Magn Reson Med. 2009 Sep;62(3):717-30</Citation><ArticleIdList><ArticleId IdType="pubmed">19623619</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2016 Nov 19;371(1708):</Citation><ArticleIdList><ArticleId IdType="pubmed">28080966</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2013 Oct 15;80:426-44</Citation><ArticleIdList><ArticleId IdType="pubmed">23643999</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2013 Jul 3;33(27):11239-52</Citation><ArticleIdList><ArticleId IdType="pubmed">23825427</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Dec;6(6):530-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15541069</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2017 Sep 15;82(6):421-430</Citation><ArticleIdList><ArticleId IdType="pubmed">28619481</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Feb-Mar;9(1-2):103-13</Citation><ArticleIdList><ArticleId IdType="pubmed">17391354</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 2002 Mar;47(2):125-34</Citation><ArticleIdList><ArticleId IdType="pubmed">11926074</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2009 Mar;14(3):252-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19065143</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Jun;3(6):501-513</Citation><ArticleIdList><ArticleId IdType="pubmed">29884281</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2013 May;14(5):365-76</Citation><ArticleIdList><ArticleId IdType="pubmed">23571845</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2017 Aug 11;357(6351):596-600</Citation><ArticleIdList><ArticleId IdType="pubmed">28798131</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2015 Jan 21;6:6149</Citation><ArticleIdList><ArticleId IdType="pubmed">25608088</ArticleId></ArticleIdList></Reference><Reference><Citation>Monogr Soc Res Child Dev. 1994;59(2-3):25-52</Citation><ArticleIdList><ArticleId IdType="pubmed">7984164</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2016 Sep;18(6):511-519</Citation><ArticleIdList><ArticleId IdType="pubmed">27759214</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2016 Feb 15;79(4):293-302</Citation><ArticleIdList><ArticleId IdType="pubmed">25891219</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Aug;17(5):486-95</Citation><ArticleIdList><ArticleId IdType="pubmed">26241359</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2013 Aug 08;4:87</Citation><ArticleIdList><ArticleId IdType="pubmed">23964248</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2015 Nov;18(11):1565-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26414616</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2015 Jul 1;114:414-26</Citation><ArticleIdList><ArticleId IdType="pubmed">25869857</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2018 Apr 26;9(1):1708</Citation><ArticleIdList><ArticleId IdType="pubmed">29700303</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Biol. 2018 May 7;28(9):1433-1439.e7</Citation><ArticleIdList><ArticleId IdType="pubmed">29706512</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2005 Jan;10(1):105-16</Citation><ArticleIdList><ArticleId IdType="pubmed">15340357</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2018 Apr;23(4):932-942</Citation><ArticleIdList><ArticleId IdType="pubmed">28461699</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2015 Oct 30;234(1):44-51</Citation><ArticleIdList><ArticleId IdType="pubmed">26382105</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2017 Jul;47(9):1609-1623</Citation><ArticleIdList><ArticleId IdType="pubmed">28573962</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2011 Feb 15;69(4):309-17</Citation><ArticleIdList><ArticleId IdType="pubmed">20926068</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2005 May;9(5):242-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15866151</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):313-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22631617</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2016 Aug;46(11):2385-96</Citation><ArticleIdList><ArticleId IdType="pubmed">27291060</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Struct Funct. 2016 Jul;221(6):2985-97</Citation><ArticleIdList><ArticleId IdType="pubmed">26197763</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2011 Aug 15;70(4):343-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21601834</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2017 Apr 15;81(8):718-727</Citation><ArticleIdList><ArticleId IdType="pubmed">28031150</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2018 Jun;173:592-603</Citation><ArticleIdList><ArticleId IdType="pubmed">29407457</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2011 Jul 15;57(2):576-82</Citation><ArticleIdList><ArticleId IdType="pubmed">21570470</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2017 Oct 15;160:97-112</Citation><ArticleIdList><ArticleId IdType="pubmed">28126550</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2009 Apr 16;62(1):42-52</Citation><ArticleIdList><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Neurosci Ther. 2015 Oct;21(10):837-45</Citation><ArticleIdList><ArticleId IdType="pubmed">25899584</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2014 Mar;40(2):438-48</Citation><ArticleIdList><ArticleId IdType="pubmed">24298172</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroinformatics. 2004;2(2):145-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15319512</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2004 Feb;7(2):189-95</Citation><ArticleIdList><ArticleId IdType="pubmed">14730305</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscientist. 2006 Dec;12(6):512-23</Citation><ArticleIdList><ArticleId IdType="pubmed">17079517</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Jan 15;73(2):127-35</Citation><ArticleIdList><ArticleId IdType="pubmed">22858151</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2006 Feb;10(2):59-63</Citation><ArticleIdList><ArticleId IdType="pubmed">16406760</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2016 Feb;37(2):808-18</Citation><ArticleIdList><ArticleId IdType="pubmed">26611711</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2016 Jul 29;6:30770</Citation><ArticleIdList><ArticleId IdType="pubmed">27468904</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2010 Dec;53(4):1197-207</Citation><ArticleIdList><ArticleId IdType="pubmed">20600983</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2014 Nov;40(6):1227-43</Citation><ArticleIdList><ArticleId IdType="pubmed">25031221</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2002 Jan;15(1):273-89</Citation><ArticleIdList><ArticleId IdType="pubmed">11771995</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2017 Nov 15;82(10):746-755</Citation><ArticleIdList><ArticleId IdType="pubmed">28734460</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurobiol. 2013 Apr;23(2):162-71</Citation><ArticleIdList><ArticleId IdType="pubmed">23294553</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2012 Nov 28;32(48):17365-72</Citation><ArticleIdList><ArticleId IdType="pubmed">23197727</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2010 Mar 1;67(5):422-31</Citation><ArticleIdList><ArticleId IdType="pubmed">20159144</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2010 Jan;35(1):192-216</Citation><ArticleIdList><ArticleId IdType="pubmed">19693001</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2000 Jun 9;288(5472):1835-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10846167</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 1965 Jun;88(2):237-94</Citation><ArticleIdList><ArticleId IdType="pubmed">5318481</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(3):e57357</Citation><ArticleIdList><ArticleId IdType="pubmed">23483904</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2008 Sep 10;28(37):9239-48</Citation><ArticleIdList><ArticleId IdType="pubmed">18784304</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2016 Jan 05;6:e706</Citation><ArticleIdList><ArticleId IdType="pubmed">26731443</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2017 Feb 23;20(3):299-303</Citation><ArticleIdList><ArticleId IdType="pubmed">28230846</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2016 Apr 9;387(10027):1561-1572</Citation><ArticleIdList><ArticleId IdType="pubmed">26388529</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2015 May;25(5):733-48</Citation><ArticleIdList><ArticleId IdType="pubmed">24726580</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2003 Aug;19(4):1273-302</Citation><ArticleIdList><ArticleId IdType="pubmed">12948688</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2018 Feb;23(2):413-421</Citation><ArticleIdList><ArticleId IdType="pubmed">27994220</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2009 Jan;10(1):48-58</Citation><ArticleIdList><ArticleId IdType="pubmed">19050712</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2009 Feb;30(2):403-16</Citation><ArticleIdList><ArticleId IdType="pubmed">18072237</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Biol. 2008 Jul 1;6(7):e159</Citation><ArticleIdList><ArticleId IdType="pubmed">18597554</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2015 Nov;138(Pt 11):3427-39</Citation><ArticleIdList><ArticleId IdType="pubmed">26373604</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurobiol. 2003 Aug;13(4):500-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12965300</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Psychobiol. 2010 Apr;52(3):225-35</Citation><ArticleIdList><ArticleId IdType="pubmed">20222060</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Feb;13(1):1-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21320248</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Sep;65(9):1041-52</Citation><ArticleIdList><ArticleId IdType="pubmed">18762590</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2010 Jul 30;183(1):59-68</Citation><ArticleIdList><ArticleId IdType="pubmed">20553873</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Exp Neuropsychol. 2017 Dec;39(10):979-987</Citation><ArticleIdList><ArticleId IdType="pubmed">28276284</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2015 Mar;16(3):159-72</Citation><ArticleIdList><ArticleId IdType="pubmed">25697159</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Comput Biol. 2008 Nov;4(11):e1000211</Citation><ArticleIdList><ArticleId IdType="pubmed">18989391</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Hum Neurosci. 2012 Jan 27;5:184</Citation><ArticleIdList><ArticleId IdType="pubmed">22363273</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2009 Feb 11;29(6):1860-73</Citation><ArticleIdList><ArticleId IdType="pubmed">19211893</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Mar 1;173:53-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25462396</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 May;170(5):533-41</Citation><ArticleIdList><ArticleId IdType="pubmed">23558337</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurobiol. 2013 Apr;23(2):172-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23265964</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 1997 Oct;6(3):218-29</Citation><ArticleIdList><ArticleId IdType="pubmed">9344826</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1994 May 24;91(11):5033-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8197179</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2009 Jul 15;46(4):1004-17</Citation><ArticleIdList><ArticleId IdType="pubmed">19306932</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2017 Feb;209:217-228</Citation><ArticleIdList><ArticleId IdType="pubmed">27930915</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2009 Mar;10(3):186-98</Citation><ArticleIdList><ArticleId IdType="pubmed">19190637</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Soc Trans. 2009 Oct;37(Pt 5):1085-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19754457</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 2016 Nov;57(11):1277-1286</Citation><ArticleIdList><ArticleId IdType="pubmed">27418025</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 May;1(3):199-208</Citation><ArticleIdList><ArticleId IdType="pubmed">29560880</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2009 May 12;364(1521):1211-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19528002</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2012 May;37(3):170-84</Citation><ArticleIdList><ArticleId IdType="pubmed">22297067</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2013 Jan;23(1):127-38</Citation><ArticleIdList><ArticleId IdType="pubmed">22275481</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Comput Biol. 2005 Sep;1(4):e42</Citation><ArticleIdList><ArticleId IdType="pubmed">16201007</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Psychol. 2016;67:613-40</Citation><ArticleIdList><ArticleId IdType="pubmed">26393868</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Sep 5;150(2):192-200</Citation><ArticleIdList><ArticleId IdType="pubmed">23810479</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 May;1(3):288-298</Citation><ArticleIdList><ArticleId IdType="pubmed">27453953</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2000 Mar;10(3):295-307</Citation><ArticleIdList><ArticleId IdType="pubmed">10731224</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2017 Jul 4;7(7):e1165</Citation><ArticleIdList><ArticleId IdType="pubmed">28675389</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2016 May;46(7):1509-22</Citation><ArticleIdList><ArticleId IdType="pubmed">26924633</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Nov;103(1-3):29-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17328959</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cogn Neurosci. 2008 Sep;20(9):1565-82</Citation><ArticleIdList><ArticleId IdType="pubmed">18345988</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 May;65(5):568-76</Citation><ArticleIdList><ArticleId IdType="pubmed">18458208</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2015 Aug 19;87(4):716-32</Citation><ArticleIdList><ArticleId IdType="pubmed">26291157</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2017 Jan 15;145(Pt B):377-388</Citation><ArticleIdList><ArticleId IdType="pubmed">27477535</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 Dec 8;72(5):692-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22153367</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2008 Dec;9(12):947-57</Citation><ArticleIdList><ArticleId IdType="pubmed">19002191</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2019 Feb;49(3):510-518</Citation><ArticleIdList><ArticleId IdType="pubmed">29734951</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2018 May;23(5):1261-1269</Citation><ArticleIdList><ArticleId IdType="pubmed">29038599</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13848-53</Citation><ArticleIdList><ArticleId IdType="pubmed">16945915</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2011 Feb 15;69(4):381-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21051038</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):442-50</Citation><ArticleIdList><ArticleId IdType="pubmed">22631623</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2017 Sep 1;174(9):895-903</Citation><ArticleIdList><ArticleId IdType="pubmed">28595489</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Sep;10(6):708-17</Citation><ArticleIdList><ArticleId IdType="pubmed">18837865</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2011 Nov 2;31(44):15775-86</Citation><ArticleIdList><ArticleId IdType="pubmed">22049421</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Sep 1;54(5):504-14</Citation><ArticleIdList><ArticleId IdType="pubmed">12946879</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2012 Aug;121(3):592-601</Citation><ArticleIdList><ArticleId IdType="pubmed">22775582</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Hum Neurosci. 2016 Nov 15;10:550</Citation><ArticleIdList><ArticleId IdType="pubmed">27895566</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2012 Oct 1;62(4):2296-314</Citation><ArticleIdList><ArticleId IdType="pubmed">22387165</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2017 Feb 23;20(3):340-352</Citation><ArticleIdList><ArticleId IdType="pubmed">28230845</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2015 May 19;370(1668):</Citation><ArticleIdList><ArticleId IdType="pubmed">25823864</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2010 Sep;52(3):1059-69</Citation><ArticleIdList><ArticleId IdType="pubmed">19819337</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Jan 15;73(2):183-93</Citation><ArticleIdList><ArticleId IdType="pubmed">23122540</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2006 Oct;87(1-3):60-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16875801</ArticleId></ArticleIdList></Reference><Reference><Citation>NMR Biomed. 2019 Apr;32(4):e3752</Citation><ArticleIdList><ArticleId IdType="pubmed">28654718</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2016 Nov 19;371(1708):</Citation><ArticleIdList><ArticleId IdType="pubmed">28080969</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2016 Jul;26(7):3285-96</Citation><ArticleIdList><ArticleId IdType="pubmed">27102654</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2005 Oct;128(Pt 10):2224-39</Citation><ArticleIdList><ArticleId IdType="pubmed">16141282</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2009 Jan;10(1):59-70</Citation><ArticleIdList><ArticleId IdType="pubmed">19096369</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2008 Nov;118(5):357-62</Citation><ArticleIdList><ArticleId IdType="pubmed">18644004</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10240-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17548818</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2017 Dec 1;74(12):1275-1276</Citation><ArticleIdList><ArticleId IdType="pubmed">29049438</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10302-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19497858</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage Clin. 2016 May 19;11:707-718</Citation><ArticleIdList><ArticleId IdType="pubmed">27330970</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2015 Aug;40(9):2258-68</Citation><ArticleIdList><ArticleId IdType="pubmed">25767910</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2015 Sep;68:37-44</Citation><ArticleIdList><ArticleId IdType="pubmed">26228398</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2015 Jul;16(7):419-29</Citation><ArticleIdList><ArticleId IdType="pubmed">26016744</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2014 Aug;171(8):829-43</Citation><ArticleIdList><ArticleId IdType="pubmed">24626773</ArticleId></ArticleIdList></Reference><Reference><Citation>Elife. 2016 Sep 06;5:</Citation><ArticleIdList><ArticleId IdType="pubmed">27596931</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Nov;1(6):518-527</Citation><ArticleIdList><ArticleId IdType="pubmed">28083566</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2015 Mar;62:71-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25700556</ArticleId></ArticleIdList></Reference><Reference><Citation>Dialogues Clin Neurosci. 2013 Sep;15(3):247-62</Citation><ArticleIdList><ArticleId IdType="pubmed">24174898</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Comput Biol. 2016 Sep 09;12(9):e1005076</Citation><ArticleIdList><ArticleId IdType="pubmed">27611328</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2012 Jul 16;61(4):1000-16</Citation><ArticleIdList><ArticleId IdType="pubmed">22484410</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2009 Sep 1;66(5):451-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19450794</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2015 Jul 1;78(1):58-66</Citation><ArticleIdList><ArticleId IdType="pubmed">25534753</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2015 Oct 1;119:338-51</Citation><ArticleIdList><ArticleId IdType="pubmed">26163802</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2009 Aug 6;460(7256):748-52</Citation><ArticleIdList><ArticleId IdType="pubmed">19571811</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2015 Apr;72(4):350-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25692565</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Struct Funct. 2017 Dec;222(9):4051-4064</Citation><ArticleIdList><ArticleId IdType="pubmed">28600678</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2010 Apr 15;50(3):970-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20035887</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2016 Aug;46(11):2351-61</Citation><ArticleIdList><ArticleId IdType="pubmed">27282778</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2015 Apr;45(6):1207-18</Citation><ArticleIdList><ArticleId IdType="pubmed">25229638</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2009 Oct 1;47(4):1628-38</Citation><ArticleIdList><ArticleId IdType="pubmed">19523523</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 May;1(3):230-244</Citation><ArticleIdList><ArticleId IdType="pubmed">27347565</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2018 Oct;48(14):2399-2408</Citation><ArticleIdList><ArticleId IdType="pubmed">29409566</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2017 Dec;19(8):661-675</Citation><ArticleIdList><ArticleId IdType="pubmed">29024194</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2009 Mar 31;171(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">19230623</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10341-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24982140</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2008 Jun 11;28(24):6211-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18550763</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2016 Jan;37(1):122-34</Citation><ArticleIdList><ArticleId IdType="pubmed">26454006</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2013 May 30;4:47</Citation><ArticleIdList><ArticleId IdType="pubmed">23750138</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Comput Biol. 2009 May;5(5):e1000381</Citation><ArticleIdList><ArticleId IdType="pubmed">19412534</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2015 Feb;36(2):666-82</Citation><ArticleIdList><ArticleId IdType="pubmed">25307723</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Jan 15;73(2):111-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22784485</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2007 Apr;17(4):816-25</Citation><ArticleIdList><ArticleId IdType="pubmed">16707738</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosurg. 2013 Jun;118(6):1367-77</Citation><ArticleIdList><ArticleId IdType="pubmed">23540269</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Dec;60(12):1209-15</Citation><ArticleIdList><ArticleId IdType="pubmed">14662553</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Brain Res. 2011 Nov 20;225(1):341-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21729721</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2014 May;40(3):523-31</Citation><ArticleIdList><ArticleId IdType="pubmed">24609453</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2016 Dec;21(12):1710-1716</Citation><ArticleIdList><ArticleId IdType="pubmed">26857596</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Mar 15;73(6):565-73</Citation><ArticleIdList><ArticleId IdType="pubmed">22980587</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage Clin. 2016 Nov 01;12:838-844</Citation><ArticleIdList><ArticleId IdType="pubmed">27857885</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2017 Jan 15;145(Pt B):180-199</Citation><ArticleIdList><ArticleId IdType="pubmed">27346545</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Imaging Behav. 2019 Jun;13(3):862-877</Citation><ArticleIdList><ArticleId IdType="pubmed">29748770</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2012 Apr 13;13(5):336-49</Citation><ArticleIdList><ArticleId IdType="pubmed">22498897</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2013 Aug;70(8):783-92</Citation><ArticleIdList><ArticleId IdType="pubmed">23739835</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2014 Feb;71(2):109-18</Citation><ArticleIdList><ArticleId IdType="pubmed">24306091</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Rev. 2001 Jul;108(3):624-52</Citation><ArticleIdList><ArticleId IdType="pubmed">11488380</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 2013 Oct 15;521(15):3371-88</Citation><ArticleIdList><ArticleId IdType="pubmed">23749500</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2015 Jun 26;5:11605</Citation><ArticleIdList><ArticleId IdType="pubmed">26112251</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2009 Jun;23(4):346-88</Citation><ArticleIdList><ArticleId IdType="pubmed">19329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 1996 Oct 29;351(1346):1433-43; discussion 1443-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8941955</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2016 Oct 5;36(40):10323-10336</Citation><ArticleIdList><ArticleId IdType="pubmed">27707969</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2015 Aug 30;233(2):243-53</Citation><ArticleIdList><ArticleId IdType="pubmed">26195295</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2008 Nov 15;43(3):554-61</Citation><ArticleIdList><ArticleId IdType="pubmed">18771736</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2017 Nov;18(11):645-657</Citation><ArticleIdList><ArticleId IdType="pubmed">28951610</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):253-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2010 Jun 30;182(3):207-10</Citation><ArticleIdList><ArticleId IdType="pubmed">20493671</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychol. 2012 May 28;3:151</Citation><ArticleIdList><ArticleId IdType="pubmed">22654776</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Nov;103(1-3):181-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17324469</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurocytol. 2002 Mar-Jun;31(3-5):373-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12815254</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2017 Oct;38(10):5094-5114</Citation><ArticleIdList><ArticleId IdType="pubmed">28685910</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2009 Jul 1;29(26):8512-24</Citation><ArticleIdList><ArticleId IdType="pubmed">19571142</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Dec 15;64(12):1088-92</Citation><ArticleIdList><ArticleId IdType="pubmed">18814861</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Comput Biol. 2017 Aug 17;13(8):e1005637</Citation><ArticleIdList><ArticleId IdType="pubmed">28817568</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2014 Aug;137(Pt 8):2382-95</Citation><ArticleIdList><ArticleId IdType="pubmed">25057133</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2016 Jan;20(1):15-24</Citation><ArticleIdList><ArticleId IdType="pubmed">26545853</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2017 Feb;140(2):487-496</Citation><ArticleIdList><ArticleId IdType="pubmed">28007987</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2013 Dec;17(12):683-96</Citation><ArticleIdList><ArticleId IdType="pubmed">24231140</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2015 Nov;18(11):1546-55</Citation><ArticleIdList><ArticleId IdType="pubmed">26505566</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2017 May;19(3):158-167</Citation><ArticleIdList><ArticleId IdType="pubmed">28470928</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2017 May;22(5):666-679</Citation><ArticleIdList><ArticleId IdType="pubmed">28289283</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2007 Jan;17(1):92-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16452642</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2008 Apr;131(Pt 4):945-61</Citation><ArticleIdList><ArticleId IdType="pubmed">18299296</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2014 Mar;40(2):469-77</Citation><ArticleIdList><ArticleId IdType="pubmed">23599250</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1998 Mar 10;30(2):115-25</Citation><ArticleIdList><ArticleId IdType="pubmed">9549774</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2017 Dec;56(12):1073-1080</Citation><ArticleIdList><ArticleId IdType="pubmed">29173741</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 1999 Sep;22(3):517-34, vii</Citation><ArticleIdList><ArticleId IdType="pubmed">10550853</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurophysiol. 2011 Sep;106(3):1125-65</Citation><ArticleIdList><ArticleId IdType="pubmed">21653723</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Sep 15;74(6):458-66</Citation><ArticleIdList><ArticleId IdType="pubmed">23746539</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2006 Jan;40(1):20-35</Citation><ArticleIdList><ArticleId IdType="pubmed">16403034</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2010 Sep;52(3):766-76</Citation><ArticleIdList><ArticleId IdType="pubmed">20116438</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2013 Dec;70(12):1303-11</Citation><ArticleIdList><ArticleId IdType="pubmed">24108394</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Sep;3(9):754-766</Citation><ArticleIdList><ArticleId IdType="pubmed">29703679</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Feb;161(2):217-22</Citation><ArticleIdList><ArticleId IdType="pubmed">14754766</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2017 Dec 1;174(12):1214-1222</Citation><ArticleIdList><ArticleId IdType="pubmed">28817956</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2018 Jan 1;28(1):281-294</Citation><ArticleIdList><ArticleId IdType="pubmed">29088339</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2017 Nov;21(11):878-892</Citation><ArticleIdList><ArticleId IdType="pubmed">28967533</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage Clin. 2015 Oct 24;9:660-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26740919</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2016 Jan 1;124(Pt A):455-463</Citation><ArticleIdList><ArticleId IdType="pubmed">26375211</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1997 Apr 24;386(6627):824-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9126739</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18347600</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2015</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Mode of action of mood stabilizers: is the arachidonic acid cascade a common target?</ArticleTitle><Pagination><MedlinePgn>585-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mp.2008.31</ELocationID><Abstract><AbstractText>Bipolar disorder is a major medical, social and economic burden worldwide. However, the mechanisms of action of effective antibipolar disorder drugs remain elusive. In this paper, we review studies using a neuropharmacological approach in unanesthetized rats, combined with kinetic, biochemical and molecular biology techniques, showing that chronic administration of three Food and Drug Administration-approved mood stabilizers (lithium, valproate and carbamazepine) at therapeutically relevant doses, selectively target the brain arachidonic acid (AA) cascade. Whereas chronic lithium and carbamazepine decrease the binding activity of activator protein-2 and in turn the transcription, translation and activity of its AA-selective calcium-dependent phospholipase A(2) gene product, valproate appears to be a non-competitive inhibitor of long-chain acyl-CoA synthetase. The net overlapping effects of the three drugs are decreased turnover of AA but not of docosahexaenoic acid in rat brain phospholipids, and decreased brain cyclooxygenase-2 and prostaglandin E(2). Although these observations support the hypothesis proposed by Rapoport and colleagues that the AA cascade is a common target of mood stabilizers, this hypothesis is not necessarily exclusive of other targets. Targeting the AA cascade with drugs or diet may be a useful therapeutic approach in bipolar disorder, and examining the AA cascade in patients might help in better understanding the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>J S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Brain Physiology and Metabolism Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>H-J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Rapoport</LastName><ForeName>S I</ForeName><Initials>SI</Initials></Author><Author ValidYN="Y"><LastName>Bazinet</LastName><ForeName>R P</ForeName><Initials>RP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>27YG812J1I</RegistryNumber><NameOfSubstance UI="D016718">Arachidonic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016718" MajorTopicYN="N">Arachidonic Acid</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>177</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>3</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>3</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18347600</ArticleId><ArticleId IdType="pii">mp200831</ArticleId><ArticleId IdType="doi">10.1038/mp.2008.31</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10360145</PMID><DateCompleted><Year>1999</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>156</Volume><Issue>6</Issue><PubDate><Year>1999</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Testosterone-patch-induced psychotic mania.</ArticleTitle><Pagination><MedlinePgn>969</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>E L</ForeName><Initials>EL</Initials></Author><Author ValidYN="Y"><LastName>Bowers</LastName><ForeName>M B</ForeName><Initials>MB</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Mazure</LastName><ForeName>C M</ForeName><Initials>CM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3XMK78S47O</RegistryNumber><NameOfSubstance UI="D013739">Testosterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000163" MajorTopicYN="N">Acquired Immunodeficiency Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000279" MajorTopicYN="N">Administration, Cutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019247" MajorTopicYN="N">HIV Wasting Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>6</Month><Day>9</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>6</Month><Day>9</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10360145</ArticleId><ArticleId IdType="doi">10.1176/ajp.156.6.969</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26001664</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>183</Volume><PubDate><Year>2015</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Comparison of precipitating factors for mania and partial seizures: Indicative of shared pathophysiology?</ArticleTitle><Pagination><MedlinePgn>57-67</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2015.04.057</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(15)00290-6</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Mania in bipolar disorder (BD) and partial (focal) seizures (PS) arising from the temporal lobes, have a number of similarities. Typically, a chronic course of the disorders is punctuated by acute illness episodes. Common features of episodes may include sensory, perceptual, cognitive and affective changes. Both respond to anticonvulsant treatment. Common mechanisms imputed include neurotransmitters and kindling processes. Further investigation may improve understanding of the occurrence of both mania and PS, casting light on the relevance of temporal lobe mediated processes and pathology. One avenue of investigation is to compare aetiological factors and determine the extent of overlap which may indicate shared brain localization or pathophysiology. Aetiology includes predisposing, precipitating or perpetuating factors. This paper examines the literature on precipitating factors of mania, first or subsequent episode, and of PS in diagnosed epilepsy, which is the second or subsequent seizure, to identify the extent and nature of their overlap.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Narrative review based on a literature search of PubMed and Google Scholar.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Precipitating factors for both mania and PS were stress, sleep deprivation, antidepressant medication and, tentatively, emotion. For mania alone, goal-attainment events, spring and summer season, postpartum, and drugs include steroids and stimulants. For PS alone, winter season, menstruation and specific triggers in complex reflex epilepsies. Those not substantiated include lunar phase and menopause. A wide range of chemicals may provoke isolated seizures but by definition epilepsy requires at least two seizures.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The overlap of precipitating factors in mania and PS imply that common brain processes may contribute to both, consistent with findings from neuroscience research.</AbstractText><CopyrightInformation>Copyright Â© 2015 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bostock</LastName><ForeName>Emmanuelle C S</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Psychology, School of Medicine, University of Tasmania, Hobart, TAS, Australia. Electronic address: ebostock@utas.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirkby</LastName><ForeName>Kenneth C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Psychiatry, School of Medicine, University of Tasmania, Hobart, TAS, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garry</LastName><ForeName>Michael I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Psychology, School of Medicine, University of Tasmania, Hobart, TAS, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Bruce V M</ForeName><Initials>BV</Initials><AffiliationInfo><Affiliation>Menzies Research Institute, Tasmania, Hobart, TAS, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="Y">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005222" MajorTopicYN="N">Mental Fatigue</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015985" MajorTopicYN="N">Precipitating Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012892" MajorTopicYN="N">Sleep Deprivation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Epilepsy</Keyword><Keyword MajorTopicYN="N">Mania</Keyword><Keyword MajorTopicYN="N">Partial seizures</Keyword><Keyword MajorTopicYN="N">Precipitating factor</Keyword><Keyword MajorTopicYN="N">Temporal lobe</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>03</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>04</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26001664</ArticleId><ArticleId IdType="pii">S0165-0327(15)00290-6</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2015.04.057</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23406546</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2013</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0447</ISSN><JournalIssue CitedMedium="Internet"><Volume>128</Volume><Issue>5</Issue><PubDate><Year>2013</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>The CACNA1C risk allele selectively impacts on executive function in bipolar type I disorder.</ArticleTitle><Pagination><MedlinePgn>362-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/acps.12073</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Calcium channels are important for converting electrical activity into biochemical events. A single nucleotide polymorphism (SNP) (rs1006737) in the CACNA1C gene has been strongly associated with increased risk for Bipolar disorder (BD) in genome-wide association studies. Recently, this same SNP has been reported to influence executive function in schizophrenia and controls, but it remains unclear whether this SNP affects behaviour, especially cognition in subjects with BD.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A total of 109 BD type I subjects and 96 controls were genotyped for CACNA1C rs1006737 and assessed with an executive function tests battery [Wechsler Adult Intelligence Scale III (WAIS-III) Letter-Number Sequence subtest (WAIS-LNS), digit span (WAISDS), trail making test (TMT), and WCST (Wisconsin Card Sorting Test)].</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In patients with BD, the CACNA1C genotype Met/Met was associated with worse performance on all four executive function tests compared to Val/Val. No influence of CACNA1C was observed in the cognitive performance of healthy controls.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our data indicate for the first time that the CACNA1C risk allele is likely associated with executive dysfunction as a trait in BD, as this association was found regardless the presence of mood symptoms. Larger studies should evaluate the potential influence of CACNA1C on other cognitive domains in BD.</AbstractText><CopyrightInformation>Â© 2013 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soeiro-de-Souza</LastName><ForeName>M G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Mood Disorders Unit (GRUDA), Department and Institute of Psychiatry, School of Medicine, University of Sao Paulo (IPq-FMUSP), SÃ£o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bio</LastName><ForeName>D S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Dias</LastName><ForeName>V V</ForeName><Initials>VV</Initials></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Machado-Vieira</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C079146">CACNA1C protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020746">Calcium Channels, L-Type</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020746" MajorTopicYN="N">Calcium Channels, L-Type</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CACNA1C</Keyword><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">calcium channel</Keyword><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">executive function</Keyword><Keyword MajorTopicYN="N">mania</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>07</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>10</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>12</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23406546</ArticleId><ArticleId IdType="doi">10.1111/acps.12073</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">28135597</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>249</Volume><PubDate><Year>2017</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Influences of patient informed cognitive complaints on activities of daily living in patients with bipolar disorder. An exploratory cross-sectional study.</ArticleTitle><Pagination><MedlinePgn>268-274</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(16)30920-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2016.12.058</ELocationID><Abstract><AbstractText>Many patients with bipolar disorder (BD) experience debilitating cognitive deficits, with risk of impaired occupational and psychosocial functioning. However, knowledge of how these deficits impact the patients' ability to perform Activities of Daily Living (ADL), tasks related to self-care and domestic life is limited. We explored the relation between impaired cognitive function and the ability to perform ADL in patients with BD. A total of 42 outpatients (mean age 36 years (range 19.0-58.0 years), 69% women) with BD in remission and with subjective cognitive complaints (â¥ 13 on the Cognitive Complaints in Bipolar Disorder Rating Assessment questionnaire (COBRA)) were included. Objective neurocognitive function was evaluated with a short comprehensive cognitive test battery and ADL ability was evaluated with the performance-based Assessment of Motor and Process Skills (AMPS) in the homes of the patients. Our findings indicate that low processing speed correlated with decreased ADL ability, and processing speed as measured by the cognitive test battery thus seems to be significantly related to patients' ability to live independently in the community. Overall, adding a performance based test to assess ADL ability in patients with BD home-surroundings seems to provide new insights regarding the effect of cognitive impairment in patients with BD.</AbstractText><CopyrightInformation>Copyright Â© 2017 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>TrÃ¤ger</LastName><ForeName>Conny</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Psychiatric Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Decker</LastName><ForeName>Lone</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Physiotherapy and Occupational Therapy, Metropolitan University College, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>WÃ¦hrens</LastName><ForeName>Eva Ejlersen</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>The Parker Institute, Copenhagen University Hospital-, Bispebjerg and Frederiksberg, Frederiksberg, Denmark; Institute of Public Health, University of Southern Denmark, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knorr</LastName><ForeName>Ulla</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Psychiatric Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miskowiak</LastName><ForeName>Kamilla</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Psychiatric Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinberg</LastName><ForeName>Maj</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Psychiatric Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: maj.vinberg@regionh.dk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012648" MajorTopicYN="N">Self Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>05</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28135597</ArticleId><ArticleId IdType="pii">S0165-1781(16)30920-9</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2016.12.058</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21443576</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2011</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Domains of cognitive impairment in bipolar disorder: commentary on "The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC)".</ArticleTitle><Pagination><MedlinePgn>217-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2011.00899.x</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bora</LastName><ForeName>Emre</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Pantelis</LastName><ForeName>Christos</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Bipolar Disord. 2010 Jun;12(4):351-63</RefSource><PMID Version="1">20636632</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21443576</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2011.00899.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17042834</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>5 Pt 2</Issue><PubDate><Year>2006</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment.</ArticleTitle><Pagination><MedlinePgn>618-24</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Among the well-established treatments for bipolar disorder (BPD), lithium continues to offer an unusually broad spectrum of benefits that may include reduction of suicidal risk.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We examined the association of suicidal acts with adherence to long-term lithium maintenance treatment and other potential risk factors in 72 BP I patients followed prospectively for up to 10 years at a Mood Disorders Research Center in Spain.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The observed rates of suicide were 0.143, and of attempts, 2.01%/year, with a 5.2-fold (95% CI: 1.5-18.6) greater risk among patients consistently rated poorly versus highly adherent to lithium prophylaxis (11.4/2.2 acts/100 person-years). Treatment non-adherence was associated with substance abuse, being unmarried, being male, and having more hypomanic-manic illness and hospitalizations. Suicidal risk was higher with prior attempts, more depression and hospitalization, familial mood disorders, and being single and younger, as well as treatment non-adherence, but with neither sex nor substance abuse. In multivariate analysis, suicidal risk was associated with previous suicidality &gt; poor treatment adherence &gt; more depressive episodes &gt; younger age.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The findings support growing evidence of lower risk of suicidal acts during closely monitored and highly adherent, long-term treatment with lithium and indicate that treatment adherence is a potentially modifiable factor contributing to antisuicidal benefits.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gonzalez-Pinto</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Stanley Institute International Mood Disorders Research Center, Vitoria, Spain. agonzalez@hsan.osakidetza.net</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosquera</LastName><ForeName>Fernando</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Alonso</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>LÃ³pez</LastName><ForeName>PurificaciÃ³n</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>RamÃ­rez</LastName><ForeName>Fernando</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Baldessarini</LastName><ForeName>Ross J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17042834</ArticleId><ArticleId IdType="pii">BDI368</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2006.00368.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24183241</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1379</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Childhood maltreatment and corpus callosum volume in recently diagnosed patients with bipolar I disorder: data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).</ArticleTitle><Pagination><MedlinePgn>65-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2013.10.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-3956(13)00329-4</ELocationID><Abstract><AbstractText>Childhood trauma (CT) has been associated with abnormalities in the corpus callosum (CC). Decreased CC volumes have been reported in children and adolescents with trauma as well as adults with CT compared to healthy controls. CC morphology is potentially susceptible to the effects of Bipolar Disorder (BD) itself. Therefore, we evaluated the relationship between CT and CC morphology in BD. We using magnetic resonance imaging in 53 adults with BD recently recovered from their first manic episode, with (n = 23) and without (n = 30) CT, defined using the Childhood Trauma Questionnaire (CTQ) and 16 healthy controls without trauma. ANCOVA was performed with age, gender and intracranial volume as covariates in order to evaluate group differences in CC volume. The total CC volume was found to be smaller in BD patients with trauma compared to BD patients without trauma (p &lt; .05). The differences were more pronounced in the anterior region of the CC. There was a significant negative correlation between CTQ scores and total CC volume in BD patients with trauma (p = .01). We did not find significant differences in the CC volume of patients with/without trauma compared to the healthy subjects. Our sample consists of patients recovered from a first episode of mania and are early in the course of illness and reductions in CC volume may occur late in the course of BD. It might mean there may be two sources of CC volume reduction in these patients: the reduction due to trauma, and the further reduction due to the illness.</AbstractText><CopyrightInformation>Copyright Â© 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>BÃ¼cker</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, Canada; Bipolar Disorder Program and Laboratory of Molecular Psychiatry, National Institute for Translational Medicine, INCT-TM, Hospital de ClÃ­nicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muralidharan</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>I J</ForeName><Initials>IJ</Initials></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Kozicky</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Silveira</LastName><ForeName>L E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Bond</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Honer</LastName><ForeName>W G</ForeName><Initials>WG</Initials></Author><Author ValidYN="Y"><LastName>Kauer-Sant'anna</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>R W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Yatham</LastName><ForeName>L N</ForeName><Initials>LN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002649" MajorTopicYN="N">Child Abuse</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003337" MajorTopicYN="N">Corpus Callosum</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Childhood trauma</Keyword><Keyword MajorTopicYN="N">Corpus callosum</Keyword><Keyword MajorTopicYN="N">First episode mania</Keyword><Keyword MajorTopicYN="N">Magnetic resonance imaging</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>06</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>08</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24183241</ArticleId><ArticleId IdType="pii">S0022-3956(13)00329-4</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2013.10.012</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14628991</PMID><DateCompleted><Year>2004</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>9</Issue><PubDate><Year>2003</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Underdiagnosis of bipolar II disorders in the community.</ArticleTitle><Pagination><MedlinePgn>1130-1</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benazzi</LastName><ForeName>Franco</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Clin Psychiatry. 2003 Jan;64(1):53-9</RefSource><PMID Version="1">12590624</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>11</Month><Day>25</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>2</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>11</Month><Day>25</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14628991</ArticleId><ArticleId IdType="doi">10.4088/jcp.v64n0921a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11185942</PMID><DateCompleted><Year>2001</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Awareness and unawareness of thought disorder.</ArticleTitle><Pagination><MedlinePgn>35-42</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">There is little systematic evidence to determine if patients with thought disorder are aware of their impaired communication. Awareness versus unawareness of deficit has important implications for neurocognitive models of thought disorder. The aims of this study were to assess awareness of impaired communication in patients prone to thought disorder, and to explore associations between degree of awareness of thought disorder, objective measurement of thought disorder and performance on tests sensitive to impaired executive ability.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Thirty-one patients with schizophrenia, 16 patients with mania and 20 well controls were included. Subjects completed a new instrument to assess awareness of thought disorder, the Communication Awareness Scale (CAS). Thought disorder was rated from free speech samples scored with Andreasen's Scale for the Assessment of Thought Language and Communication. Four tests sensitive to impaired executive ability were administered.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Subjects with higher levels of positive thought disorder had significantly higher CAS scores. Unexpectedly, those with lower scores on executive ability had significantly higher scores on the CAS.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The significant correlation between objective levels of positive thought disorder and higher scores on the CAS suggests that, overall, patients with thought disorder are aware of their deficit. A neurocognitive model of thought disorder is described that involves a dissociation between the ability to monitor errors (required for accurate awareness of deficit) and the ability to correct errors (required for the production of efficient communication).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McGrath</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Queensland Centre for Schizophrenia Research, Wolston Park Hospital, Wacol, Australia. jjim@brain.wph.uq.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allman</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001364" MajorTopicYN="Y">Awareness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003142" MajorTopicYN="N">Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012564" MajorTopicYN="N">Schizophrenic Language</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013850" MajorTopicYN="Y">Thinking</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>2</Month><Day>24</Day><Hour>12</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>7</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>2</Month><Day>24</Day><Hour>12</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11185942</ArticleId><ArticleId IdType="doi">10.1046/j.1440-1614.2000.00699.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2613186</PMID><DateCompleted><Year>1990</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0193-5216</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>1989</Year></PubDate></JournalIssue><Title>The Hillside journal of clinical psychiatry</Title><ISOAbbreviation>Hillside J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Schizophrenia and bipolar affective disorders: likenesses and differences.</ArticleTitle><Pagination><MedlinePgn>3-15</MedlinePgn></Pagination><Abstract><AbstractText>We pay tribute to Lew Robbins and Hillside Hospital for the opportunity given me to develop work in the psychopharmacological treatment of mental disorders. A historical review is given of early experience with antipsychotics and antidepressants and the failed attempts to relate therapeutic effect of psychoanalytic formulations. Work done at Hillside demonstrated the importance of developmental history for schizophrenic prognosis and drug responsivity. Surprising findings such as the positive antidepressant benefits of chlorpromazine are detailed and discussed. The resemblances between bipolar affective disorder and schizophrenia are detailed and related to the peculiar finding that all anti-schizophrenic drugs are also anti-manic. The converse of this is also discussed. The psychopharmacological resemblances between bipolar disorder and schizophrenia, as well as the relationship to genetic findings, lead to a two factor theory of schizophrenia and hypotheses concerning the nature of delusional and deteriorative processes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>D F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>New York State Psychiatric Institute, N.Y. 10032.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-30906</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hillside J Clin Psychiatry</MedlineTA><NlmUniqueID>7905001</NlmUniqueID><ISSNLinking>0193-5216</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>OGG85SX4E4</RegistryNumber><NameOfSubstance UI="D007099">Imipramine</NameOfSubstance></Chemical><Chemical><RegistryNumber>U42B7VYA4P</RegistryNumber><NameOfSubstance UI="D002746">Chlorpromazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002746" MajorTopicYN="N">Chlorpromazine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007099" MajorTopicYN="N">Imipramine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2613186</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20413280</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>182</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Month>May</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Brain glutamatergic characteristics of pediatric offspring of parents with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>165-71</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pscychresns.2010.01.003</ELocationID><Abstract><AbstractText>We wished to determine whether decreases in prefrontal glutamate concentrations occur in offspring of parents with bipolar disorder with and at high risk for mania. Sixty children and adolescents, 9-18 years old, of parents with bipolar I or II disorder (20 offspring with established history of mania, "BD", 20 offspring with symptoms subsyndromal to mania, "SS", and 20 healthy controls "HC") were examined using proton magnetic resonance spectroscopy at 3T to study glutamatergic metabolite concentrations in the anterior cingulate cortex (ACC). A signal for reductions in absolute glutamate concentrations in the ACC was seen in the BD compared with HC and SS groups. No other statistically significant differences among groups were found. Offspring of parents with BD with prior histories of mania may have disruptions in glutamatergic function compared with HC or children at risk for BD who have not yet developed mania. Longitudinal studies are necessary to confirm whether prefrontal glutamate decreases only after the onset of full mania.</AbstractText><CopyrightInformation>Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Manpreet</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Division of Child and Adolescent Psychiatry, Stanford University School of Medicine, 401 Quarry Road, Stanford, CA 94305, USA. mksingh@stanford.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spielman</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Adleman</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Alegria</LastName><ForeName>Dylan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Howe</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Reiss</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Kiki</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 MH085919</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH085919-01</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH 077047</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH077047-04</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH 064460</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH077047</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH019908</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH064460</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011522">Protons</NameOfSubstance></Chemical><Chemical><RegistryNumber>30KYC7MIAI</RegistryNumber><NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>997-55-7</RegistryNumber><NameOfSubstance UI="C000179">N-acetylaspartate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001224" MajorTopicYN="N">Aspartic Acid</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016241" MajorTopicYN="Y">Child of Impaired Parents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006179" MajorTopicYN="N">Gyrus Cinguli</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010372" MajorTopicYN="N">Pediatrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011522" MajorTopicYN="N">Protons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>04</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>01</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20413280</ArticleId><ArticleId IdType="pii">S0925-4927(10)00028-4</ArticleId><ArticleId IdType="doi">10.1016/j.pscychresns.2010.01.003</ArticleId><ArticleId IdType="pmc">PMC2866778</ArticleId><ArticleId IdType="mid">NIHMS172320</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eur Neuropsychopharmacol. 2006 Jan;16(1):71-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16023835</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2008 Apr;18(2):132-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18439111</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Sep;11(6):628-36</Citation><ArticleIdList><ArticleId IdType="pubmed">19689505</ArticleId></ArticleIdList></Reference><Reference><Citation>NMR Biomed. 2001 Jun;14(4):260-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11410943</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):316-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16449488</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13290-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9789081</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Sep;162(9):1637-43</Citation><ArticleIdList><ArticleId IdType="pubmed">16135622</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2007 Aug;17(4):461-73</Citation><ArticleIdList><ArticleId IdType="pubmed">17822341</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Jan 15;61(2):162-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16735030</ArticleId></ArticleIdList></Reference><Reference><Citation>Magn Reson Med. 2009 Oct;62(4):868-79</Citation><ArticleIdList><ArticleId IdType="pubmed">19591201</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2005 Jul 1;26(3):839-51</Citation><ArticleIdList><ArticleId IdType="pubmed">15955494</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14940-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18824690</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2008 May;7(5):426-37</Citation><ArticleIdList><ArticleId IdType="pubmed">18425072</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9204677</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Jun 1;53(11):1059-65</Citation><ArticleIdList><ArticleId IdType="pubmed">12788251</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Med Chem. 2009;16(23):2965-76</Citation><ArticleIdList><ArticleId IdType="pubmed">19689277</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2003 Jul;168(3):344-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12684737</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2007 Dec;32(12):2490-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17429412</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2007 Jan 5;1127(1):108-18</Citation><ArticleIdList><ArticleId IdType="pubmed">17113057</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2005 Oct;10(10):808-19</Citation><ArticleIdList><ArticleId IdType="pubmed">16400244</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Jun 1;53(11):945-51</Citation><ArticleIdList><ArticleId IdType="pubmed">12788239</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Aug;160(8):1442-52</Citation><ArticleIdList><ArticleId IdType="pubmed">12900307</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 1993 Oct;56(3):539-55</Citation><ArticleIdList><ArticleId IdType="pubmed">7902967</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Oct 15;64(8):718-26</Citation><ArticleIdList><ArticleId IdType="pubmed">18602089</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Aug;61(8):781-92</Citation><ArticleIdList><ArticleId IdType="pubmed">15289277</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2003 Winter;13(4):545-55</Citation><ArticleIdList><ArticleId IdType="pubmed">14977467</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1977 Oct;34(10):1229-35</Citation><ArticleIdList><ArticleId IdType="pubmed">911222</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2006 Aug 30;30(6):1155-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16707201</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Aug;5(4):257-64</Citation><ArticleIdList><ArticleId IdType="pubmed">12895203</ArticleId></ArticleIdList></Reference><Reference><Citation>AJNR Am J Neuroradiol. 2000 May;21(5):832-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10815657</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2008 May 30;163(1):30-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18403184</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2008 Nov;33(6):531-40</Citation><ArticleIdList><ArticleId IdType="pubmed">18982176</ArticleId></ArticleIdList></Reference><Reference><Citation>Dialogues Clin Neurosci. 2008;10(2):193-201</Citation><ArticleIdList><ArticleId IdType="pubmed">18689289</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Dec 1;62(11):1310-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17574216</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 1979 Oct;64(4):442-50</Citation><ArticleIdList><ArticleId IdType="pubmed">492809</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Radiol. 2007 Jul;17(7):1651-62</Citation><ArticleIdList><ArticleId IdType="pubmed">17235536</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2005 Sep;44(9):846-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16113615</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):249-56</Citation><ArticleIdList><ArticleId IdType="pubmed">17913322</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Feb;63(2):175-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16461861</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2007 Apr;46(4):524-34</Citation><ArticleIdList><ArticleId IdType="pubmed">17420688</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2007 Sep;95(1-3):174-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17630258</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Nov 1;60(9):998-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">17056394</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Aug;11(5):523-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19624391</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Psychopharmacol. 2001 Mar;16(2):139-146</Citation><ArticleIdList><ArticleId IdType="pubmed">12404584</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2009 Jan;56(1):47-55</Citation><ArticleIdList><ArticleId IdType="pubmed">18789340</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 May;61(5):450-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15123489</ArticleId></ArticleIdList></Reference><Reference><Citation>Magn Reson Med. 2005 Aug;54(2):439-42</Citation><ArticleIdList><ArticleId IdType="pubmed">16032664</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2006 Oct;188(2):236-43</Citation><ArticleIdList><ArticleId IdType="pubmed">16944105</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Dec;7(6):589-97</Citation><ArticleIdList><ArticleId IdType="pubmed">16403184</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Apr;99(1-3):19-25</Citation><ArticleIdList><ArticleId IdType="pubmed">17005256</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2001 Dec;3(6):325-34</Citation><ArticleIdList><ArticleId IdType="pubmed">11843782</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2006 Jun;31(6):1264-73</Citation><ArticleIdList><ArticleId IdType="pubmed">16292323</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3295932</PMID><DateCompleted><Year>1987</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0702-8466</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>1987</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Psychiatric journal of the University of Ottawa : Revue de psychiatrie de l'Universite d'Ottawa</Title><ISOAbbreviation>Psychiatr J Univ Ott</ISOAbbreviation></Journal><ArticleTitle>Secondary mania: aggravation of a sub-clinical condition.</ArticleTitle><Pagination><MedlinePgn>47-8</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hoaken</LastName><ForeName>P C</ForeName><Initials>PC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Psychiatr J Univ Ott</MedlineTA><NlmUniqueID>7703518</NlmUniqueID><ISSNLinking>0702-8466</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>33RU150WUN</RegistryNumber><NameOfSubstance UI="D010665">Phenylpropanolamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>GN83C131XS</RegistryNumber><NameOfSubstance UI="D004809">Ephedrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004809" MajorTopicYN="N">Ephedrine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010665" MajorTopicYN="N">Phenylpropanolamine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3295932</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20176702</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-1833</ISSN><JournalIssue CitedMedium="Internet"><Volume>340</Volume><PubDate><Year>2010</Year><Month>Feb</Month><Day>22</Day></PubDate></JournalIssue><Title>BMJ (Clinical research ed.)</Title><ISOAbbreviation>BMJ</ISOAbbreviation></Journal><ArticleTitle>Is underdiagnosis the main pitfall in diagnosing bipolar disorder? No.</ArticleTitle><Pagination><MedlinePgn>c855</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmj.c855</ELocationID><ELocationID EIdType="pii" ValidYN="Y">bmj.c855</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Rhode Island Hospital, Bayside Medical Building, 235 Plain Street, Providence, RI 02905, USA. mzimmerman@lifespan.org</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>02</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ</MedlineTA><NlmUniqueID>8900488</NlmUniqueID><ISSNLinking>0959-8138</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>BMJ. 2010;340:c854</RefSource><PMID Version="1">20176701</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003951" MajorTopicYN="Y">Diagnostic Errors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20176702</ArticleId><ArticleId IdType="doi">10.1136/bmj.c855</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>